Background  ||| S:24 E:43 ||| NN
The  ||| S:43 E:47 ||| DT
cysteine-loop  ||| S:47 E:61 ||| JJ
family  ||| S:61 E:68 ||| NN
of  ||| S:68 E:71 ||| IN
ligand  ||| S:71 E:78 ||| FW
gated  ||| S:78 E:84 ||| FW
ion  ||| S:84 E:88 ||| FW
channels  ||| S:88 E:105 ||| FW
( ||| S:105 E:106 ||| -LRB-
LGIC ||| S:106 E:110 ||| NNP
)  ||| S:110 E:112 ||| -RRB-
is  ||| S:112 E:115 ||| VBZ
comprised  ||| S:115 E:125 ||| VBN
of  ||| S:125 E:128 ||| IN
receptors  ||| S:128 E:138 ||| NNS
with  ||| S:138 E:143 ||| IN
pentameric  ||| S:143 E:154 ||| JJ
quaternary  ||| S:154 E:173 ||| JJ
structure  ||| S:173 E:183 ||| NN
and  ||| S:183 E:187 ||| CC
at  ||| S:187 E:190 ||| IN
least  ||| S:190 E:196 ||| JJS
two  ||| S:196 E:200 ||| CD
ligand  ||| S:200 E:207 ||| CD
binding  ||| S:207 E:215 ||| JJ
sites  ||| S:215 E:221 ||| NNS
present  ||| S:221 E:229 ||| JJ
at  ||| S:229 E:240 ||| IN
the  ||| S:240 E:244 ||| DT
subunit  ||| S:244 E:252 ||| JJ
interfaces  ||| S:252 E:263 ||| NNS
[  ||| S:263 E:265 ||| -LRB-
1  ||| S:265 E:267 ||| CD
2  ||| S:267 E:269 ||| CD
]  ||| S:269 E:271 ||| -RRB-
.  ||| S:271 E:273 ||| .
This  ||| S:273 E:278 ||| DT
receptor  ||| S:278 E:287 ||| NN
family  ||| S:287 E:294 ||| NN
is  ||| S:294 E:305 ||| VBZ
characterized  ||| S:305 E:319 ||| VBN
by  ||| S:319 E:322 ||| IN
the  ||| S:322 E:326 ||| DT
presence  ||| S:326 E:335 ||| NN
of  ||| S:335 E:338 ||| IN
a  ||| S:338 E:340 ||| DT
critical  ||| S:340 E:349 ||| JJ
disulfide  ||| S:349 E:359 ||| JJ
loop  ||| S:359 E:372 ||| JJ
structure  ||| S:372 E:382 ||| NN
within  ||| S:382 E:389 ||| IN
the  ||| S:389 E:393 ||| DT
binding  ||| S:393 E:401 ||| JJ
site  ||| S:401 E:406 ||| NN
and  ||| S:406 E:410 ||| CC
an  ||| S:410 E:413 ||| DT
integral  ||| S:413 E:422 ||| JJ
ion  ||| S:422 E:434 ||| JJ
selective  ||| S:434 E:444 ||| JJ
channel ||| S:444 E:451 ||| NN
.  ||| S:451 E:453 ||| .
LGIC  ||| S:453 E:458 ||| NNP
receptors  ||| S:458 E:468 ||| NNS
are  ||| S:468 E:472 ||| VBP
found  ||| S:472 E:478 ||| VBN
in  ||| S:478 E:481 ||| IN
both  ||| S:481 E:486 ||| PDT
the  ||| S:486 E:498 ||| DT
peripheral  ||| S:498 E:509 ||| JJ
and  ||| S:509 E:513 ||| CC
central  ||| S:513 E:521 ||| JJ
nervous  ||| S:521 E:529 ||| JJ
systems ||| S:529 E:536 ||| NNS
.  ||| S:536 E:538 ||| .
Members  ||| S:538 E:546 ||| NNS
of  ||| S:546 E:549 ||| IN
this  ||| S:549 E:562 ||| DT
family  ||| S:562 E:569 ||| NN
include  ||| S:569 E:577 ||| VBP
the  ||| S:577 E:581 ||| DT
acetylcholine  ||| S:581 E:595 ||| JJ
receptors  ||| S:595 E:605 ||| NNS
[  ||| S:605 E:607 ||| -LRB-
3  ||| S:607 E:609 ||| CD
4  ||| S:609 E:611 ||| CD
]  ||| S:611 E:613 ||| -RRB-
,  ||| S:613 E:615 ||| ,
the  ||| S:615 E:627 ||| DT
γ-amino  ||| S:627 E:635 ||| JJ
butyric  ||| S:635 E:643 ||| JJ
acid  ||| S:643 E:648 ||| NN
type  ||| S:648 E:653 ||| NN
A  ||| S:653 E:655 ||| DT
receptor  ||| S:655 E:664 ||| NN
( ||| S:664 E:665 ||| -LRB-
GABA  ||| S:665 E:679 ||| NNP
A  ||| S:679 E:681 ||| NNP
R ||| S:681 E:682 ||| NNP
)  ||| S:682 E:684 ||| -RRB-
[  ||| S:684 E:686 ||| -LRB-
5  ||| S:686 E:688 ||| LS
]  ||| S:688 E:690 ||| -RRB-
,  ||| S:690 E:692 ||| ,
and  ||| S:692 E:696 ||| CC
the  ||| S:696 E:700 ||| DT
glycine  ||| S:700 E:708 ||| JJ
receptor  ||| S:708 E:725 ||| NN
( ||| S:725 E:726 ||| -LRB-
GlyR ||| S:726 E:730 ||| NNP
)  ||| S:730 E:732 ||| -RRB-
[  ||| S:732 E:734 ||| -LRB-
6  ||| S:734 E:736 ||| CD
]  ||| S:736 E:738 ||| -RRB-
.  ||| S:738 E:748 ||| .
The  ||| S:748 E:752 ||| DT
first  ||| S:752 E:758 ||| JJ
subunit  ||| S:758 E:766 ||| NN
of  ||| S:766 E:769 ||| IN
the  ||| S:769 E:773 ||| DT
5-HT  ||| S:773 E:787 ||| CD
3  ||| S:787 E:789 ||| CD
R  ||| S:789 E:791 ||| NN
was  ||| S:791 E:795 ||| VBD
cloned  ||| S:795 E:802 ||| VBN
in  ||| S:802 E:805 ||| IN
1991  ||| S:805 E:810 ||| CD
[  ||| S:810 E:812 ||| -LRB-
7  ||| S:812 E:814 ||| CD
]  ||| S:814 E:816 ||| -RRB-
.  ||| S:816 E:818 ||| .
The  ||| S:818 E:830 ||| DT
sequence  ||| S:830 E:839 ||| NN
of  ||| S:839 E:842 ||| IN
this  ||| S:842 E:847 ||| DT
subunit  ||| S:847 E:855 ||| NN
was  ||| S:855 E:859 ||| VBD
shown  ||| S:859 E:865 ||| VBN
to  ||| S:865 E:868 ||| TO
be  ||| S:868 E:871 ||| VB
highly  ||| S:871 E:878 ||| RB
homologous  ||| S:878 E:897 ||| VBN
to  ||| S:897 E:900 ||| TO
LGIC  ||| S:900 E:905 ||| NNP
receptors  ||| S:905 E:915 ||| NNS
and  ||| S:915 E:919 ||| CC
thus  ||| S:919 E:924 ||| RB
identified  ||| S:924 E:935 ||| VBN
the  ||| S:935 E:939 ||| DT
5-HT  ||| S:939 E:953 ||| CD
3  ||| S:953 E:955 ||| CD
R  ||| S:955 E:957 ||| NN
receptor  ||| S:957 E:966 ||| NN
as  ||| S:966 E:969 ||| IN
another  ||| S:969 E:977 ||| DT
member  ||| S:977 E:984 ||| NN
of  ||| S:984 E:987 ||| IN
this  ||| S:987 E:1000 ||| DT
superfamily  ||| S:1000 E:1012 ||| NN
[  ||| S:1012 E:1014 ||| -LRB-
7  ||| S:1014 E:1016 ||| CD
8  ||| S:1016 E:1018 ||| CD
9  ||| S:1018 E:1020 ||| CD
]  ||| S:1020 E:1022 ||| -RRB-
.  ||| S:1022 E:1024 ||| .
Similar  ||| S:1024 E:1032 ||| JJ
to  ||| S:1032 E:1035 ||| TO
other  ||| S:1035 E:1041 ||| JJ
LGIC  ||| S:1041 E:1046 ||| NN
receptors ||| S:1046 E:1055 ||| NNS
,  ||| S:1055 E:1065 ||| ,
more  ||| S:1065 E:1070 ||| JJR
than  ||| S:1070 E:1075 ||| IN
one  ||| S:1075 E:1079 ||| CD
subtype  ||| S:1079 E:1087 ||| NN
has  ||| S:1087 E:1091 ||| VBZ
been  ||| S:1091 E:1096 ||| VBN
identified ||| S:1096 E:1106 ||| VBN
.  ||| S:1106 E:1108 ||| .
Two  ||| S:1108 E:1112 ||| CD
splice  ||| S:1112 E:1127 ||| JJ
variants  ||| S:1127 E:1136 ||| NN
of  ||| S:1136 E:1139 ||| IN
an  ||| S:1139 E:1142 ||| DT
A  ||| S:1142 E:1144 ||| DT
subunit  ||| S:1144 E:1152 ||| NN
( ||| S:1152 E:1153 ||| -LRB-
long  ||| S:1153 E:1158 ||| JJ
and  ||| S:1158 E:1162 ||| CC
short  ||| S:1162 E:1168 ||| JJ
forms ||| S:1168 E:1173 ||| NNS
) ||| S:1173 E:1174 ||| -RRB-
,  ||| S:1174 E:1176 ||| ,
and  ||| S:1176 E:1180 ||| CC
a  ||| S:1180 E:1190 ||| DT
single  ||| S:1190 E:1197 ||| JJ
B  ||| S:1197 E:1199 ||| NN
subunit  ||| S:1199 E:1207 ||| NNS
have  ||| S:1207 E:1212 ||| VBP
been  ||| S:1212 E:1217 ||| VBN
cloned  ||| S:1217 E:1224 ||| NNS
[  ||| S:1224 E:1226 ||| -LRB-
10  ||| S:1226 E:1229 ||| CD
11  ||| S:1229 E:1232 ||| CD
12  ||| S:1232 E:1235 ||| CD
13  ||| S:1235 E:1238 ||| CD
]  ||| S:1238 E:1240 ||| -RRB-
.  ||| S:1240 E:1242 ||| .
Both  ||| S:1242 E:1255 ||| PDT
the  ||| S:1255 E:1259 ||| DT
long  ||| S:1259 E:1264 ||| JJ
and  ||| S:1264 E:1268 ||| CC
short  ||| S:1268 E:1274 ||| JJ
forms  ||| S:1274 E:1280 ||| NNS
of  ||| S:1280 E:1283 ||| IN
the  ||| S:1283 E:1287 ||| DT
A  ||| S:1287 E:1289 ||| NN
subunit  ||| S:1289 E:1297 ||| NNS
are  ||| S:1297 E:1301 ||| VBP
capable  ||| S:1301 E:1309 ||| JJ
of  ||| S:1309 E:1320 ||| IN
forming  ||| S:1320 E:1328 ||| FW
functional  ||| S:1328 E:1339 ||| FW
homomeric  ||| S:1339 E:1349 ||| FW
receptors  ||| S:1349 E:1359 ||| FW
[ ||| S:1359 E:1360 ||| -LRB-
5-HT  ||| S:1360 E:1374 ||| NNP
3AL  ||| S:1374 E:1378 ||| NNP
R  ||| S:1378 E:1380 ||| NNP
and  ||| S:1380 E:1384 ||| CC
5-HT  ||| S:1384 E:1398 ||| NNP
3AS  ||| S:1398 E:1402 ||| NNP
R ||| S:1402 E:1403 ||| NNP
]  ||| S:1403 E:1405 ||| -RRB-
although  ||| S:1405 E:1414 ||| IN
some  ||| S:1414 E:1419 ||| DT
differences  ||| S:1419 E:1431 ||| NNS
between  ||| S:1431 E:1447 ||| IN
an  ||| S:1447 E:1450 ||| DT
agonist  ||| S:1450 E:1458 ||| NN
and  ||| S:1458 E:1462 ||| CC
partial  ||| S:1462 E:1470 ||| JJ
agonist  ||| S:1470 E:1478 ||| JJ
activity  ||| S:1478 E:1487 ||| NN
have  ||| S:1487 E:1492 ||| VBP
been  ||| S:1492 E:1497 ||| VBN
observed  ||| S:1497 E:1514 ||| VBN
[  ||| S:1514 E:1516 ||| -LRB-
14  ||| S:1516 E:1519 ||| CD
]  ||| S:1519 E:1521 ||| -RRB-
.  ||| S:1521 E:1523 ||| .
A  ||| S:1523 E:1525 ||| DT
third  ||| S:1525 E:1531 ||| JJ
subtype  ||| S:1531 E:1539 ||| NN
is  ||| S:1539 E:1542 ||| VBZ
formed  ||| S:1542 E:1549 ||| VBN
by  ||| S:1549 E:1552 ||| IN
a  ||| S:1552 E:1554 ||| DT
combination  ||| S:1554 E:1566 ||| NN
of  ||| S:1566 E:1569 ||| IN
the  ||| S:1569 E:1581 ||| DT
A  ||| S:1581 E:1583 ||| NNP
and  ||| S:1583 E:1587 ||| CC
B  ||| S:1587 E:1589 ||| NNP
subunits  ||| S:1589 E:1598 ||| VBD
to  ||| S:1598 E:1601 ||| TO
produce  ||| S:1601 E:1609 ||| VB
a  ||| S:1609 E:1611 ||| DT
heteromeric  ||| S:1611 E:1623 ||| JJ
receptor  ||| S:1623 E:1632 ||| NN
of  ||| S:1632 E:1643 ||| IN
unknown  ||| S:1643 E:1651 ||| JJ
stoichiometry  ||| S:1651 E:1665 ||| NNS
[  ||| S:1665 E:1667 ||| -LRB-
10  ||| S:1667 E:1670 ||| CD
]  ||| S:1670 E:1672 ||| -RRB-
.  ||| S:1672 E:1674 ||| .
Heteromeric  ||| S:1674 E:1686 ||| JJ
receptors  ||| S:1686 E:1696 ||| NNS
are  ||| S:1696 E:1708 ||| VBP
pharmacologically  ||| S:1708 E:1726 ||| VBN
and  ||| S:1726 E:1730 ||| CC
functionally  ||| S:1730 E:1743 ||| JJ
distinct  ||| S:1743 E:1752 ||| NN
from  ||| S:1752 E:1757 ||| IN
the  ||| S:1757 E:1769 ||| DT
homomeric  ||| S:1769 E:1779 ||| JJ
5-HT  ||| S:1779 E:1793 ||| NNP
3AL  ||| S:1793 E:1797 ||| NNP
and  ||| S:1797 E:1801 ||| CC
5-HT  ||| S:1801 E:1815 ||| CD
3AS  ||| S:1815 E:1819 ||| CD
receptors  ||| S:1819 E:1829 ||| NNS
[  ||| S:1829 E:1831 ||| -LRB-
11  ||| S:1831 E:1834 ||| CD
]  ||| S:1834 E:1836 ||| -RRB-
.  ||| S:1836 E:1846 ||| .
5-HT  ||| S:1846 E:1860 ||| CD
3  ||| S:1860 E:1862 ||| CD
Rs  ||| S:1862 E:1865 ||| NNS
are  ||| S:1865 E:1869 ||| VBP
distributed  ||| S:1869 E:1881 ||| VBN
throughout  ||| S:1881 E:1892 ||| IN
the  ||| S:1892 E:1904 ||| DT
central  ||| S:1904 E:1912 ||| JJ
and  ||| S:1912 E:1916 ||| CC
peripheral  ||| S:1916 E:1927 ||| JJ
nervous  ||| S:1927 E:1935 ||| JJ
system ||| S:1935 E:1941 ||| NN
,  ||| S:1941 E:1943 ||| ,
playing  ||| S:1943 E:1951 ||| VBG
a  ||| S:1951 E:1961 ||| DT
significant  ||| S:1961 E:1973 ||| JJ
role  ||| S:1973 E:1978 ||| NN
in  ||| S:1978 E:1981 ||| IN
phenomenon  ||| S:1981 E:1992 ||| NN
such  ||| S:1992 E:1997 ||| JJ
as  ||| S:1997 E:2000 ||| IN
anxiety ||| S:2000 E:2007 ||| NN
,  ||| S:2007 E:2009 ||| ,
emesis  ||| S:2009 E:2016 ||| NN
and  ||| S:2016 E:2028 ||| CC
alcoholism ||| S:2028 E:2038 ||| NN
.  ||| S:2038 E:2040 ||| .
Antagonists  ||| S:2040 E:2052 ||| NNS
to  ||| S:2052 E:2055 ||| TO
5-HT  ||| S:2055 E:2069 ||| CD
3  ||| S:2069 E:2071 ||| CD
Rs  ||| S:2071 E:2074 ||| NNS
are  ||| S:2074 E:2078 ||| VBP
clinically  ||| S:2078 E:2089 ||| RB
efficacious  ||| S:2089 E:2101 ||| VBN
in  ||| S:2101 E:2104 ||| IN
the  ||| S:2104 E:2116 ||| DT
treatment  ||| S:2116 E:2126 ||| NN
of  ||| S:2126 E:2129 ||| IN
chemotherapy-induced  ||| S:2129 E:2150 ||| JJ
emesis  ||| S:2150 E:2157 ||| NNS
[  ||| S:2157 E:2159 ||| -LRB-
15  ||| S:2159 E:2162 ||| CD
]  ||| S:2162 E:2164 ||| -RRB-
and  ||| S:2164 E:2168 ||| CC
recent  ||| S:2168 E:2183 ||| JJ
studies  ||| S:2183 E:2191 ||| NNS
on  ||| S:2191 E:2194 ||| IN
human  ||| S:2194 E:2200 ||| JJ
subjects  ||| S:2200 E:2209 ||| NNS
have  ||| S:2209 E:2214 ||| VBP
suggested  ||| S:2214 E:2224 ||| VBN
their  ||| S:2224 E:2230 ||| PRP$
potential  ||| S:2230 E:2248 ||| JJ
application  ||| S:2248 E:2260 ||| NN
in  ||| S:2260 E:2263 ||| IN
the  ||| S:2263 E:2267 ||| DT
treatment  ||| S:2267 E:2277 ||| NN
of  ||| S:2277 E:2280 ||| IN
early  ||| S:2280 E:2286 ||| JJ
onset  ||| S:2286 E:2292 ||| NN
alcoholism  ||| S:2292 E:2303 ||| NN
[  ||| S:2303 E:2305 ||| -LRB-
16  ||| S:2305 E:2316 ||| CD
17  ||| S:2316 E:2319 ||| CD
]  ||| S:2319 E:2321 ||| -RRB-
.  ||| S:2321 E:2331 ||| .
Hibert  ||| S:2331 E:2347 ||| FW
et  ||| S:2347 E:2350 ||| FW
al  ||| S:2350 E:2353 ||| FW
proposed  ||| S:2353 E:2362 ||| VBN
an  ||| S:2362 E:2365 ||| DT
early  ||| S:2365 E:2371 ||| JJ
model  ||| S:2371 E:2377 ||| NN
for  ||| S:2377 E:2381 ||| IN
the  ||| S:2381 E:2393 ||| DT
antagonist  ||| S:2393 E:2404 ||| JJ
pharmacophore  ||| S:2404 E:2418 ||| NN
of  ||| S:2418 E:2421 ||| IN
the  ||| S:2421 E:2425 ||| DT
5-HT  ||| S:2425 E:2439 ||| CD
3  ||| S:2439 E:2441 ||| CD
R  ||| S:2441 E:2443 ||| NN
[  ||| S:2443 E:2445 ||| -LRB-
18  ||| S:2445 E:2448 ||| CD
]  ||| S:2448 E:2450 ||| -RRB-
.  ||| S:2450 E:2452 ||| .
According  ||| S:2452 E:2462 ||| VBG
to  ||| S:2462 E:2465 ||| TO
this  ||| S:2465 E:2470 ||| DT
model ||| S:2470 E:2475 ||| NN
,  ||| S:2475 E:2485 ||| ,
all  ||| S:2485 E:2489 ||| DT
5-HT  ||| S:2489 E:2503 ||| CD
3  ||| S:2503 E:2505 ||| CD
R  ||| S:2505 E:2507 ||| NN
antagonists  ||| S:2507 E:2519 ||| NNS
contain  ||| S:2519 E:2527 ||| VBP
an  ||| S:2527 E:2530 ||| DT
aromatic  ||| S:2530 E:2547 ||| JJ
ring ||| S:2547 E:2551 ||| NN
,  ||| S:2551 E:2553 ||| ,
a  ||| S:2553 E:2555 ||| DT
carbonyl  ||| S:2555 E:2564 ||| JJ
oxygen  ||| S:2564 E:2571 ||| NN
or  ||| S:2571 E:2574 ||| CC
bioisosteric  ||| S:2574 E:2587 ||| JJ
equivalent ||| S:2587 E:2597 ||| NN
,  ||| S:2597 E:2599 ||| ,
and  ||| S:2599 E:2603 ||| CC
a  ||| S:2603 E:2613 ||| DT
basic  ||| S:2613 E:2619 ||| JJ
nitrogen ||| S:2619 E:2627 ||| NN
.  ||| S:2627 E:2629 ||| .
According  ||| S:2629 E:2639 ||| VBG
to  ||| S:2639 E:2642 ||| TO
Hibert ||| S:2642 E:2648 ||| NNP
's  ||| S:2648 E:2651 ||| POS
model ||| S:2651 E:2656 ||| NN
,  ||| S:2656 E:2658 ||| ,
the  ||| S:2658 E:2662 ||| DT
basic  ||| S:2662 E:2676 ||| JJ
nitrogen  ||| S:2676 E:2685 ||| NN
is  ||| S:2685 E:2688 ||| VBZ
located  ||| S:2688 E:2696 ||| VBN
5.2A°  ||| S:2696 E:2702 ||| CD
from  ||| S:2702 E:2707 ||| IN
the  ||| S:2707 E:2711 ||| DT
centre  ||| S:2711 E:2718 ||| NN
of  ||| S:2718 E:2721 ||| IN
the  ||| S:2721 E:2725 ||| DT
aromatic  ||| S:2725 E:2742 ||| JJ
ring  ||| S:2742 E:2747 ||| NN
and  ||| S:2747 E:2751 ||| CC
approximately  ||| S:2751 E:2765 ||| RB
1.7A°  ||| S:2765 E:2771 ||| CD
above  ||| S:2771 E:2777 ||| IN
plane  ||| S:2777 E:2783 ||| NN
of  ||| S:2783 E:2786 ||| IN
the  ||| S:2786 E:2790 ||| DT
ring ||| S:2790 E:2794 ||| NN
.  ||| S:2794 E:2796 ||| .
The  ||| S:2796 E:2808 ||| DT
carbonyl  ||| S:2808 E:2817 ||| JJ
oxygen  ||| S:2817 E:2824 ||| NN
and  ||| S:2824 E:2828 ||| CC
the  ||| S:2828 E:2832 ||| DT
aromatic  ||| S:2832 E:2841 ||| JJ
ring  ||| S:2841 E:2846 ||| NNS
are  ||| S:2846 E:2850 ||| VBP
coplanar  ||| S:2850 E:2859 ||| VBN
and  ||| S:2859 E:2871 ||| CC
separated  ||| S:2871 E:2881 ||| VBN
by  ||| S:2881 E:2884 ||| IN
a  ||| S:2884 E:2886 ||| DT
distance  ||| S:2886 E:2895 ||| NN
of  ||| S:2895 E:2898 ||| IN
3.3A° ||| S:2898 E:2903 ||| CD
.  ||| S:2903 E:2905 ||| .
Recent  ||| S:2905 E:2912 ||| JJ
studies  ||| S:2912 E:2920 ||| NNS
have  ||| S:2920 E:2933 ||| VBP
expanded  ||| S:2933 E:2942 ||| VBN
on  ||| S:2942 E:2945 ||| IN
this  ||| S:2945 E:2950 ||| DT
model  ||| S:2950 E:2956 ||| NN
to  ||| S:2956 E:2959 ||| TO
include  ||| S:2959 E:2967 ||| VB
another  ||| S:2967 E:2975 ||| DT
lipophilic  ||| S:2975 E:2986 ||| JJ
region  ||| S:2986 E:3001 ||| NN
and  ||| S:3001 E:3005 ||| CC
a  ||| S:3005 E:3007 ||| DT
second  ||| S:3007 E:3014 ||| JJ
hydrogen  ||| S:3014 E:3023 ||| NN
bonding  ||| S:3023 E:3031 ||| VBD
interaction  ||| S:3031 E:3043 ||| CD
two  ||| S:3043 E:3047 ||| CD
atoms  ||| S:3047 E:3053 ||| NNS
away  ||| S:3053 E:3066 ||| RB
from  ||| S:3066 E:3071 ||| IN
the  ||| S:3071 E:3075 ||| DT
first  ||| S:3075 E:3081 ||| JJ
[  ||| S:3081 E:3083 ||| -LRB-
19  ||| S:3083 E:3086 ||| CD
20  ||| S:3086 E:3089 ||| CD
21  ||| S:3089 E:3092 ||| CD
]  ||| S:3092 E:3094 ||| -RRB-
.  ||| S:3094 E:3096 ||| .
A  ||| S:3096 E:3098 ||| DT
compound  ||| S:3098 E:3107 ||| NN
that  ||| S:3107 E:3112 ||| WDT
contains  ||| S:3112 E:3121 ||| VBZ
all  ||| S:3121 E:3133 ||| DT
five  ||| S:3133 E:3138 ||| CD
pharmacophoric  ||| S:3138 E:3153 ||| CD
regions  ||| S:3153 E:3161 ||| NNS
was  ||| S:3161 E:3165 ||| VBD
synthesized  ||| S:3165 E:3177 ||| VBN
by  ||| S:3177 E:3180 ||| IN
Orjales  ||| S:3180 E:3197 ||| NNP
et  ||| S:3197 E:3200 ||| FW
al  ||| S:3200 E:3203 ||| FW
[  ||| S:3203 E:3205 ||| -LRB-
22  ||| S:3205 E:3208 ||| CD
]  ||| S:3208 E:3210 ||| -RRB-
.  ||| S:3210 E:3212 ||| .
This  ||| S:3212 E:3217 ||| DT
compound  ||| S:3217 E:3234 ||| NN
( ||| S:3234 E:3235 ||| -LRB-
1- ||| S:3235 E:3237 ||| NNP
( ||| S:3237 E:3238 ||| -LRB-
phenylmethyl ||| S:3238 E:3250 ||| LS
) ||| S:3250 E:3251 ||| -RRB-
-2-piperizinyl  ||| S:3251 E:3266 ||| CD
benzimidazole  ||| S:3266 E:3280 ||| NNS
or  ||| S:3280 E:3291 ||| CC
lerisetron ||| S:3291 E:3301 ||| CD
)  ||| S:3301 E:3303 ||| -RRB-
is  ||| S:3303 E:3306 ||| VBZ
shown  ||| S:3306 E:3312 ||| VBN
in  ||| S:3312 E:3315 ||| IN
figure  ||| S:3315 E:3322 ||| NN
1and  ||| S:3322 E:3327 ||| NN
is  ||| S:3327 E:3330 ||| VBZ
a  ||| S:3330 E:3332 ||| DT
potent  ||| S:3332 E:3339 ||| JJ
5-HT  ||| S:3339 E:3353 ||| CD
3  ||| S:3353 E:3355 ||| CD
R  ||| S:3355 E:3357 ||| NN
antagonist ||| S:3357 E:3367 ||| NN
.  ||| S:3367 E:3369 ||| .
Functional  ||| S:3369 E:3380 ||| JJ
groups  ||| S:3380 E:3387 ||| NNS
on  ||| S:3387 E:3398 ||| IN
this  ||| S:3398 E:3403 ||| DT
compound  ||| S:3403 E:3412 ||| JJ
capable  ||| S:3412 E:3420 ||| JJ
of  ||| S:3420 E:3423 ||| IN
forming  ||| S:3423 E:3431 ||| VBG
interactions  ||| S:3431 E:3444 ||| NNS
with  ||| S:3444 E:3449 ||| IN
the  ||| S:3449 E:3461 ||| DT
receptor  ||| S:3461 E:3470 ||| NN
are  ||| S:3470 E:3474 ||| VBP
the  ||| S:3474 E:3478 ||| DT
distal  ||| S:3478 E:3485 ||| JJ
amino  ||| S:3485 E:3491 ||| JJ
group ||| S:3491 E:3496 ||| NN
,  ||| S:3496 E:3498 ||| ,
a  ||| S:3498 E:3500 ||| DT
benzimidazole  ||| S:3500 E:3514 ||| NN
and  ||| S:3514 E:3518 ||| CC
a  ||| S:3518 E:3528 ||| DT
benzyl  ||| S:3528 E:3535 ||| JJ
group  ||| S:3535 E:3541 ||| NN
in  ||| S:3541 E:3544 ||| IN
the  ||| S:3544 E:3548 ||| DT
N1  ||| S:3548 E:3551 ||| JJ
position  ||| S:3551 E:3560 ||| NN
of  ||| S:3560 E:3563 ||| IN
the  ||| S:3563 E:3567 ||| DT
benzimidazole ||| S:3567 E:3580 ||| NN
.  ||| S:3580 E:3582 ||| .
While  ||| S:3582 E:3596 ||| IN
Lerisetron  ||| S:3596 E:3607 ||| NNP
contains  ||| S:3607 E:3616 ||| VBZ
no  ||| S:3616 E:3619 ||| DT
carbonyl  ||| S:3619 E:3628 ||| JJ
group ||| S:3628 E:3633 ||| NN
,  ||| S:3633 E:3635 ||| ,
the  ||| S:3635 E:3639 ||| DT
second  ||| S:3639 E:3646 ||| JJ
nitrogen  ||| S:3646 E:3663 ||| NNS
contained  ||| S:3663 E:3673 ||| VBN
in  ||| S:3673 E:3676 ||| IN
the  ||| S:3676 E:3680 ||| DT
benzimidazole  ||| S:3680 E:3694 ||| JJ
heterocycle  ||| S:3694 E:3706 ||| NN
could  ||| S:3706 E:3712 ||| MD
act  ||| S:3712 E:3716 ||| VB
as  ||| S:3716 E:3727 ||| IN
bioisostere  ||| S:3727 E:3739 ||| NN
of  ||| S:3739 E:3742 ||| IN
this  ||| S:3742 E:3747 ||| DT
functional  ||| S:3747 E:3758 ||| JJ
group  ||| S:3758 E:3764 ||| NN
[  ||| S:3764 E:3766 ||| -LRB-
22  ||| S:3766 E:3769 ||| CD
]  ||| S:3769 E:3771 ||| -RRB-
.  ||| S:3771 E:3773 ||| .
Orjales  ||| S:3773 E:3789 ||| NNP
demonstrated  ||| S:3789 E:3802 ||| VBD
the  ||| S:3802 E:3806 ||| DT
importance  ||| S:3806 E:3817 ||| NN
of  ||| S:3817 E:3820 ||| IN
the  ||| S:3820 E:3824 ||| DT
N-benzyl  ||| S:3824 E:3833 ||| JJ
group  ||| S:3833 E:3839 ||| NN
by  ||| S:3839 E:3850 ||| IN
synthesizing  ||| S:3850 E:3863 ||| JJ
several  ||| S:3863 E:3871 ||| JJ
N1  ||| S:3871 E:3874 ||| NN
substituted  ||| S:3874 E:3886 ||| VBD
analogs  ||| S:3886 E:3894 ||| VBN
of  ||| S:3894 E:3897 ||| IN
Lerisetron ||| S:3897 E:3907 ||| NNP
.  ||| S:3907 E:3917 ||| .
Removal  ||| S:3917 E:3925 ||| NN
of  ||| S:3925 E:3928 ||| IN
the  ||| S:3928 E:3932 ||| DT
N-benzyl  ||| S:3932 E:3941 ||| JJ
group  ||| S:3941 E:3947 ||| NN
produced  ||| S:3947 E:3956 ||| VBD
a  ||| S:3956 E:3958 ||| DT
80-fold  ||| S:3958 E:3966 ||| JJ
decrease  ||| S:3966 E:3983 ||| NN
in  ||| S:3983 E:3986 ||| IN
affinity ||| S:3986 E:3994 ||| NN
,  ||| S:3994 E:3996 ||| ,
indicating  ||| S:3996 E:4007 ||| VBG
a  ||| S:4007 E:4009 ||| DT
role  ||| S:4009 E:4014 ||| NN
for  ||| S:4014 E:4018 ||| IN
this  ||| S:4018 E:4023 ||| DT
group  ||| S:4023 E:4029 ||| NN
in  ||| S:4029 E:4040 ||| IN
interacting  ||| S:4040 E:4052 ||| NN
with  ||| S:4052 E:4057 ||| IN
the  ||| S:4057 E:4061 ||| DT
5-HT  ||| S:4061 E:4075 ||| CD
3  ||| S:4075 E:4077 ||| CD
R.  ||| S:4077 E:4080 ||| NNP
Other  ||| S:4080 E:4086 ||| JJ
studies  ||| S:4086 E:4094 ||| NNS
have  ||| S:4094 E:4099 ||| VBP
supported  ||| S:4099 E:4109 ||| VBN
this  ||| S:4109 E:4122 ||| DT
observation  ||| S:4122 E:4134 ||| NN
and  ||| S:4134 E:4138 ||| CC
suggest  ||| S:4138 E:4146 ||| VB
a  ||| S:4146 E:4148 ||| DT
more  ||| S:4148 E:4153 ||| RBR
specific  ||| S:4153 E:4162 ||| JJ
electrostatic  ||| S:4162 E:4184 ||| JJ
interaction  ||| S:4184 E:4196 ||| NNS
[  ||| S:4196 E:4198 ||| -LRB-
23  ||| S:4198 E:4201 ||| CD
]  ||| S:4201 E:4203 ||| -RRB-
.  ||| S:4203 E:4213 ||| .
While  ||| S:4213 E:4219 ||| IN
structure-activity  ||| S:4219 E:4238 ||| JJ
relationship  ||| S:4238 E:4251 ||| NN
studies  ||| S:4251 E:4259 ||| NNS
and  ||| S:4259 E:4271 ||| CC
molecular  ||| S:4271 E:4281 ||| JJ
modeling  ||| S:4281 E:4290 ||| NNS
have  ||| S:4290 E:4295 ||| VBP
led  ||| S:4295 E:4299 ||| VBN
to  ||| S:4299 E:4302 ||| TO
the  ||| S:4302 E:4306 ||| DT
development  ||| S:4306 E:4318 ||| NN
of  ||| S:4318 E:4321 ||| IN
a  ||| S:4321 E:4331 ||| DT
detailed  ||| S:4331 E:4340 ||| JJ
pharmacophore  ||| S:4340 E:4354 ||| JJ
model ||| S:4354 E:4359 ||| NN
,  ||| S:4359 E:4361 ||| ,
determining  ||| S:4361 E:4373 ||| VBG
specific  ||| S:4373 E:4382 ||| JJ
point  ||| S:4382 E:4396 ||| NN
interactions  ||| S:4396 E:4409 ||| NNS
between  ||| S:4409 E:4417 ||| IN
5-HT  ||| S:4417 E:4431 ||| CD
3  ||| S:4431 E:4433 ||| CD
antagonists  ||| S:4433 E:4445 ||| NNS
and  ||| S:4445 E:4449 ||| CC
binding  ||| S:4449 E:4457 ||| JJ
site  ||| S:4457 E:4462 ||| NN
amino  ||| S:4462 E:4476 ||| NN
acids  ||| S:4476 E:4482 ||| NN
has  ||| S:4482 E:4486 ||| VBZ
proven  ||| S:4486 E:4493 ||| VBN
difficult ||| S:4493 E:4502 ||| JJ
.  ||| S:4502 E:4504 ||| .
Mutagenesis  ||| S:4504 E:4516 ||| JJ
studies  ||| S:4516 E:4524 ||| NNS
have  ||| S:4524 E:4537 ||| VBP
identified  ||| S:4537 E:4548 ||| VBN
the  ||| S:4548 E:4552 ||| DT
interaction  ||| S:4552 E:4564 ||| NN
of  ||| S:4564 E:4567 ||| IN
amino  ||| S:4567 E:4573 ||| JJ
acids  ||| S:4573 E:4579 ||| JJ
W89  ||| S:4579 E:4583 ||| NN
and  ||| S:4583 E:4587 ||| CC
R91  ||| S:4587 E:4591 ||| CD
in  ||| S:4591 E:4602 ||| IN
the  ||| S:4602 E:4606 ||| DT
binding  ||| S:4606 E:4614 ||| NN
of  ||| S:4614 E:4617 ||| IN
5-HT  ||| S:4617 E:4631 ||| CD
3  ||| S:4631 E:4633 ||| CD
R  ||| S:4633 E:4635 ||| NN
ligands  ||| S:4635 E:4643 ||| NNS
[  ||| S:4643 E:4645 ||| -LRB-
24  ||| S:4645 E:4648 ||| CD
23  ||| S:4648 E:4651 ||| CD
]  ||| S:4651 E:4653 ||| -RRB-
.  ||| S:4653 E:4655 ||| .
Studies  ||| S:4655 E:4671 ||| NNS
conducted  ||| S:4671 E:4681 ||| VBN
in  ||| S:4681 E:4684 ||| IN
our  ||| S:4684 E:4688 ||| PRP$
laboratory  ||| S:4688 E:4699 ||| NN
have  ||| S:4699 E:4704 ||| VBP
identified  ||| S:4704 E:4715 ||| VBN
three  ||| S:4715 E:4729 ||| CD
additional  ||| S:4729 E:4740 ||| JJ
putative  ||| S:4740 E:4749 ||| JJ
binding  ||| S:4749 E:4757 ||| JJ
site  ||| S:4757 E:4762 ||| NN
residues  ||| S:4762 E:4771 ||| NNS
( ||| S:4771 E:4772 ||| -LRB-
Y140 ||| S:4772 E:4776 ||| NNP
,  ||| S:4776 E:4778 ||| ,
Y142 ||| S:4778 E:4782 ||| NNP
,  ||| S:4782 E:4784 ||| ,
and  ||| S:4784 E:4796 ||| CC
Y152 ||| S:4796 E:4800 ||| CD
)  ||| S:4800 E:4802 ||| -RRB-
[  ||| S:4802 E:4804 ||| -LRB-
25  ||| S:4804 E:4807 ||| CD
]  ||| S:4807 E:4809 ||| -RRB-
.  ||| S:4809 E:4811 ||| .
W89  ||| S:4811 E:4815 ||| NNP
and  ||| S:4815 E:4819 ||| CC
R91  ||| S:4819 E:4823 ||| NNP
are  ||| S:4823 E:4827 ||| VBP
present  ||| S:4827 E:4835 ||| JJ
in  ||| S:4835 E:4838 ||| IN
a  ||| S:4838 E:4840 ||| DT
conserved  ||| S:4840 E:4858 ||| JJ
region  ||| S:4858 E:4865 ||| NN
of  ||| S:4865 E:4868 ||| IN
LGIC  ||| S:4868 E:4873 ||| NNP
receptors  ||| S:4873 E:4883 ||| VBD
often  ||| S:4883 E:4889 ||| RB
referred  ||| S:4889 E:4898 ||| VBN
to  ||| S:4898 E:4901 ||| TO
as  ||| S:4901 E:4904 ||| RB
loop  ||| S:4904 E:4909 ||| JJ
D  ||| S:4909 E:4911 ||| NNP
[  ||| S:4911 E:4913 ||| -LRB-
24  ||| S:4913 E:4924 ||| CD
26  ||| S:4924 E:4927 ||| CD
]  ||| S:4927 E:4929 ||| -RRB-
.  ||| S:4929 E:4931 ||| .
Similarly ||| S:4931 E:4940 ||| RB
,  ||| S:4940 E:4942 ||| ,
Y140 ||| S:4942 E:4946 ||| NNP
,  ||| S:4946 E:4948 ||| ,
Y142  ||| S:4948 E:4953 ||| NNP
and  ||| S:4953 E:4957 ||| CC
Y152  ||| S:4957 E:4962 ||| NNP
are  ||| S:4962 E:4966 ||| VBP
located  ||| S:4966 E:4974 ||| VBN
in  ||| S:4974 E:4977 ||| IN
the  ||| S:4977 E:4989 ||| DT
region  ||| S:4989 E:4996 ||| NN
homologus  ||| S:4996 E:5006 ||| NN
to  ||| S:5006 E:5009 ||| TO
E  ||| S:5009 E:5011 ||| NN
loop  ||| S:5011 E:5016 ||| NN
region  ||| S:5016 E:5023 ||| NN
of  ||| S:5023 E:5026 ||| IN
nicotinic  ||| S:5026 E:5036 ||| JJ
AchR ||| S:5036 E:5040 ||| NN
.  ||| S:5040 E:5050 ||| .
In  ||| S:5050 E:5053 ||| IN
this  ||| S:5053 E:5058 ||| DT
study ||| S:5058 E:5063 ||| NN
,  ||| S:5063 E:5065 ||| ,
we  ||| S:5065 E:5068 ||| PRP
have  ||| S:5068 E:5073 ||| VBP
endeavoured  ||| S:5073 E:5085 ||| VBN
to  ||| S:5085 E:5088 ||| TO
identify  ||| S:5088 E:5097 ||| VB
the  ||| S:5097 E:5101 ||| DT
amino  ||| S:5101 E:5115 ||| JJ
acids  ||| S:5115 E:5121 ||| JJ
interacting  ||| S:5121 E:5133 ||| NN
with  ||| S:5133 E:5138 ||| IN
the  ||| S:5138 E:5142 ||| DT
different  ||| S:5142 E:5152 ||| JJ
functional  ||| S:5152 E:5163 ||| JJ
groups  ||| S:5163 E:5178 ||| NNS
present  ||| S:5178 E:5186 ||| JJ
on  ||| S:5186 E:5189 ||| IN
the  ||| S:5189 E:5193 ||| DT
lerisetron  ||| S:5193 E:5204 ||| JJ
molecule  ||| S:5204 E:5213 ||| NN
in  ||| S:5213 E:5216 ||| IN
order  ||| S:5216 E:5222 ||| NN
to  ||| S:5222 E:5225 ||| TO
develop  ||| S:5225 E:5233 ||| VB
a  ||| S:5233 E:5243 ||| DT
model  ||| S:5243 E:5249 ||| NN
for  ||| S:5249 E:5253 ||| IN
interaction  ||| S:5253 E:5265 ||| NN
of  ||| S:5265 E:5268 ||| IN
this  ||| S:5268 E:5273 ||| DT
compound  ||| S:5273 E:5282 ||| NN
with  ||| S:5282 E:5287 ||| IN
the  ||| S:5287 E:5291 ||| DT
5-HT  ||| S:5291 E:5305 ||| CD
3  ||| S:5305 E:5307 ||| CD
R.  ||| S:5307 E:5310 ||| NNP
Using  ||| S:5310 E:5316 ||| NNP
site  ||| S:5316 E:5321 ||| NN
directed  ||| S:5321 E:5330 ||| VBD
mutagenesis  ||| S:5330 E:5342 ||| VBN
in  ||| S:5342 E:5353 ||| IN
combination  ||| S:5353 E:5365 ||| NN
with  ||| S:5365 E:5370 ||| IN
analogs  ||| S:5370 E:5378 ||| NN
of  ||| S:5378 E:5381 ||| IN
lerisetron ||| S:5381 E:5391 ||| NN
,  ||| S:5391 E:5393 ||| ,
we  ||| S:5393 E:5396 ||| PRP
have  ||| S:5396 E:5401 ||| VBP
identified  ||| S:5401 E:5420 ||| VBN
amino  ||| S:5420 E:5426 ||| JJ
acids  ||| S:5426 E:5432 ||| NNS
that  ||| S:5432 E:5437 ||| WDT
appear  ||| S:5437 E:5444 ||| VBP
to  ||| S:5444 E:5447 ||| TO
interact  ||| S:5447 E:5456 ||| VB
selectively  ||| S:5456 E:5468 ||| RB
with  ||| S:5468 E:5473 ||| IN
the  ||| S:5473 E:5485 ||| DT
terminal  ||| S:5485 E:5494 ||| NN
amino  ||| S:5494 E:5500 ||| NN
group ||| S:5500 E:5505 ||| NN
,  ||| S:5505 E:5507 ||| ,
the  ||| S:5507 E:5511 ||| DT
N-benzyl  ||| S:5511 E:5520 ||| JJ
group  ||| S:5520 E:5526 ||| NN
and  ||| S:5526 E:5530 ||| CC
the  ||| S:5530 E:5534 ||| DT
aromatic  ||| S:5534 E:5551 ||| JJ
benzimidazole ||| S:5551 E:5564 ||| NN
.  ||| S:5564 E:5588 ||| .
Results  ||| S:5588 E:5615 ||| NNS
Functional  ||| S:5615 E:5626 ||| JJ
activity  ||| S:5626 E:5635 ||| NN
of  ||| S:5635 E:5638 ||| IN
lerisetron  ||| S:5638 E:5659 ||| JJ
Whole  ||| S:5659 E:5665 ||| JJ
cell  ||| S:5665 E:5670 ||| NN
patch-clamp  ||| S:5670 E:5682 ||| JJ
experiments  ||| S:5682 E:5694 ||| NNS
were  ||| S:5694 E:5699 ||| VBD
performed  ||| S:5699 E:5709 ||| VBN
to  ||| S:5709 E:5722 ||| TO
test  ||| S:5722 E:5727 ||| VB
the  ||| S:5727 E:5731 ||| DT
functional  ||| S:5731 E:5742 ||| JJ
activity  ||| S:5742 E:5751 ||| NN
of  ||| S:5751 E:5754 ||| IN
lerisetron ||| S:5754 E:5764 ||| NN
.  ||| S:5764 E:5766 ||| .
No  ||| S:5766 E:5769 ||| DT
response  ||| S:5769 E:5788 ||| NN
was  ||| S:5788 E:5792 ||| VBD
observed  ||| S:5792 E:5801 ||| VBN
when  ||| S:5801 E:5806 ||| WRB
lerisetron  ||| S:5806 E:5817 ||| NNS
was  ||| S:5817 E:5821 ||| VBD
applied  ||| S:5821 E:5829 ||| VBN
alone  ||| S:5829 E:5835 ||| RB
( ||| S:5835 E:5836 ||| -LRB-
data  ||| S:5836 E:5841 ||| NNS
not  ||| S:5841 E:5855 ||| RB
shown ||| S:5855 E:5860 ||| VBN
) ||| S:5860 E:5861 ||| -RRB-
.  ||| S:5861 E:5863 ||| .
When  ||| S:5863 E:5868 ||| WRB
co-applied  ||| S:5868 E:5879 ||| JJ
with  ||| S:5879 E:5884 ||| IN
5-HT ||| S:5884 E:5888 ||| NNP
,  ||| S:5888 E:5890 ||| ,
lerisetron  ||| S:5890 E:5901 ||| NN
inhibited  ||| S:5901 E:5921 ||| VBD
the  ||| S:5921 E:5925 ||| DT
absolute  ||| S:5925 E:5934 ||| JJ
magnitude  ||| S:5934 E:5944 ||| NN
of  ||| S:5944 E:5947 ||| IN
the  ||| S:5947 E:5951 ||| DT
response  ||| S:5951 E:5960 ||| NN
with  ||| S:5960 E:5965 ||| IN
no  ||| S:5965 E:5968 ||| DT
apparent  ||| S:5968 E:5987 ||| JJ
alteration  ||| S:5987 E:5998 ||| NN
of  ||| S:5998 E:6001 ||| IN
the  ||| S:6001 E:6005 ||| DT
response  ||| S:6005 E:6014 ||| NN
profile  ||| S:6014 E:6022 ||| NN
( ||| S:6022 E:6023 ||| -LRB-
Figure  ||| S:6023 E:6030 ||| NNP
2 ||| S:6030 E:6031 ||| CD
) ||| S:6031 E:6032 ||| -RRB-
.  ||| S:6032 E:6034 ||| .
The  ||| S:6034 E:6048 ||| DT
combination  ||| S:6048 E:6060 ||| NN
of  ||| S:6060 E:6063 ||| IN
several  ||| S:6063 E:6071 ||| JJ
identical  ||| S:6071 E:6081 ||| JJ
inhibition  ||| S:6081 E:6092 ||| JJ
experiments  ||| S:6092 E:6114 ||| NNS
produced  ||| S:6114 E:6123 ||| VBD
a  ||| S:6123 E:6125 ||| DT
K  ||| S:6125 E:6138 ||| NNP
i  ||| S:6138 E:6140 ||| FW
value  ||| S:6140 E:6146 ||| NN
of  ||| S:6146 E:6149 ||| IN
0.2  ||| S:6149 E:6153 ||| CD
±  ||| S:6153 E:6155 ||| CD
0.03  ||| S:6155 E:6160 ||| CD
nM  ||| S:6160 E:6163 ||| NN
for  ||| S:6163 E:6177 ||| IN
lerisetron  ||| S:6177 E:6188 ||| JJ
inhibition  ||| S:6188 E:6199 ||| NN
of  ||| S:6199 E:6202 ||| IN
the  ||| S:6202 E:6206 ||| DT
5-HT  ||| S:6206 E:6211 ||| JJ
induced  ||| S:6211 E:6219 ||| JJ
response ||| S:6219 E:6227 ||| NN
.  ||| S:6227 E:6229 ||| .
These  ||| S:6229 E:6245 ||| DT
data  ||| S:6245 E:6250 ||| NNS
correspond  ||| S:6250 E:6261 ||| VBP
well  ||| S:6261 E:6266 ||| RB
with  ||| S:6266 E:6271 ||| IN
previously  ||| S:6271 E:6282 ||| RB
reported  ||| S:6282 E:6291 ||| VBN
data  ||| S:6291 E:6296 ||| NNS
for  ||| S:6296 E:6310 ||| IN
this  ||| S:6310 E:6315 ||| DT
compound  ||| S:6315 E:6324 ||| NN
[  ||| S:6324 E:6326 ||| -LRB-
22  ||| S:6326 E:6329 ||| CD
]  ||| S:6329 E:6331 ||| -RRB-
and  ||| S:6331 E:6335 ||| CC
verify  ||| S:6335 E:6342 ||| VB
the  ||| S:6342 E:6346 ||| DT
competitive  ||| S:6346 E:6368 ||| JJ
antagonist  ||| S:6368 E:6379 ||| JJ
action  ||| S:6379 E:6386 ||| NN
of  ||| S:6386 E:6389 ||| IN
lerisetron ||| S:6389 E:6399 ||| NN
.  ||| S:6399 E:6401 ||| .
Analogs  ||| S:6401 E:6409 ||| NNP
of  ||| S:6409 E:6412 ||| IN
lerisetron  ||| S:6412 E:6433 ||| NNS
have  ||| S:6433 E:6438 ||| VBP
been  ||| S:6438 E:6443 ||| VBN
shown  ||| S:6443 E:6449 ||| VBN
to  ||| S:6449 E:6452 ||| TO
inhibit  ||| S:6452 E:6460 ||| VB
5-HT  ||| S:6460 E:6476 ||| CD
3  ||| S:6476 E:6478 ||| CD
Rs  ||| S:6478 E:6481 ||| NNS
in  ||| S:6481 E:6484 ||| IN
a  ||| S:6484 E:6486 ||| DT
similar  ||| S:6486 E:6494 ||| JJ
manner  ||| S:6494 E:6501 ||| NN
[  ||| S:6501 E:6503 ||| -LRB-
23  ||| S:6503 E:6506 ||| CD
]  ||| S:6506 E:6508 ||| -RRB-
.  ||| S:6508 E:6538 ||| .
Importance  ||| S:6538 E:6549 ||| NN
of  ||| S:6549 E:6552 ||| IN
the  ||| S:6552 E:6556 ||| DT
N-benzyl  ||| S:6556 E:6565 ||| JJ
and  ||| S:6565 E:6569 ||| CC
distal  ||| S:6569 E:6576 ||| JJ
piperazine  ||| S:6576 E:6597 ||| JJ
nitrogen  ||| S:6597 E:6606 ||| NN
to  ||| S:6606 E:6609 ||| TO
binding  ||| S:6609 E:6617 ||| VB
of  ||| S:6617 E:6620 ||| IN
lerisetron  ||| S:6620 E:6641 ||| VBG
The  ||| S:6641 E:6645 ||| DT
K  ||| S:6645 E:6658 ||| NNP
i  ||| S:6658 E:6660 ||| FW
value  ||| S:6660 E:6666 ||| NN
for  ||| S:6666 E:6670 ||| IN
lerisetron  ||| S:6670 E:6681 ||| JJ
inhibition  ||| S:6681 E:6692 ||| NN
of  ||| S:6692 E:6695 ||| IN
[  ||| S:6695 E:6707 ||| -LRB-
3H ||| S:6707 E:6709 ||| NNP
] ||| S:6709 E:6710 ||| -RRB-
-granisetron  ||| S:6710 E:6723 ||| JJ
binding  ||| S:6723 E:6731 ||| NN
to  ||| S:6731 E:6734 ||| TO
wildtype  ||| S:6734 E:6743 ||| VB
receptors  ||| S:6743 E:6753 ||| NNS
was  ||| S:6753 E:6767 ||| VBD
determined  ||| S:6767 E:6778 ||| VBN
to  ||| S:6778 E:6781 ||| TO
be  ||| S:6781 E:6784 ||| VB
0.8  ||| S:6784 E:6788 ||| CD
±  ||| S:6788 E:6790 ||| CD
0.19  ||| S:6790 E:6795 ||| CD
nM  ||| S:6795 E:6798 ||| NNS
( ||| S:6798 E:6799 ||| -LRB-
Figure  ||| S:6799 E:6806 ||| NNP
3and  ||| S:6806 E:6811 ||| NNP
Table  ||| S:6811 E:6817 ||| NNP
1 ||| S:6817 E:6818 ||| CD
) ||| S:6818 E:6819 ||| -RRB-
.  ||| S:6819 E:6831 ||| .
This  ||| S:6831 E:6836 ||| DT
value  ||| S:6836 E:6842 ||| NN
agrees  ||| S:6842 E:6849 ||| VBZ
with  ||| S:6849 E:6854 ||| IN
previously  ||| S:6854 E:6865 ||| RB
published  ||| S:6865 E:6875 ||| VBN
data  ||| S:6875 E:6880 ||| NNS
for  ||| S:6880 E:6884 ||| IN
this  ||| S:6884 E:6899 ||| DT
compound ||| S:6899 E:6907 ||| NN
.  ||| S:6907 E:6909 ||| .
The  ||| S:6909 E:6913 ||| DT
K  ||| S:6913 E:6926 ||| NNP
i  ||| S:6926 E:6928 ||| FW
values  ||| S:6928 E:6935 ||| NNS
for  ||| S:6935 E:6939 ||| IN
analogs  ||| S:6939 E:6947 ||| CD
1  ||| S:6947 E:6949 ||| CD
and  ||| S:6949 E:6953 ||| CC
2  ||| S:6953 E:6955 ||| CD
under  ||| S:6955 E:6971 ||| IN
identical  ||| S:6971 E:6981 ||| JJ
conditions  ||| S:6981 E:6992 ||| NNS
are  ||| S:6992 E:6996 ||| VBP
25  ||| S:6996 E:6999 ||| CD
±  ||| S:6999 E:7001 ||| CD
3.2  ||| S:7001 E:7005 ||| CD
nM  ||| S:7005 E:7008 ||| JJ
and  ||| S:7008 E:7012 ||| CC
320  ||| S:7012 E:7016 ||| CD
±  ||| S:7016 E:7018 ||| CD
82  ||| S:7018 E:7021 ||| CD
nM  ||| S:7021 E:7034 ||| JJ
respectively  ||| S:7034 E:7047 ||| NNS
( ||| S:7047 E:7048 ||| -LRB-
Figure  ||| S:7048 E:7055 ||| NNP
4A ||| S:7055 E:7057 ||| NNP
,  ||| S:7057 E:7059 ||| ,
Table  ||| S:7059 E:7065 ||| NNP
1 ||| S:7065 E:7066 ||| CD
) ||| S:7066 E:7067 ||| -RRB-
.  ||| S:7067 E:7069 ||| .
The  ||| S:7069 E:7073 ||| DT
observed  ||| S:7073 E:7082 ||| JJ
change  ||| S:7082 E:7089 ||| NN
in  ||| S:7089 E:7102 ||| IN
K  ||| S:7102 E:7115 ||| NNP
i  ||| S:7115 E:7117 ||| FW
represents  ||| S:7117 E:7128 ||| VBZ
the  ||| S:7128 E:7132 ||| DT
decreases  ||| S:7132 E:7142 ||| NN
in  ||| S:7142 E:7145 ||| IN
binding  ||| S:7145 E:7163 ||| JJ
energy  ||| S:7163 E:7170 ||| NN
resulting  ||| S:7170 E:7180 ||| VBG
from  ||| S:7180 E:7185 ||| IN
removal  ||| S:7185 E:7193 ||| NN
of  ||| S:7193 E:7196 ||| IN
the  ||| S:7196 E:7200 ||| DT
N-benzyl  ||| S:7200 E:7209 ||| JJ
group  ||| S:7209 E:7225 ||| NN
( ||| S:7225 E:7226 ||| -LRB-
analog  ||| S:7226 E:7233 ||| CD
1 ||| S:7233 E:7234 ||| CD
)  ||| S:7234 E:7236 ||| -RRB-
and  ||| S:7236 E:7240 ||| CC
the  ||| S:7240 E:7244 ||| DT
distal  ||| S:7244 E:7251 ||| FW
piperazine  ||| S:7251 E:7262 ||| FW
nitrogen  ||| S:7262 E:7271 ||| FW
( ||| S:7271 E:7272 ||| -LRB-
analog  ||| S:7272 E:7289 ||| CD
2 ||| S:7289 E:7290 ||| CD
) ||| S:7290 E:7291 ||| -RRB-
.  ||| S:7291 E:7321 ||| .
Identification  ||| S:7321 E:7336 ||| NN
of  ||| S:7336 E:7339 ||| IN
amino  ||| S:7339 E:7345 ||| JJ
acids  ||| S:7345 E:7351 ||| JJ
interacting  ||| S:7351 E:7363 ||| NN
with  ||| S:7363 E:7378 ||| IN
Lerisetron  ||| S:7378 E:7399 ||| NNP
In  ||| S:7399 E:7402 ||| IN
order  ||| S:7402 E:7408 ||| NN
to  ||| S:7408 E:7411 ||| TO
determine  ||| S:7411 E:7421 ||| VB
the  ||| S:7421 E:7425 ||| DT
nature  ||| S:7425 E:7432 ||| NN
of  ||| S:7432 E:7435 ||| IN
the  ||| S:7435 E:7439 ||| DT
amino  ||| S:7439 E:7445 ||| JJ
acids  ||| S:7445 E:7461 ||| JJ
interacting  ||| S:7461 E:7473 ||| NN
with  ||| S:7473 E:7478 ||| IN
the  ||| S:7478 E:7482 ||| DT
distal  ||| S:7482 E:7489 ||| JJ
amino  ||| S:7489 E:7495 ||| NN
and  ||| S:7495 E:7499 ||| CC
N-benzyl  ||| S:7499 E:7508 ||| JJ
groups  ||| S:7508 E:7515 ||| NNS
of  ||| S:7515 E:7528 ||| IN
lerisetron ||| S:7528 E:7538 ||| NN
,  ||| S:7538 E:7540 ||| ,
we  ||| S:7540 E:7543 ||| PRP
constructed  ||| S:7543 E:7555 ||| VBD
5-HT  ||| S:7555 E:7571 ||| NNP
3AS  ||| S:7571 E:7575 ||| NNP
Rs  ||| S:7575 E:7578 ||| NNP
containing  ||| S:7578 E:7589 ||| VBG
mutations  ||| S:7589 E:7599 ||| NNS
at  ||| S:7599 E:7602 ||| IN
W89 ||| S:7602 E:7605 ||| NNP
,  ||| S:7605 E:7617 ||| ,
R91 ||| S:7617 E:7620 ||| NNP
,  ||| S:7620 E:7622 ||| ,
Y140 ||| S:7622 E:7626 ||| NNP
,  ||| S:7626 E:7628 ||| ,
Y142  ||| S:7628 E:7633 ||| NNP
and  ||| S:7633 E:7637 ||| CC
Y152 ||| S:7637 E:7641 ||| NNP
.  ||| S:7641 E:7643 ||| .
Figure  ||| S:7643 E:7650 ||| NNP
3shows  ||| S:7650 E:7657 ||| NNP
inhibition  ||| S:7657 E:7668 ||| NN
of  ||| S:7668 E:7671 ||| IN
[  ||| S:7671 E:7683 ||| -LRB-
3H ||| S:7683 E:7685 ||| NNP
] ||| S:7685 E:7686 ||| -RRB-
-granisetron  ||| S:7686 E:7699 ||| JJ
binding  ||| S:7699 E:7707 ||| NN
by  ||| S:7707 E:7710 ||| IN
lerisetron  ||| S:7710 E:7721 ||| NN
on  ||| S:7721 E:7724 ||| IN
wildtype  ||| S:7724 E:7733 ||| NN
and  ||| S:7733 E:7747 ||| CC
mutant  ||| S:7747 E:7754 ||| JJ
receptors ||| S:7754 E:7763 ||| NNS
.  ||| S:7763 E:7765 ||| .
For  ||| S:7765 E:7769 ||| IN
most  ||| S:7769 E:7774 ||| RBS
amino  ||| S:7774 E:7780 ||| JJ
acids ||| S:7780 E:7785 ||| NNS
,  ||| S:7785 E:7787 ||| ,
an  ||| S:7787 E:7790 ||| DT
alanine  ||| S:7790 E:7808 ||| JJ
substitution  ||| S:7808 E:7821 ||| NN
was  ||| S:7821 E:7825 ||| VBD
constructed  ||| S:7825 E:7837 ||| VBN
in  ||| S:7837 E:7840 ||| IN
order  ||| S:7840 E:7846 ||| NN
to  ||| S:7846 E:7849 ||| TO
effectively  ||| S:7849 E:7871 ||| RB
remove  ||| S:7871 E:7878 ||| VB
any  ||| S:7878 E:7882 ||| DT
amino  ||| S:7882 E:7888 ||| JJ
acid  ||| S:7888 E:7893 ||| NN
interaction  ||| S:7893 E:7905 ||| NN
with  ||| S:7905 E:7910 ||| IN
the  ||| S:7910 E:7914 ||| DT
ligand ||| S:7914 E:7920 ||| NN
.  ||| S:7920 E:7922 ||| .
For  ||| S:7922 E:7936 ||| IN
W89 ||| S:7936 E:7939 ||| NNP
,  ||| S:7939 E:7941 ||| ,
an  ||| S:7941 E:7944 ||| DT
alanine  ||| S:7944 E:7952 ||| JJ
substitution  ||| S:7952 E:7965 ||| NN
has  ||| S:7965 E:7969 ||| VBZ
been  ||| S:7969 E:7974 ||| VBN
shown  ||| S:7974 E:7980 ||| VBN
to  ||| S:7980 E:7983 ||| TO
prevent  ||| S:7983 E:8001 ||| VB
binding  ||| S:8001 E:8009 ||| VBN
of  ||| S:8009 E:8012 ||| IN
[  ||| S:8012 E:8014 ||| -LRB-
3H ||| S:8014 E:8016 ||| NNP
] ||| S:8016 E:8017 ||| -RRB-
granisetron ||| S:8017 E:8028 ||| NN
;  ||| S:8028 E:8030 ||| :
therefore  ||| S:8030 E:8040 ||| RB
a  ||| S:8040 E:8042 ||| DT
less  ||| S:8042 E:8047 ||| RBR
severe  ||| S:8047 E:8064 ||| JJ
mutation  ||| S:8064 E:8073 ||| NN
was  ||| S:8073 E:8077 ||| VBD
constructed ||| S:8077 E:8088 ||| VBN
.  ||| S:8088 E:8100 ||| .
The  ||| S:8100 E:8104 ||| DT
W89F  ||| S:8104 E:8109 ||| JJ
mutation  ||| S:8109 E:8118 ||| NN
produces  ||| S:8118 E:8127 ||| VBZ
a  ||| S:8127 E:8129 ||| DT
18-fold  ||| S:8129 E:8137 ||| JJ
change  ||| S:8137 E:8144 ||| NN
in  ||| S:8144 E:8147 ||| IN
K  ||| S:8147 E:8160 ||| NNP
d  ||| S:8160 E:8162 ||| NN
for  ||| S:8162 E:8166 ||| IN
[  ||| S:8166 E:8168 ||| -LRB-
3H ||| S:8168 E:8170 ||| NNP
] ||| S:8170 E:8171 ||| -RRB-
-granisetron  ||| S:8171 E:8184 ||| JJ
binding  ||| S:8184 E:8192 ||| NNS
( ||| S:8192 E:8193 ||| -LRB-
18  ||| S:8193 E:8196 ||| CD
±  ||| S:8196 E:8208 ||| CD
2  ||| S:8208 E:8210 ||| CD
nM ||| S:8210 E:8212 ||| NN
)  ||| S:8212 E:8214 ||| -RRB-
and  ||| S:8214 E:8218 ||| CC
the  ||| S:8218 E:8222 ||| DT
W89Y  ||| S:8222 E:8227 ||| JJ
mutation  ||| S:8227 E:8236 ||| NN
produces  ||| S:8236 E:8245 ||| VBZ
a  ||| S:8245 E:8247 ||| DT
5.8-fold  ||| S:8247 E:8256 ||| JJ
change  ||| S:8256 E:8263 ||| NN
in  ||| S:8263 E:8276 ||| IN
K  ||| S:8276 E:8289 ||| NNP
d  ||| S:8289 E:8291 ||| NNS
( ||| S:8291 E:8292 ||| -LRB-
5.7  ||| S:8292 E:8296 ||| CD
±  ||| S:8296 E:8298 ||| CD
0.7  ||| S:8298 E:8302 ||| CD
nM ||| S:8302 E:8304 ||| NN
) ||| S:8304 E:8305 ||| -RRB-
.  ||| S:8305 E:8307 ||| .
Mutation  ||| S:8307 E:8316 ||| NN
of  ||| S:8316 E:8319 ||| IN
amino  ||| S:8319 E:8335 ||| JJ
acid  ||| S:8335 E:8340 ||| NN
R91  ||| S:8340 E:8344 ||| NN
to  ||| S:8344 E:8347 ||| TO
alanine  ||| S:8347 E:8355 ||| VB
produced  ||| S:8355 E:8364 ||| VBN
a  ||| S:8364 E:8366 ||| DT
5-fold  ||| S:8366 E:8373 ||| JJ
change  ||| S:8373 E:8380 ||| NN
in  ||| S:8380 E:8383 ||| IN
K  ||| S:8383 E:8396 ||| NNP
d  ||| S:8396 E:8398 ||| NN
for  ||| S:8398 E:8402 ||| IN
[  ||| S:8402 E:8404 ||| -LRB-
3H ||| S:8404 E:8406 ||| NNP
] ||| S:8406 E:8407 ||| -RRB-
granisetron  ||| S:8407 E:8419 ||| FW
binding  ||| S:8419 E:8427 ||| FW
( ||| S:8427 E:8428 ||| -LRB-
4.9  ||| S:8428 E:8432 ||| CD
±  ||| S:8432 E:8444 ||| CD
0.7  ||| S:8444 E:8448 ||| CD
nM ||| S:8448 E:8450 ||| NN
)  ||| S:8450 E:8452 ||| -RRB-
( ||| S:8452 E:8453 ||| -LRB-
Table  ||| S:8453 E:8459 ||| NNP
1 ||| S:8459 E:8460 ||| CD
) ||| S:8460 E:8461 ||| -RRB-
.  ||| S:8461 E:8463 ||| .
These  ||| S:8463 E:8469 ||| DT
data  ||| S:8469 E:8474 ||| NNS
agree  ||| S:8474 E:8480 ||| VBP
well  ||| S:8480 E:8485 ||| RB
with  ||| S:8485 E:8490 ||| IN
previously  ||| S:8490 E:8511 ||| RB
reported  ||| S:8511 E:8520 ||| VBN
values  ||| S:8520 E:8527 ||| NNS
[  ||| S:8527 E:8529 ||| -LRB-
24  ||| S:8529 E:8532 ||| CD
]  ||| S:8532 E:8534 ||| -RRB-
.  ||| S:8534 E:8536 ||| .
Alanine  ||| S:8536 E:8544 ||| JJ
mutations  ||| S:8544 E:8554 ||| NNS
at  ||| S:8554 E:8557 ||| IN
the  ||| S:8557 E:8571 ||| DT
tyrosine  ||| S:8571 E:8580 ||| JJ
positions  ||| S:8580 E:8590 ||| NNS
Y140 ||| S:8590 E:8594 ||| RB
,  ||| S:8594 E:8596 ||| ,
Y142  ||| S:8596 E:8601 ||| NNP
and  ||| S:8601 E:8605 ||| CC
Y152  ||| S:8605 E:8610 ||| NNP
also  ||| S:8610 E:8615 ||| RB
produced  ||| S:8615 E:8634 ||| VBN
minor  ||| S:8634 E:8640 ||| JJ
increases  ||| S:8640 E:8650 ||| NNS
in  ||| S:8650 E:8653 ||| IN
K  ||| S:8653 E:8666 ||| NNP
d  ||| S:8666 E:8668 ||| NN
for  ||| S:8668 E:8672 ||| IN
[  ||| S:8672 E:8674 ||| -LRB-
3H ||| S:8674 E:8676 ||| NNP
] ||| S:8676 E:8677 ||| -RRB-
granisetron  ||| S:8677 E:8689 ||| FW
binding  ||| S:8689 E:8697 ||| FW
( ||| S:8697 E:8698 ||| -LRB-
2.7  ||| S:8698 E:8702 ||| CD
±  ||| S:8702 E:8714 ||| CD
0.19  ||| S:8714 E:8719 ||| CD
nM ||| S:8719 E:8721 ||| NN
,  ||| S:8721 E:8723 ||| ,
4.5  ||| S:8723 E:8727 ||| CD
±  ||| S:8727 E:8729 ||| CD
0.5  ||| S:8729 E:8733 ||| CD
nM  ||| S:8733 E:8736 ||| JJ
and  ||| S:8736 E:8740 ||| CC
7.8  ||| S:8740 E:8744 ||| CD
±  ||| S:8744 E:8746 ||| CD
1.1  ||| S:8746 E:8750 ||| CD
nM  ||| S:8750 E:8753 ||| JJ
respectively ||| S:8753 E:8765 ||| NN
)  ||| S:8765 E:8767 ||| -RRB-
[  ||| S:8767 E:8769 ||| -LRB-
25  ||| S:8769 E:8782 ||| CD
]  ||| S:8782 E:8784 ||| -RRB-
( ||| S:8784 E:8785 ||| -LRB-
Table  ||| S:8785 E:8791 ||| NNP
1 ||| S:8791 E:8792 ||| CD
) ||| S:8792 E:8793 ||| -RRB-
.  ||| S:8793 E:8805 ||| .
Only  ||| S:8805 E:8810 ||| RB
small  ||| S:8810 E:8816 ||| JJ
changes  ||| S:8816 E:8824 ||| NNS
in  ||| S:8824 E:8827 ||| IN
K  ||| S:8827 E:8840 ||| NNP
i  ||| S:8840 E:8842 ||| NN
for  ||| S:8842 E:8846 ||| IN
lerisetron  ||| S:8846 E:8857 ||| NN
were  ||| S:8857 E:8862 ||| VBD
observed  ||| S:8862 E:8871 ||| VBN
for  ||| S:8871 E:8875 ||| IN
the  ||| S:8875 E:8889 ||| DT
Y140A  ||| S:8889 E:8895 ||| JJ
mutation  ||| S:8895 E:8904 ||| NN
while  ||| S:8904 E:8910 ||| IN
the  ||| S:8910 E:8914 ||| DT
Y142A  ||| S:8914 E:8920 ||| NNP
and  ||| S:8920 E:8924 ||| CC
Y152A  ||| S:8924 E:8930 ||| CD
mutations  ||| S:8930 E:8950 ||| NNS
produced  ||| S:8950 E:8959 ||| VBD
large  ||| S:8959 E:8965 ||| JJ
increases  ||| S:8965 E:8975 ||| NNS
in  ||| S:8975 E:8978 ||| IN
the  ||| S:8978 E:8982 ||| DT
K  ||| S:8982 E:8995 ||| NNP
i  ||| S:8995 E:8997 ||| FW
( ||| S:8997 E:8998 ||| -LRB-
Table  ||| S:8998 E:9004 ||| NNP
1and  ||| S:9004 E:9009 ||| NNP
Figure  ||| S:9009 E:9016 ||| NNP
3 ||| S:9016 E:9017 ||| CD
) ||| S:9017 E:9018 ||| -RRB-
.  ||| S:9018 E:9020 ||| .
For  ||| S:9020 E:9024 ||| IN
W89F  ||| S:9024 E:9029 ||| NNP
and  ||| S:9029 E:9043 ||| CC
W89Y ||| S:9043 E:9047 ||| NNP
,  ||| S:9047 E:9049 ||| ,
the  ||| S:9049 E:9053 ||| DT
changes  ||| S:9053 E:9061 ||| NNS
in  ||| S:9061 E:9064 ||| IN
K  ||| S:9064 E:9077 ||| NNP
i  ||| S:9077 E:9079 ||| VBD
observed  ||| S:9079 E:9088 ||| VBN
for  ||| S:9088 E:9092 ||| IN
lerisetron  ||| S:9092 E:9103 ||| NN
were  ||| S:9103 E:9108 ||| VBD
much  ||| S:9108 E:9123 ||| RB
smaller  ||| S:9123 E:9131 ||| JJR
than  ||| S:9131 E:9136 ||| IN
for  ||| S:9136 E:9140 ||| IN
the  ||| S:9140 E:9144 ||| DT
alanine  ||| S:9144 E:9152 ||| JJ
mutations  ||| S:9152 E:9162 ||| NNS
at  ||| S:9162 E:9165 ||| IN
Y142A  ||| S:9165 E:9171 ||| NNP
and  ||| S:9171 E:9185 ||| CC
Y152A ||| S:9185 E:9190 ||| NNP
,  ||| S:9190 E:9192 ||| ,
as  ||| S:9192 E:9195 ||| RB
would  ||| S:9195 E:9201 ||| MD
be  ||| S:9201 E:9204 ||| VB
expected  ||| S:9204 E:9213 ||| VBN
for  ||| S:9213 E:9217 ||| IN
the  ||| S:9217 E:9221 ||| DT
less  ||| S:9221 E:9226 ||| RBR
severe  ||| S:9226 E:9233 ||| JJ
nature  ||| S:9233 E:9240 ||| NN
of  ||| S:9240 E:9253 ||| IN
these  ||| S:9253 E:9259 ||| DT
mutations ||| S:9259 E:9268 ||| NN
.  ||| S:9268 E:9270 ||| .
The  ||| S:9270 E:9274 ||| DT
changes  ||| S:9274 E:9282 ||| NNS
were ||| S:9282 E:9286 ||| VBD
,  ||| S:9286 E:9288 ||| ,
however  ||| S:9288 E:9296 ||| RB
significant  ||| S:9296 E:9308 ||| JJ
( ||| S:9308 E:9309 ||| -LRB-
p  ||| S:9309 E:9321 ||| JJ
< ||| S:9321 E:9323 ||| SYM
0.001  ||| S:9323 E:9329 ||| NN
in  ||| S:9329 E:9332 ||| IN
both  ||| S:9332 E:9337 ||| DT
cases ||| S:9337 E:9342 ||| NNS
)  ||| S:9342 E:9344 ||| -RRB-
and  ||| S:9344 E:9348 ||| CC
are  ||| S:9348 E:9352 ||| VBP
similar  ||| S:9352 E:9360 ||| JJ
to  ||| S:9360 E:9363 ||| TO
the  ||| S:9363 E:9367 ||| DT
changes  ||| S:9367 E:9385 ||| NNS
in  ||| S:9385 E:9388 ||| IN
K  ||| S:9388 E:9401 ||| NNP
d  ||| S:9401 E:9403 ||| VBD
reported  ||| S:9403 E:9412 ||| VBN
for  ||| S:9412 E:9416 ||| IN
[  ||| S:9416 E:9418 ||| -LRB-
3H ||| S:9418 E:9420 ||| NNP
] ||| S:9420 E:9421 ||| -RRB-
granisetron ||| S:9421 E:9432 ||| NN
.  ||| S:9432 E:9434 ||| .
The  ||| S:9434 E:9448 ||| DT
increase  ||| S:9448 E:9457 ||| NN
in  ||| S:9457 E:9460 ||| IN
K  ||| S:9460 E:9473 ||| NNP
i  ||| S:9473 E:9475 ||| NN
on  ||| S:9475 E:9478 ||| IN
the  ||| S:9478 E:9482 ||| DT
W89F  ||| S:9482 E:9487 ||| JJ
mutant  ||| S:9487 E:9494 ||| JJ
receptor  ||| S:9494 E:9503 ||| NN
was  ||| S:9503 E:9507 ||| VBD
4.8  ||| S:9507 E:9521 ||| CD
±  ||| S:9521 E:9523 ||| CD
0.56  ||| S:9523 E:9528 ||| CD
fold  ||| S:9528 E:9533 ||| NNS
and  ||| S:9533 E:9537 ||| CC
the  ||| S:9537 E:9541 ||| DT
increase  ||| S:9541 E:9550 ||| NN
in  ||| S:9550 E:9553 ||| IN
K  ||| S:9553 E:9566 ||| NNP
i  ||| S:9566 E:9568 ||| NN
on  ||| S:9568 E:9571 ||| IN
the  ||| S:9571 E:9575 ||| DT
W89Y  ||| S:9575 E:9580 ||| JJ
receptor  ||| S:9580 E:9589 ||| NN
was  ||| S:9589 E:9593 ||| VBD
3.6  ||| S:9593 E:9597 ||| CD
±  ||| S:9597 E:9599 ||| CD
0.4  ||| S:9599 E:9613 ||| CD
fold ||| S:9613 E:9617 ||| NNS
.  ||| S:9617 E:9619 ||| .
The  ||| S:9619 E:9623 ||| DT
R91A  ||| S:9623 E:9628 ||| CD
mutant  ||| S:9628 E:9635 ||| NNS
produced  ||| S:9635 E:9644 ||| VBD
an  ||| S:9644 E:9647 ||| DT
increase  ||| S:9647 E:9656 ||| NN
in  ||| S:9656 E:9659 ||| IN
K  ||| S:9659 E:9672 ||| NNP
i  ||| S:9672 E:9674 ||| NN
of  ||| S:9674 E:9677 ||| IN
7.6  ||| S:9677 E:9681 ||| CD
±  ||| S:9681 E:9683 ||| CD
1.5  ||| S:9683 E:9687 ||| CD
fold  ||| S:9687 E:9692 ||| NNS
as  ||| S:9692 E:9695 ||| RB
compared  ||| S:9695 E:9704 ||| VBN
to  ||| S:9704 E:9707 ||| TO
the  ||| S:9707 E:9721 ||| DT
wildtype  ||| S:9721 E:9730 ||| JJ
receptor ||| S:9730 E:9738 ||| NN
.  ||| S:9738 E:9740 ||| .
These  ||| S:9740 E:9746 ||| DT
data  ||| S:9746 E:9751 ||| NNS
indicated  ||| S:9751 E:9761 ||| VBD
potential  ||| S:9761 E:9781 ||| JJ
interactions  ||| S:9781 E:9794 ||| NNS
of  ||| S:9794 E:9797 ||| IN
lerisetron  ||| S:9797 E:9808 ||| NN
with  ||| S:9808 E:9813 ||| IN
W89 ||| S:9813 E:9816 ||| NNP
,  ||| S:9816 E:9818 ||| ,
R91 ||| S:9818 E:9821 ||| NNP
,  ||| S:9821 E:9823 ||| ,
Y142  ||| S:9823 E:9828 ||| NNP
and  ||| S:9828 E:9842 ||| CC
Y152 ||| S:9842 E:9846 ||| NNP
.  ||| S:9846 E:9876 ||| .
Mutation  ||| S:9876 E:9885 ||| NN
of  ||| S:9885 E:9888 ||| IN
W89  ||| S:9888 E:9902 ||| CD
As  ||| S:9902 E:9905 ||| IN
mentioned  ||| S:9905 E:9915 ||| VBN
above ||| S:9915 E:9920 ||| IN
,  ||| S:9920 E:9922 ||| ,
the  ||| S:9922 E:9926 ||| DT
lack  ||| S:9926 E:9931 ||| NN
of  ||| S:9931 E:9934 ||| IN
[  ||| S:9934 E:9936 ||| -LRB-
3H ||| S:9936 E:9938 ||| NNP
] ||| S:9938 E:9939 ||| -RRB-
-granisetron  ||| S:9939 E:9962 ||| JJ
binding  ||| S:9962 E:9970 ||| NN
to  ||| S:9970 E:9973 ||| TO
W89A  ||| S:9973 E:9978 ||| CD
mutant  ||| S:9978 E:9985 ||| CD
receptors  ||| S:9985 E:9995 ||| NNS
necessitated  ||| S:9995 E:10008 ||| VBD
the  ||| S:10008 E:10012 ||| DT
use  ||| S:10012 E:10016 ||| NN
of  ||| S:10016 E:10029 ||| IN
W89F  ||| S:10029 E:10034 ||| NNP
and  ||| S:10034 E:10038 ||| CC
W89Y  ||| S:10038 E:10043 ||| CD
mutations  ||| S:10043 E:10053 ||| NNS
to  ||| S:10053 E:10056 ||| TO
analyze  ||| S:10056 E:10064 ||| VB
functional  ||| S:10064 E:10075 ||| JJ
group  ||| S:10075 E:10091 ||| NN
interactions ||| S:10091 E:10103 ||| NNS
.  ||| S:10103 E:10105 ||| .
The  ||| S:10105 E:10109 ||| DT
effects  ||| S:10109 E:10117 ||| NNS
of  ||| S:10117 E:10120 ||| IN
these  ||| S:10120 E:10126 ||| DT
mutations  ||| S:10126 E:10136 ||| NN
on  ||| S:10136 E:10139 ||| IN
the  ||| S:10139 E:10143 ||| DT
K  ||| S:10143 E:10156 ||| NNP
i  ||| S:10156 E:10158 ||| NN
for  ||| S:10158 E:10162 ||| IN
analogs  ||| S:10162 E:10170 ||| CD
1  ||| S:10170 E:10172 ||| CD
and  ||| S:10172 E:10176 ||| CC
2  ||| S:10176 E:10178 ||| CD
are  ||| S:10178 E:10182 ||| VBP
shown  ||| S:10182 E:10188 ||| VBN
in  ||| S:10188 E:10201 ||| IN
figure  ||| S:10201 E:10208 ||| NN
4B ||| S:10208 E:10210 ||| NN
,  ||| S:10210 E:10212 ||| ,
4Cand  ||| S:10212 E:10218 ||| NNP
Table  ||| S:10218 E:10224 ||| NNP
1 ||| S:10224 E:10225 ||| CD
.  ||| S:10225 E:10227 ||| .
Analog  ||| S:10227 E:10234 ||| NNP
1  ||| S:10234 E:10236 ||| CD
inhibited  ||| S:10236 E:10246 ||| NNS
[  ||| S:10246 E:10258 ||| -LRB-
3H ||| S:10258 E:10260 ||| NNP
] ||| S:10260 E:10261 ||| -RRB-
-granisetron  ||| S:10261 E:10274 ||| JJ
binding  ||| S:10274 E:10282 ||| NN
to  ||| S:10282 E:10285 ||| TO
W89F  ||| S:10285 E:10290 ||| CD
receptors  ||| S:10290 E:10300 ||| NNS
with  ||| S:10300 E:10305 ||| IN
a  ||| S:10305 E:10307 ||| DT
K  ||| S:10307 E:10320 ||| NNP
i  ||| S:10320 E:10322 ||| NN
of  ||| S:10322 E:10325 ||| IN
170  ||| S:10325 E:10329 ||| CD
±  ||| S:10329 E:10331 ||| CD
54  ||| S:10331 E:10334 ||| CD
nM  ||| S:10334 E:10337 ||| NNS
( ||| S:10337 E:10338 ||| -LRB-
7  ||| S:10338 E:10340 ||| CD
±  ||| S:10340 E:10342 ||| CD
3.2  ||| S:10342 E:10346 ||| CD
fold  ||| S:10346 E:10361 ||| JJ
increase ||| S:10361 E:10369 ||| NN
,  ||| S:10369 E:10371 ||| ,
p  ||| S:10371 E:10373 ||| CD
< ||| S:10373 E:10375 ||| SYM
0.001 ||| S:10375 E:10380 ||| CD
)  ||| S:10380 E:10382 ||| -RRB-
and  ||| S:10382 E:10386 ||| CC
W89Y  ||| S:10386 E:10391 ||| CD
receptors  ||| S:10391 E:10401 ||| NNS
with  ||| S:10401 E:10406 ||| IN
a  ||| S:10406 E:10408 ||| DT
K  ||| S:10408 E:10421 ||| NNP
i  ||| S:10421 E:10423 ||| NN
of  ||| S:10423 E:10426 ||| IN
81  ||| S:10426 E:10429 ||| CD
±  ||| S:10429 E:10431 ||| CD
14  ||| S:10431 E:10434 ||| CD
nM  ||| S:10434 E:10437 ||| NNS
( ||| S:10437 E:10438 ||| -LRB-
3.2  ||| S:10438 E:10442 ||| CD
±  ||| S:10442 E:10444 ||| CD
0.6  ||| S:10444 E:10448 ||| CD
fold  ||| S:10448 E:10463 ||| JJ
increase ||| S:10463 E:10471 ||| NN
,  ||| S:10471 E:10473 ||| ,
p  ||| S:10473 E:10475 ||| CD
< ||| S:10475 E:10477 ||| SYM
0.001 ||| S:10477 E:10482 ||| CD
) ||| S:10482 E:10483 ||| -RRB-
.  ||| S:10483 E:10485 ||| .
This  ||| S:10485 E:10490 ||| DT
reflects  ||| S:10490 E:10499 ||| VBZ
a  ||| S:10499 E:10501 ||| DT
significant  ||| S:10501 E:10523 ||| JJ
increase  ||| S:10523 E:10532 ||| NN
in  ||| S:10532 E:10535 ||| IN
K  ||| S:10535 E:10548 ||| NNP
i  ||| S:10548 E:10550 ||| FW
and  ||| S:10550 E:10554 ||| CC
reflects  ||| S:10554 E:10563 ||| VBZ
a  ||| S:10563 E:10565 ||| DT
potential  ||| S:10565 E:10575 ||| JJ
interaction  ||| S:10575 E:10597 ||| NN
of  ||| S:10597 E:10600 ||| IN
analog  ||| S:10600 E:10607 ||| CD
1  ||| S:10607 E:10609 ||| CD
with  ||| S:10609 E:10614 ||| IN
W89 ||| S:10614 E:10617 ||| CD
.  ||| S:10617 E:10619 ||| .
The  ||| S:10619 E:10623 ||| DT
strength  ||| S:10623 E:10632 ||| NN
of  ||| S:10632 E:10635 ||| IN
this  ||| S:10635 E:10640 ||| DT
interaction  ||| S:10640 E:10652 ||| NN
is  ||| S:10652 E:10665 ||| VBZ
apparently  ||| S:10665 E:10676 ||| RB
similar  ||| S:10676 E:10684 ||| JJ
to  ||| S:10684 E:10687 ||| TO
the  ||| S:10687 E:10691 ||| DT
strength  ||| S:10691 E:10700 ||| NN
of  ||| S:10700 E:10703 ||| IN
the  ||| S:10703 E:10707 ||| DT
interaction  ||| S:10707 E:10729 ||| NN
with  ||| S:10729 E:10734 ||| IN
[  ||| S:10734 E:10736 ||| -LRB-
3H ||| S:10736 E:10738 ||| NNP
] ||| S:10738 E:10739 ||| -RRB-
-granisetron  ||| S:10739 E:10752 ||| JJ
and  ||| S:10752 E:10756 ||| CC
lerisetron  ||| S:10756 E:10767 ||| NN
since  ||| S:10767 E:10773 ||| IN
the  ||| S:10773 E:10777 ||| DT
magnitude  ||| S:10777 E:10797 ||| NN
of  ||| S:10797 E:10800 ||| IN
the  ||| S:10800 E:10804 ||| DT
change  ||| S:10804 E:10811 ||| NN
is  ||| S:10811 E:10814 ||| VBZ
similar  ||| S:10814 E:10822 ||| JJ
in  ||| S:10822 E:10825 ||| IN
both  ||| S:10825 E:10830 ||| DT
cases ||| S:10830 E:10835 ||| NNS
.  ||| S:10835 E:10837 ||| .
Analog  ||| S:10837 E:10844 ||| NNP
2  ||| S:10844 E:10846 ||| CD
also  ||| S:10846 E:10861 ||| RB
showed  ||| S:10861 E:10868 ||| VBD
a  ||| S:10868 E:10870 ||| DT
significant  ||| S:10870 E:10882 ||| JJ
increase  ||| S:10882 E:10891 ||| NN
in  ||| S:10891 E:10894 ||| IN
K  ||| S:10894 E:10907 ||| NNP
i  ||| S:10907 E:10909 ||| NN
as  ||| S:10909 E:10912 ||| IN
a  ||| S:10912 E:10914 ||| DT
result  ||| S:10914 E:10921 ||| NN
of  ||| S:10921 E:10924 ||| IN
the  ||| S:10924 E:10928 ||| DT
W89F  ||| S:10928 E:10933 ||| NNP
and  ||| S:10933 E:10937 ||| CC
W89Y  ||| S:10937 E:10952 ||| CD
mutations ||| S:10952 E:10961 ||| NNS
.  ||| S:10961 E:10963 ||| .
The  ||| S:10963 E:10967 ||| DT
magnitude  ||| S:10967 E:10977 ||| NN
of  ||| S:10977 E:10980 ||| IN
the  ||| S:10980 E:10984 ||| DT
change  ||| S:10984 E:10991 ||| NN
for  ||| S:10991 E:10995 ||| IN
W89F  ||| S:10995 E:11000 ||| NNP
( ||| S:11000 E:11001 ||| -LRB-
5.1  ||| S:11001 E:11005 ||| CD
±  ||| S:11005 E:11017 ||| CD
1.3  ||| S:11017 E:11021 ||| CD
fold ||| S:11021 E:11025 ||| NN
,  ||| S:11025 E:11027 ||| ,
p  ||| S:11027 E:11029 ||| CD
< ||| S:11029 E:11031 ||| SYM
0.05 ||| S:11031 E:11035 ||| CD
)  ||| S:11035 E:11037 ||| -RRB-
was  ||| S:11037 E:11041 ||| VBD
similar  ||| S:11041 E:11049 ||| JJ
to  ||| S:11049 E:11052 ||| TO
that  ||| S:11052 E:11057 ||| WDT
observed  ||| S:11057 E:11066 ||| VBD
for  ||| S:11066 E:11080 ||| IN
lerisetron  ||| S:11080 E:11091 ||| NN
and  ||| S:11091 E:11095 ||| CC
analog  ||| S:11095 E:11102 ||| CD
1 ||| S:11102 E:11103 ||| CD
.  ||| S:11103 E:11105 ||| .
The  ||| S:11105 E:11109 ||| DT
W89Y  ||| S:11109 E:11114 ||| JJ
mutation  ||| S:11114 E:11123 ||| NN
produced  ||| S:11123 E:11132 ||| VBD
a  ||| S:11132 E:11134 ||| DT
6.8  ||| S:11134 E:11148 ||| CD
±  ||| S:11148 E:11150 ||| CD
1.6  ||| S:11150 E:11154 ||| CD
fold  ||| S:11154 E:11159 ||| JJ
change  ||| S:11159 E:11166 ||| NN
in  ||| S:11166 E:11169 ||| IN
K  ||| S:11169 E:11182 ||| NNP
i  ||| S:11182 E:11184 ||| FW
( ||| S:11184 E:11185 ||| -LRB-
p  ||| S:11185 E:11187 ||| CD
< ||| S:11187 E:11189 ||| SYM
0.05 ||| S:11189 E:11193 ||| CD
) ||| S:11193 E:11194 ||| -RRB-
.  ||| S:11194 E:11196 ||| .
Thus ||| S:11196 E:11200 ||| RB
,  ||| S:11200 E:11202 ||| ,
all  ||| S:11202 E:11206 ||| DT
three  ||| S:11206 E:11222 ||| CD
compounds  ||| S:11222 E:11232 ||| NNS
appear  ||| S:11232 E:11239 ||| VBP
to  ||| S:11239 E:11242 ||| TO
form  ||| S:11242 E:11247 ||| VB
similar  ||| S:11247 E:11255 ||| JJ
interactions  ||| S:11255 E:11268 ||| NNS
with  ||| S:11268 E:11283 ||| IN
W89 ||| S:11283 E:11286 ||| CD
.  ||| S:11286 E:11316 ||| .
Mutation  ||| S:11316 E:11325 ||| NN
of  ||| S:11325 E:11328 ||| IN
R91  ||| S:11328 E:11342 ||| NNP
Mutation  ||| S:11342 E:11351 ||| NNP
of  ||| S:11351 E:11354 ||| IN
R91  ||| S:11354 E:11358 ||| CD
to  ||| S:11358 E:11361 ||| TO
alanine  ||| S:11361 E:11369 ||| VB
( ||| S:11369 E:11370 ||| -LRB-
R91A ||| S:11370 E:11374 ||| NNP
)  ||| S:11374 E:11376 ||| -RRB-
resulted  ||| S:11376 E:11385 ||| VBD
in  ||| S:11385 E:11388 ||| IN
a  ||| S:11388 E:11400 ||| DT
significant ||| S:11400 E:11411 ||| JJ
,  ||| S:11411 E:11413 ||| ,
but  ||| S:11413 E:11417 ||| CC
small  ||| S:11417 E:11423 ||| JJ
increase  ||| S:11423 E:11432 ||| NN
in  ||| S:11432 E:11435 ||| IN
K  ||| S:11435 E:11448 ||| NNP
i  ||| S:11448 E:11450 ||| NN
for  ||| S:11450 E:11454 ||| IN
lerisetron  ||| S:11454 E:11465 ||| NN
of  ||| S:11465 E:11468 ||| IN
7.6  ||| S:11468 E:11472 ||| CD
±  ||| S:11472 E:11474 ||| CD
1.5  ||| S:11474 E:11478 ||| CD
fold  ||| S:11478 E:11483 ||| NNS
( ||| S:11483 E:11484 ||| -LRB-
p  ||| S:11484 E:11496 ||| CD
< ||| S:11496 E:11498 ||| SYM
0.01 ||| S:11498 E:11502 ||| CD
) ||| S:11502 E:11503 ||| -RRB-
.  ||| S:11503 E:11505 ||| .
Figure  ||| S:11505 E:11512 ||| NN
4Dshows  ||| S:11512 E:11520 ||| VBZ
the  ||| S:11520 E:11524 ||| DT
inhibition  ||| S:11524 E:11535 ||| NN
of  ||| S:11535 E:11538 ||| IN
[  ||| S:11538 E:11550 ||| -LRB-
3H ||| S:11550 E:11552 ||| NNP
] ||| S:11552 E:11553 ||| -RRB-
-granisetron  ||| S:11553 E:11566 ||| JJ
binding  ||| S:11566 E:11574 ||| NN
by  ||| S:11574 E:11577 ||| IN
analogs  ||| S:11577 E:11585 ||| CD
1  ||| S:11585 E:11587 ||| CD
and  ||| S:11587 E:11591 ||| CC
2  ||| S:11591 E:11593 ||| CD
at  ||| S:11593 E:11596 ||| IN
R91A  ||| S:11596 E:11601 ||| CD
mutant  ||| S:11601 E:11618 ||| CD
receptors ||| S:11618 E:11627 ||| NNS
.  ||| S:11627 E:11629 ||| .
No  ||| S:11629 E:11632 ||| DT
significant  ||| S:11632 E:11644 ||| JJ
change  ||| S:11644 E:11651 ||| NN
in  ||| S:11651 E:11654 ||| IN
K  ||| S:11654 E:11667 ||| NNP
i  ||| S:11667 E:11669 ||| NN
was  ||| S:11669 E:11673 ||| VBD
observed  ||| S:11673 E:11682 ||| VBN
on  ||| S:11682 E:11685 ||| IN
these  ||| S:11685 E:11691 ||| DT
receptors  ||| S:11691 E:11701 ||| NN
for  ||| S:11701 E:11715 ||| IN
either  ||| S:11715 E:11722 ||| DT
analog  ||| S:11722 E:11729 ||| JJ
1  ||| S:11729 E:11731 ||| CD
( ||| S:11731 E:11732 ||| -LRB-
0.9  ||| S:11732 E:11736 ||| CD
±  ||| S:11736 E:11738 ||| CD
0.28  ||| S:11738 E:11743 ||| CD
fold ||| S:11743 E:11747 ||| CD
)  ||| S:11747 E:11749 ||| -RRB-
or  ||| S:11749 E:11752 ||| CC
analog  ||| S:11752 E:11759 ||| CD
2  ||| S:11759 E:11761 ||| CD
( ||| S:11761 E:11762 ||| -LRB-
0.56  ||| S:11762 E:11767 ||| CD
±  ||| S:11767 E:11779 ||| CD
0.14  ||| S:11779 E:11784 ||| CD
fold ||| S:11784 E:11788 ||| CD
)  ||| S:11788 E:11790 ||| -RRB-
( ||| S:11790 E:11791 ||| -LRB-
Table  ||| S:11791 E:11797 ||| NNP
1 ||| S:11797 E:11798 ||| CD
)  ||| S:11798 E:11800 ||| -RRB-
as  ||| S:11800 E:11803 ||| RB
compared  ||| S:11803 E:11812 ||| VBN
to  ||| S:11812 E:11815 ||| TO
the  ||| S:11815 E:11819 ||| DT
wildtype  ||| S:11819 E:11838 ||| JJ
receptor ||| S:11838 E:11846 ||| NN
.  ||| S:11846 E:11876 ||| .
Mutation  ||| S:11876 E:11885 ||| NN
of  ||| S:11885 E:11888 ||| IN
Y142  ||| S:11888 E:11903 ||| NNP
Mutation  ||| S:11903 E:11912 ||| NNP
of  ||| S:11912 E:11915 ||| IN
Y142  ||| S:11915 E:11920 ||| CD
to  ||| S:11920 E:11923 ||| TO
alanine  ||| S:11923 E:11931 ||| VB
produced  ||| S:11931 E:11940 ||| VBN
one  ||| S:11940 E:11944 ||| CD
of  ||| S:11944 E:11947 ||| IN
the  ||| S:11947 E:11961 ||| DT
largest  ||| S:11961 E:11969 ||| JJS
observed  ||| S:11969 E:11978 ||| JJ
changes  ||| S:11978 E:11986 ||| NNS
in  ||| S:11986 E:11989 ||| IN
K  ||| S:11989 E:12002 ||| NNP
i  ||| S:12002 E:12004 ||| NN
for  ||| S:12004 E:12008 ||| IN
lerisetron  ||| S:12008 E:12019 ||| NNS
( ||| S:12019 E:12020 ||| -LRB-
Figure  ||| S:12020 E:12027 ||| NNP
3and  ||| S:12027 E:12032 ||| NNP
Table  ||| S:12032 E:12048 ||| NNP
1 ||| S:12048 E:12049 ||| CD
) ||| S:12049 E:12050 ||| -RRB-
.  ||| S:12050 E:12052 ||| .
The  ||| S:12052 E:12056 ||| DT
K  ||| S:12056 E:12069 ||| NNP
i  ||| S:12069 E:12071 ||| VBD
obtained  ||| S:12071 E:12080 ||| VBN
for  ||| S:12080 E:12084 ||| IN
lerisetron  ||| S:12084 E:12095 ||| NN
was  ||| S:12095 E:12099 ||| VBD
130  ||| S:12099 E:12103 ||| CD
±  ||| S:12103 E:12105 ||| CD
28  ||| S:12105 E:12118 ||| CD
nM ||| S:12118 E:12120 ||| NN
,  ||| S:12120 E:12122 ||| ,
reflecting  ||| S:12122 E:12133 ||| VBG
a  ||| S:12133 E:12135 ||| DT
change  ||| S:12135 E:12142 ||| NN
of  ||| S:12142 E:12145 ||| IN
160  ||| S:12145 E:12149 ||| CD
±  ||| S:12149 E:12151 ||| CD
37  ||| S:12151 E:12154 ||| CD
fold  ||| S:12154 E:12159 ||| NNS
compared  ||| S:12159 E:12168 ||| VBN
to  ||| S:12168 E:12181 ||| TO
wildtype  ||| S:12181 E:12190 ||| VB
receptors ||| S:12190 E:12199 ||| NNS
.  ||| S:12199 E:12201 ||| .
The  ||| S:12201 E:12205 ||| DT
K  ||| S:12205 E:12218 ||| NNP
i  ||| S:12218 E:12220 ||| FW
value  ||| S:12220 E:12226 ||| NN
for  ||| S:12226 E:12230 ||| IN
analog  ||| S:12230 E:12237 ||| CD
1 ||| S:12237 E:12238 ||| CD
,  ||| S:12238 E:12240 ||| ,
in  ||| S:12240 E:12243 ||| IN
contrast ||| S:12243 E:12251 ||| NN
,  ||| S:12251 E:12263 ||| ,
increased  ||| S:12263 E:12273 ||| VBD
only  ||| S:12273 E:12278 ||| RB
6.8  ||| S:12278 E:12282 ||| CD
±  ||| S:12282 E:12284 ||| CD
2.3  ||| S:12284 E:12288 ||| CD
fold  ||| S:12288 E:12293 ||| NNS
( ||| S:12293 E:12294 ||| -LRB-
p  ||| S:12294 E:12296 ||| CD
< ||| S:12296 E:12298 ||| SYM
0.01 ||| S:12298 E:12302 ||| CD
)  ||| S:12302 E:12304 ||| -RRB-
as  ||| S:12304 E:12307 ||| IN
a  ||| S:12307 E:12309 ||| DT
result  ||| S:12309 E:12326 ||| NN
of  ||| S:12326 E:12329 ||| IN
this  ||| S:12329 E:12334 ||| DT
mutation  ||| S:12334 E:12343 ||| NN
( ||| S:12343 E:12344 ||| -LRB-
Figure  ||| S:12344 E:12351 ||| NNP
4Eand  ||| S:12351 E:12357 ||| NNP
Table  ||| S:12357 E:12363 ||| NNP
1 ||| S:12363 E:12364 ||| CD
) ||| S:12364 E:12365 ||| -RRB-
.  ||| S:12365 E:12367 ||| .
The  ||| S:12367 E:12371 ||| DT
K  ||| S:12371 E:12384 ||| NNP
i  ||| S:12384 E:12386 ||| NN
for  ||| S:12386 E:12390 ||| IN
analog  ||| S:12390 E:12397 ||| CD
2  ||| S:12397 E:12399 ||| CD
showed  ||| S:12399 E:12406 ||| VBD
a  ||| S:12406 E:12408 ||| DT
similar  ||| S:12408 E:12416 ||| JJ
change  ||| S:12416 E:12433 ||| NN
of  ||| S:12433 E:12436 ||| IN
17  ||| S:12436 E:12439 ||| CD
±  ||| S:12439 E:12441 ||| CD
0.77  ||| S:12441 E:12446 ||| CD
fold  ||| S:12446 E:12451 ||| NNS
( ||| S:12451 E:12452 ||| -LRB-
p  ||| S:12452 E:12454 ||| CD
< ||| S:12454 E:12456 ||| SYM
0.01 ||| S:12456 E:12460 ||| CD
) ||| S:12460 E:12461 ||| -RRB-
.  ||| S:12461 E:12463 ||| .
While  ||| S:12463 E:12469 ||| IN
these  ||| S:12469 E:12475 ||| DT
K  ||| S:12475 E:12488 ||| NNP
i  ||| S:12488 E:12490 ||| FW
values  ||| S:12490 E:12497 ||| NNS
are  ||| S:12497 E:12501 ||| VBP
significantly  ||| S:12501 E:12515 ||| RB
different  ||| S:12515 E:12535 ||| JJ
from  ||| S:12535 E:12540 ||| IN
wildtype  ||| S:12540 E:12549 ||| JJ
values  ||| S:12549 E:12556 ||| NNS
for  ||| S:12556 E:12560 ||| IN
each  ||| S:12560 E:12565 ||| DT
analog ||| S:12565 E:12571 ||| NN
,  ||| S:12571 E:12573 ||| ,
the  ||| S:12573 E:12577 ||| DT
lack  ||| S:12577 E:12582 ||| NN
of  ||| S:12582 E:12585 ||| IN
larger  ||| S:12585 E:12602 ||| JJR
effects  ||| S:12602 E:12610 ||| NNS
suggests  ||| S:12610 E:12619 ||| VBZ
that  ||| S:12619 E:12624 ||| IN
neither  ||| S:12624 E:12632 ||| DT
analog  ||| S:12632 E:12639 ||| JJ
1  ||| S:12639 E:12641 ||| CD
nor  ||| S:12641 E:12645 ||| CC
analog  ||| S:12645 E:12652 ||| CD
2  ||| S:12652 E:12654 ||| CD
bind  ||| S:12654 E:12669 ||| NN
as  ||| S:12669 E:12672 ||| IN
strongly  ||| S:12672 E:12681 ||| RB
as  ||| S:12681 E:12684 ||| IN
lerisetron  ||| S:12684 E:12695 ||| VBG
to  ||| S:12695 E:12698 ||| TO
Y142 ||| S:12698 E:12702 ||| CD
.  ||| S:12702 E:12732 ||| .
Mutation  ||| S:12732 E:12741 ||| NN
of  ||| S:12741 E:12744 ||| IN
Y152  ||| S:12744 E:12759 ||| CD
The  ||| S:12759 E:12763 ||| DT
Y152A  ||| S:12763 E:12769 ||| JJ
mutation  ||| S:12769 E:12778 ||| NN
showed  ||| S:12778 E:12785 ||| VBD
the  ||| S:12785 E:12789 ||| DT
most  ||| S:12789 E:12794 ||| RBS
variability  ||| S:12794 E:12806 ||| JJ
in  ||| S:12806 E:12809 ||| IN
its  ||| S:12809 E:12823 ||| PRP$
effects  ||| S:12823 E:12831 ||| NNS
on  ||| S:12831 E:12834 ||| IN
K  ||| S:12834 E:12847 ||| NNP
i  ||| S:12847 E:12849 ||| FW
values  ||| S:12849 E:12856 ||| NNS
for  ||| S:12856 E:12860 ||| IN
lerisetron ||| S:12860 E:12870 ||| NN
,  ||| S:12870 E:12872 ||| ,
analog  ||| S:12872 E:12879 ||| CD
1  ||| S:12879 E:12881 ||| CD
and  ||| S:12881 E:12895 ||| CC
analog  ||| S:12895 E:12902 ||| CD
2  ||| S:12902 E:12904 ||| CD
( ||| S:12904 E:12905 ||| -LRB-
Figure  ||| S:12905 E:12912 ||| NNP
3 ||| S:12912 E:12913 ||| CD
,  ||| S:12913 E:12915 ||| ,
Figure  ||| S:12915 E:12922 ||| NNP
4Fand  ||| S:12922 E:12928 ||| NNP
Table  ||| S:12928 E:12934 ||| NNP
1 ||| S:12934 E:12935 ||| CD
) ||| S:12935 E:12936 ||| -RRB-
.  ||| S:12936 E:12938 ||| .
Lerisetron  ||| S:12938 E:12959 ||| JJ
inhibited  ||| S:12959 E:12969 ||| NNS
[  ||| S:12969 E:12971 ||| -LRB-
3H ||| S:12971 E:12973 ||| NNP
] ||| S:12973 E:12974 ||| -RRB-
-granisetron  ||| S:12974 E:12987 ||| JJ
binding  ||| S:12987 E:12995 ||| NN
with  ||| S:12995 E:13000 ||| IN
a  ||| S:13000 E:13002 ||| DT
K  ||| S:13002 E:13015 ||| NNP
i  ||| S:13015 E:13017 ||| FW
value  ||| S:13017 E:13023 ||| NN
of  ||| S:13023 E:13026 ||| IN
150  ||| S:13026 E:13030 ||| CD
±  ||| S:13030 E:13032 ||| CD
36 ||| S:13032 E:13034 ||| CD
;  ||| S:13034 E:13036 ||| :
an  ||| S:13036 E:13039 ||| DT
increase  ||| S:13039 E:13048 ||| NN
of  ||| S:13048 E:13061 ||| IN
190  ||| S:13061 E:13065 ||| CD
±  ||| S:13065 E:13067 ||| CD
43  ||| S:13067 E:13070 ||| CD
fold  ||| S:13070 E:13075 ||| NNS
compared  ||| S:13075 E:13084 ||| VBN
to  ||| S:13084 E:13087 ||| TO
wildtype  ||| S:13087 E:13096 ||| VB
values ||| S:13096 E:13102 ||| NNS
.  ||| S:13102 E:13104 ||| .
The  ||| S:13104 E:13108 ||| DT
K  ||| S:13108 E:13121 ||| NNP
i  ||| S:13121 E:13123 ||| FW
value  ||| S:13123 E:13129 ||| NN
for  ||| S:13129 E:13133 ||| IN
analog  ||| S:13133 E:13140 ||| CD
1  ||| S:13140 E:13142 ||| CD
increased  ||| S:13142 E:13152 ||| VBN
from  ||| S:13152 E:13157 ||| IN
25  ||| S:13157 E:13170 ||| CD
±  ||| S:13170 E:13172 ||| CD
3.2  ||| S:13172 E:13176 ||| CD
nM  ||| S:13176 E:13179 ||| NNS
( ||| S:13179 E:13180 ||| -LRB-
wildtype ||| S:13180 E:13188 ||| LS
)  ||| S:13188 E:13190 ||| -RRB-
to  ||| S:13190 E:13193 ||| TO
2.5  ||| S:13193 E:13197 ||| CD
±  ||| S:13197 E:13199 ||| CD
0.40  ||| S:13199 E:13204 ||| CD
μM ||| S:13204 E:13206 ||| NN
.  ||| S:13206 E:13208 ||| .
This  ||| S:13208 E:13213 ||| DT
change  ||| S:13213 E:13220 ||| NN
of  ||| S:13220 E:13223 ||| IN
100  ||| S:13223 E:13237 ||| CD
±  ||| S:13237 E:13239 ||| CD
16  ||| S:13239 E:13242 ||| CD
fold  ||| S:13242 E:13247 ||| NN
is  ||| S:13247 E:13250 ||| VBZ
slightly  ||| S:13250 E:13259 ||| RB
smaller ||| S:13259 E:13266 ||| JJR
,  ||| S:13266 E:13268 ||| ,
but  ||| S:13268 E:13272 ||| CC
not  ||| S:13272 E:13276 ||| RB
significantly  ||| S:13276 E:13300 ||| RB
different  ||| S:13300 E:13310 ||| JJ
from  ||| S:13310 E:13315 ||| IN
the  ||| S:13315 E:13319 ||| DT
relative  ||| S:13319 E:13328 ||| JJ
change  ||| S:13328 E:13335 ||| NN
observed  ||| S:13335 E:13344 ||| VBD
for  ||| S:13344 E:13358 ||| IN
lerisetron ||| S:13358 E:13368 ||| NN
.  ||| S:13368 E:13370 ||| .
The  ||| S:13370 E:13374 ||| DT
K  ||| S:13374 E:13387 ||| NNP
i  ||| S:13387 E:13389 ||| NN
for  ||| S:13389 E:13393 ||| IN
analog  ||| S:13393 E:13400 ||| CD
2  ||| S:13400 E:13402 ||| CD
increased  ||| S:13402 E:13412 ||| VBN
from  ||| S:13412 E:13417 ||| IN
0.32  ||| S:13417 E:13422 ||| CD
±  ||| S:13422 E:13434 ||| CD
0.08  ||| S:13434 E:13439 ||| CD
μM  ||| S:13439 E:13442 ||| NN
on  ||| S:13442 E:13445 ||| IN
wildtype  ||| S:13445 E:13454 ||| VBG
to  ||| S:13454 E:13457 ||| TO
13  ||| S:13457 E:13460 ||| CD
±  ||| S:13460 E:13462 ||| CD
4.2  ||| S:13462 E:13466 ||| CD
μM  ||| S:13466 E:13469 ||| NN
on  ||| S:13469 E:13472 ||| IN
Y152A  ||| S:13472 E:13478 ||| FW
mutant  ||| S:13478 E:13495 ||| FW
receptors  ||| S:13495 E:13505 ||| FW
( ||| S:13505 E:13506 ||| -LRB-
40  ||| S:13506 E:13509 ||| CD
±  ||| S:13509 E:13511 ||| CD
12  ||| S:13511 E:13514 ||| CD
fold  ||| S:13514 E:13519 ||| JJ
increase ||| S:13519 E:13527 ||| NN
) ||| S:13527 E:13528 ||| -RRB-
.  ||| S:13528 E:13530 ||| .
The  ||| S:13530 E:13534 ||| DT
increase  ||| S:13534 E:13543 ||| NN
observed  ||| S:13543 E:13562 ||| VBD
for  ||| S:13562 E:13566 ||| IN
analog  ||| S:13566 E:13573 ||| CD
2  ||| S:13573 E:13575 ||| CD
was  ||| S:13575 E:13579 ||| VBD
significantly  ||| S:13579 E:13593 ||| RB
less  ||| S:13593 E:13598 ||| JJR
than  ||| S:13598 E:13603 ||| IN
that  ||| S:13603 E:13608 ||| WDT
observed  ||| S:13608 E:13627 ||| VBD
for  ||| S:13627 E:13631 ||| IN
both  ||| S:13631 E:13636 ||| DT
lerisetron  ||| S:13636 E:13647 ||| NN
and  ||| S:13647 E:13651 ||| CC
analog  ||| S:13651 E:13658 ||| CD
1 ||| S:13658 E:13659 ||| CD
.  ||| S:13659 E:13661 ||| .
The  ||| S:13661 E:13665 ||| DT
smaller  ||| S:13665 E:13673 ||| JJR
change  ||| S:13673 E:13680 ||| NN
in  ||| S:13680 E:13683 ||| IN
K  ||| S:13683 E:13706 ||| NNP
i  ||| S:13706 E:13708 ||| NN
for  ||| S:13708 E:13712 ||| IN
analog  ||| S:13712 E:13719 ||| CD
2  ||| S:13719 E:13721 ||| CD
suggests  ||| S:13721 E:13730 ||| VBZ
that  ||| S:13730 E:13735 ||| IN
analog  ||| S:13735 E:13742 ||| CD
2  ||| S:13742 E:13754 ||| CD
binds  ||| S:13754 E:13760 ||| JJ
weakly  ||| S:13760 E:13767 ||| NN
to  ||| S:13767 E:13770 ||| TO
Y152  ||| S:13770 E:13775 ||| CD
while  ||| S:13775 E:13781 ||| IN
lerisetron  ||| S:13781 E:13792 ||| NN
and  ||| S:13792 E:13796 ||| CC
analog  ||| S:13796 E:13803 ||| CD
1  ||| S:13803 E:13805 ||| CD
bind  ||| S:13805 E:13820 ||| NN
more  ||| S:13820 E:13825 ||| RBR
tightly ||| S:13825 E:13832 ||| RB
.  ||| S:13832 E:13865 ||| .
Discussion  ||| S:13865 E:13895 ||| NNP
Functional  ||| S:13895 E:13906 ||| NNP
group  ||| S:13906 E:13912 ||| NN
interactions  ||| S:13912 E:13925 ||| NNS
of  ||| S:13925 E:13928 ||| IN
W89  ||| S:13928 E:13942 ||| CD
The  ||| S:13942 E:13946 ||| DT
W89F  ||| S:13946 E:13951 ||| JJ
mutation  ||| S:13951 E:13960 ||| NN
produced  ||| S:13960 E:13969 ||| VBD
a  ||| S:13969 E:13971 ||| DT
significant  ||| S:13971 E:13983 ||| JJ
increase  ||| S:13983 E:13992 ||| NN
in  ||| S:13992 E:13995 ||| IN
K  ||| S:13995 E:14018 ||| NNP
i  ||| S:14018 E:14020 ||| NN
for  ||| S:14020 E:14024 ||| IN
all  ||| S:14024 E:14028 ||| DT
three  ||| S:14028 E:14034 ||| CD
compounds ||| S:14034 E:14043 ||| NNS
.  ||| S:14043 E:14045 ||| .
The  ||| S:14045 E:14059 ||| DT
magnitude  ||| S:14059 E:14069 ||| NN
of  ||| S:14069 E:14072 ||| IN
the  ||| S:14072 E:14076 ||| DT
change  ||| S:14076 E:14083 ||| NN
was  ||| S:14083 E:14087 ||| VBD
similar  ||| S:14087 E:14095 ||| JJ
in  ||| S:14095 E:14098 ||| IN
all  ||| S:14098 E:14102 ||| DT
cases ||| S:14102 E:14107 ||| NNS
.  ||| S:14107 E:14109 ||| .
In  ||| S:14109 E:14122 ||| IN
addition ||| S:14122 E:14130 ||| NN
,  ||| S:14130 E:14132 ||| ,
the  ||| S:14132 E:14136 ||| DT
increase  ||| S:14136 E:14145 ||| NN
in  ||| S:14145 E:14148 ||| IN
K  ||| S:14148 E:14161 ||| NNP
i  ||| S:14161 E:14163 ||| NN
was  ||| S:14163 E:14167 ||| VBD
identical  ||| S:14167 E:14177 ||| JJ
to  ||| S:14177 E:14180 ||| TO
the  ||| S:14180 E:14184 ||| DT
increase  ||| S:14184 E:14193 ||| NN
in  ||| S:14193 E:14196 ||| IN
K  ||| S:14196 E:14209 ||| NNP
d  ||| S:14209 E:14211 ||| NN
that  ||| S:14211 E:14216 ||| WDT
has  ||| S:14216 E:14220 ||| VBZ
been  ||| S:14220 E:14225 ||| VBN
observed  ||| S:14225 E:14234 ||| VBN
for  ||| S:14234 E:14238 ||| IN
[  ||| S:14238 E:14250 ||| -LRB-
3H ||| S:14250 E:14252 ||| NNP
] ||| S:14252 E:14253 ||| -RRB-
granisetron  ||| S:14253 E:14265 ||| JJ
binding  ||| S:14265 E:14273 ||| NN
on  ||| S:14273 E:14276 ||| IN
this  ||| S:14276 E:14281 ||| DT
mutant  ||| S:14281 E:14288 ||| NN
[  ||| S:14288 E:14290 ||| -LRB-
24  ||| S:14290 E:14293 ||| CD
]  ||| S:14293 E:14295 ||| -RRB-
.  ||| S:14295 E:14307 ||| .
Alterations  ||| S:14307 E:14319 ||| NNP
in  ||| S:14319 E:14322 ||| IN
K  ||| S:14322 E:14335 ||| NNP
i  ||| S:14335 E:14337 ||| VBZ
resulting  ||| S:14337 E:14347 ||| VBG
from  ||| S:14347 E:14352 ||| IN
the  ||| S:14352 E:14356 ||| DT
W89Y  ||| S:14356 E:14361 ||| JJ
mutation  ||| S:14361 E:14380 ||| NN
were  ||| S:14380 E:14385 ||| VBD
slightly  ||| S:14385 E:14394 ||| RB
less ||| S:14394 E:14398 ||| RBR
,  ||| S:14398 E:14400 ||| ,
however  ||| S:14400 E:14408 ||| RB
the  ||| S:14408 E:14412 ||| DT
change  ||| S:14412 E:14419 ||| NN
was  ||| S:14419 E:14423 ||| VBD
again  ||| S:14423 E:14429 ||| RB
the  ||| S:14429 E:14433 ||| DT
same  ||| S:14433 E:14448 ||| JJ
for  ||| S:14448 E:14452 ||| IN
lerisetron ||| S:14452 E:14462 ||| NN
,  ||| S:14462 E:14464 ||| ,
analog  ||| S:14464 E:14471 ||| CD
1  ||| S:14471 E:14473 ||| CD
and  ||| S:14473 E:14477 ||| CC
analog  ||| S:14477 E:14484 ||| CD
2 ||| S:14484 E:14485 ||| CD
.  ||| S:14485 E:14487 ||| .
These  ||| S:14487 E:14493 ||| DT
data  ||| S:14493 E:14498 ||| NNS
suggest  ||| S:14498 E:14516 ||| VBP
that  ||| S:14516 E:14521 ||| IN
all  ||| S:14521 E:14525 ||| DT
three  ||| S:14525 E:14531 ||| CD
compounds  ||| S:14531 E:14541 ||| NNS
form  ||| S:14541 E:14546 ||| VBP
binding  ||| S:14546 E:14554 ||| JJ
site  ||| S:14554 E:14559 ||| NN
interactions  ||| S:14559 E:14582 ||| NNS
with  ||| S:14582 E:14587 ||| IN
W89 ||| S:14587 E:14590 ||| CD
.  ||| S:14590 E:14592 ||| .
The  ||| S:14592 E:14596 ||| DT
interaction  ||| S:14596 E:14608 ||| NN
between  ||| S:14608 E:14616 ||| IN
lerisetron  ||| S:14616 E:14627 ||| NN
and  ||| S:14627 E:14631 ||| CC
W89  ||| S:14631 E:14635 ||| NNP
is  ||| S:14635 E:14648 ||| VBZ
unlikely  ||| S:14648 E:14657 ||| JJ
to  ||| S:14657 E:14660 ||| TO
be  ||| S:14660 E:14663 ||| VB
via  ||| S:14663 E:14667 ||| IN
the  ||| S:14667 E:14671 ||| DT
N-benzyl  ||| S:14671 E:14680 ||| JJ
functional  ||| S:14680 E:14691 ||| JJ
group  ||| S:14691 E:14697 ||| NN
since  ||| S:14697 E:14713 ||| IN
the  ||| S:14713 E:14717 ||| DT
K  ||| S:14717 E:14730 ||| NNP
i  ||| S:14730 E:14732 ||| NN
for  ||| S:14732 E:14736 ||| IN
analog  ||| S:14736 E:14743 ||| CD
1  ||| S:14743 E:14745 ||| CD
was  ||| S:14745 E:14749 ||| VBD
also  ||| S:14749 E:14754 ||| RB
altered  ||| S:14754 E:14762 ||| VBN
by  ||| S:14762 E:14775 ||| IN
this  ||| S:14775 E:14780 ||| DT
mutation ||| S:14780 E:14788 ||| NN
.  ||| S:14788 E:14790 ||| .
The  ||| S:14790 E:14794 ||| DT
same  ||| S:14794 E:14799 ||| JJ
argument  ||| S:14799 E:14808 ||| NN
can  ||| S:14808 E:14812 ||| MD
be  ||| S:14812 E:14815 ||| VB
made  ||| S:14815 E:14820 ||| VBN
for  ||| S:14820 E:14824 ||| IN
the  ||| S:14824 E:14838 ||| DT
distal  ||| S:14838 E:14845 ||| JJ
piperazine  ||| S:14845 E:14856 ||| JJ
nitrogen  ||| S:14856 E:14865 ||| NN
since  ||| S:14865 E:14871 ||| IN
the  ||| S:14871 E:14875 ||| DT
K  ||| S:14875 E:14888 ||| NNP
i  ||| S:14888 E:14890 ||| NN
for  ||| S:14890 E:14894 ||| IN
analog  ||| S:14894 E:14901 ||| CD
2  ||| S:14901 E:14903 ||| CD
also  ||| S:14903 E:14908 ||| RB
increased ||| S:14908 E:14917 ||| VBN
.  ||| S:14917 E:14919 ||| .
The  ||| S:14919 E:14933 ||| DT
portion  ||| S:14933 E:14941 ||| NN
of  ||| S:14941 E:14944 ||| IN
the  ||| S:14944 E:14948 ||| DT
molecule  ||| S:14948 E:14957 ||| JJ
common  ||| S:14957 E:14964 ||| JJ
to  ||| S:14964 E:14967 ||| TO
all  ||| S:14967 E:14971 ||| DT
three  ||| S:14971 E:14977 ||| CD
compounds ||| S:14977 E:14986 ||| NN
,  ||| S:14986 E:14998 ||| ,
the  ||| S:14998 E:15002 ||| DT
aromatic  ||| S:15002 E:15011 ||| JJ
benzimidazole ||| S:15011 E:15024 ||| NN
,  ||| S:15024 E:15026 ||| ,
is  ||| S:15026 E:15029 ||| VBZ
thus  ||| S:15029 E:15034 ||| RB
the  ||| S:15034 E:15038 ||| DT
most  ||| S:15038 E:15043 ||| RBS
likely  ||| S:15043 E:15050 ||| JJ
point  ||| S:15050 E:15066 ||| NN
of  ||| S:15066 E:15069 ||| IN
interaction  ||| S:15069 E:15081 ||| NN
for  ||| S:15081 E:15085 ||| IN
W89 ||| S:15085 E:15088 ||| CD
.  ||| S:15088 E:15118 ||| .
Functional  ||| S:15118 E:15129 ||| JJ
group  ||| S:15129 E:15135 ||| NN
interactions  ||| S:15135 E:15148 ||| NNS
of  ||| S:15148 E:15151 ||| IN
R91  ||| S:15151 E:15165 ||| CD
The  ||| S:15165 E:15169 ||| DT
R91A  ||| S:15169 E:15174 ||| JJ
mutation  ||| S:15174 E:15183 ||| NN
increased  ||| S:15183 E:15193 ||| VBD
the  ||| S:15193 E:15197 ||| DT
K  ||| S:15197 E:15210 ||| NNP
i  ||| S:15210 E:15212 ||| FW
value  ||| S:15212 E:15218 ||| NN
for  ||| S:15218 E:15222 ||| IN
lerisetron  ||| S:15222 E:15233 ||| JJ
inhibition  ||| S:15233 E:15244 ||| NN
of  ||| S:15244 E:15247 ||| IN
[  ||| S:15247 E:15259 ||| -LRB-
3H ||| S:15259 E:15261 ||| NNP
] ||| S:15261 E:15262 ||| -RRB-
granisetron  ||| S:15262 E:15274 ||| JJ
binding  ||| S:15274 E:15282 ||| NN
by  ||| S:15282 E:15285 ||| IN
7.6  ||| S:15285 E:15289 ||| CD
fold ||| S:15289 E:15293 ||| NNS
.  ||| S:15293 E:15295 ||| .
This  ||| S:15295 E:15300 ||| DT
is  ||| S:15300 E:15303 ||| VBZ
a  ||| S:15303 E:15305 ||| DT
moderately  ||| S:15305 E:15326 ||| RB
small  ||| S:15326 E:15332 ||| JJ
change  ||| S:15332 E:15339 ||| NN
for  ||| S:15339 E:15343 ||| IN
an  ||| S:15343 E:15346 ||| DT
alanine  ||| S:15346 E:15354 ||| JJ
mutation ||| S:15354 E:15362 ||| NN
,  ||| S:15362 E:15364 ||| ,
particularly  ||| S:15364 E:15387 ||| RB
considering  ||| S:15387 E:15399 ||| VBG
that  ||| S:15399 E:15404 ||| IN
the  ||| S:15404 E:15408 ||| DT
smallest  ||| S:15408 E:15417 ||| JJS
change  ||| S:15417 E:15424 ||| NN
in  ||| S:15424 E:15427 ||| IN
K  ||| S:15427 E:15440 ||| NNP
i  ||| S:15440 E:15442 ||| NN
for  ||| S:15442 E:15446 ||| IN
removal  ||| S:15446 E:15454 ||| NN
of  ||| S:15454 E:15457 ||| IN
a  ||| S:15457 E:15459 ||| DT
functional  ||| S:15459 E:15470 ||| JJ
group  ||| S:15470 E:15476 ||| NN
on  ||| S:15476 E:15489 ||| IN
lerisetron  ||| S:15489 E:15500 ||| NNS
( ||| S:15500 E:15501 ||| -LRB-
the  ||| S:15501 E:15505 ||| DT
N-benzyl  ||| S:15505 E:15514 ||| JJ
group ||| S:15514 E:15519 ||| NN
)  ||| S:15519 E:15521 ||| -RRB-
was  ||| S:15521 E:15525 ||| VBD
31  ||| S:15525 E:15528 ||| CD
fold ||| S:15528 E:15532 ||| NNS
.  ||| S:15532 E:15534 ||| .
It  ||| S:15534 E:15537 ||| PRP
is  ||| S:15537 E:15550 ||| VBZ
therefore  ||| S:15550 E:15560 ||| RB
likely  ||| S:15560 E:15567 ||| JJ
that  ||| S:15567 E:15572 ||| IN
this  ||| S:15572 E:15577 ||| DT
interaction  ||| S:15577 E:15589 ||| NN
is  ||| S:15589 E:15592 ||| VBZ
either  ||| S:15592 E:15609 ||| RB
extremely  ||| S:15609 E:15619 ||| RB
weak  ||| S:15619 E:15624 ||| JJ
or  ||| S:15624 E:15627 ||| CC
the  ||| S:15627 E:15631 ||| DT
change  ||| S:15631 E:15638 ||| NN
in  ||| S:15638 E:15641 ||| IN
K  ||| S:15641 E:15654 ||| NNP
i  ||| S:15654 E:15656 ||| FW
is  ||| S:15656 E:15659 ||| VBZ
the  ||| S:15659 E:15663 ||| DT
result  ||| S:15663 E:15670 ||| NN
of  ||| S:15670 E:15673 ||| IN
a  ||| S:15673 E:15675 ||| DT
structural  ||| S:15675 E:15686 ||| JJ
change  ||| S:15686 E:15703 ||| NN
in  ||| S:15703 E:15706 ||| IN
the  ||| S:15706 E:15710 ||| DT
binding  ||| S:15710 E:15718 ||| JJ
site ||| S:15718 E:15722 ||| NN
.  ||| S:15722 E:15724 ||| .
Previous  ||| S:15724 E:15733 ||| JJ
studies  ||| S:15733 E:15741 ||| NNS
concluded  ||| S:15741 E:15751 ||| VBD
that  ||| S:15751 E:15756 ||| IN
R91  ||| S:15756 E:15770 ||| NNP
was  ||| S:15770 E:15774 ||| VBD
an  ||| S:15774 E:15777 ||| DT
important  ||| S:15777 E:15787 ||| JJ
interaction  ||| S:15787 E:15799 ||| NN
for  ||| S:15799 E:15803 ||| IN
the  ||| S:15803 E:15807 ||| DT
5-HT  ||| S:15807 E:15823 ||| CD
3  ||| S:15823 E:15825 ||| CD
R  ||| S:15825 E:15827 ||| NN
agonist  ||| S:15827 E:15835 ||| VBD
5-hydroxytryptamine  ||| S:15835 E:15865 ||| CD
( ||| S:15865 E:15866 ||| -LRB-
5-HT ||| S:15866 E:15870 ||| NNP
) ||| S:15870 E:15871 ||| -RRB-
,  ||| S:15871 E:15873 ||| ,
since  ||| S:15873 E:15879 ||| IN
the  ||| S:15879 E:15883 ||| DT
K  ||| S:15883 E:15896 ||| NNP
i  ||| S:15896 E:15898 ||| NN
for  ||| S:15898 E:15902 ||| IN
5-HT  ||| S:15902 E:15907 ||| NNP
inhibition  ||| S:15907 E:15918 ||| VBD
increased  ||| S:15918 E:15928 ||| VBN
over  ||| S:15928 E:15943 ||| IN
3000  ||| S:15943 E:15948 ||| CD
fold  ||| S:15948 E:15953 ||| NN
as  ||| S:15953 E:15956 ||| IN
a  ||| S:15956 E:15958 ||| DT
result  ||| S:15958 E:15965 ||| NN
of  ||| S:15965 E:15968 ||| IN
the  ||| S:15968 E:15972 ||| DT
R91A  ||| S:15972 E:15977 ||| JJ
mutation  ||| S:15977 E:15986 ||| NN
[  ||| S:15986 E:15988 ||| -LRB-
24  ||| S:15988 E:15991 ||| CD
]  ||| S:15991 E:15993 ||| -RRB-
.  ||| S:15993 E:15995 ||| .
A  ||| S:15995 E:16007 ||| DT
change  ||| S:16007 E:16014 ||| NN
in  ||| S:16014 E:16017 ||| IN
K  ||| S:16017 E:16030 ||| NNP
d  ||| S:16030 E:16032 ||| NN
for  ||| S:16032 E:16036 ||| IN
[  ||| S:16036 E:16038 ||| -LRB-
3H ||| S:16038 E:16040 ||| NNP
] ||| S:16040 E:16041 ||| -RRB-
granisetron  ||| S:16041 E:16053 ||| VBP
binding  ||| S:16053 E:16061 ||| VBG
to  ||| S:16061 E:16064 ||| TO
R91A  ||| S:16064 E:16079 ||| NNP
was  ||| S:16079 E:16083 ||| VBD
also  ||| S:16083 E:16088 ||| RB
observed ||| S:16088 E:16096 ||| VBD
.  ||| S:16096 E:16098 ||| .
In  ||| S:16098 E:16101 ||| IN
order  ||| S:16101 E:16107 ||| NN
to  ||| S:16107 E:16110 ||| TO
determine  ||| S:16110 E:16120 ||| VB
whether  ||| S:16120 E:16128 ||| IN
the  ||| S:16128 E:16142 ||| DT
N-benzyl  ||| S:16142 E:16151 ||| JJ
or  ||| S:16151 E:16154 ||| CC
distal  ||| S:16154 E:16161 ||| JJ
piperazine  ||| S:16161 E:16172 ||| JJ
nitrogen  ||| S:16172 E:16181 ||| NN
of  ||| S:16181 E:16184 ||| IN
lerisetron  ||| S:16184 E:16195 ||| NN
was  ||| S:16195 E:16209 ||| VBD
involved  ||| S:16209 E:16218 ||| VBN
in  ||| S:16218 E:16221 ||| IN
an  ||| S:16221 E:16224 ||| DT
interaction  ||| S:16224 E:16236 ||| NN
with  ||| S:16236 E:16241 ||| IN
R91 ||| S:16241 E:16244 ||| NNP
,  ||| S:16244 E:16246 ||| ,
we  ||| S:16246 E:16249 ||| PRP
tested  ||| S:16249 E:16256 ||| VBD
both  ||| S:16256 E:16271 ||| DT
analog  ||| S:16271 E:16278 ||| JJ
1  ||| S:16278 E:16280 ||| CD
and  ||| S:16280 E:16284 ||| CC
2  ||| S:16284 E:16286 ||| CD
on  ||| S:16286 E:16289 ||| IN
R91A  ||| S:16289 E:16294 ||| CD
mutant  ||| S:16294 E:16301 ||| CD
receptors ||| S:16301 E:16310 ||| NNS
.  ||| S:16310 E:16312 ||| .
No  ||| S:16312 E:16315 ||| DT
change  ||| S:16315 E:16322 ||| NN
in  ||| S:16322 E:16325 ||| IN
K  ||| S:16325 E:16338 ||| NNP
i  ||| S:16338 E:16340 ||| NN
was  ||| S:16340 E:16344 ||| VBD
observed  ||| S:16344 E:16353 ||| VBN
for  ||| S:16353 E:16357 ||| IN
either  ||| S:16357 E:16364 ||| DT
compound ||| S:16364 E:16372 ||| NN
.  ||| S:16372 E:16384 ||| .
This  ||| S:16384 E:16389 ||| DT
result  ||| S:16389 E:16396 ||| NN
makes  ||| S:16396 E:16402 ||| VBZ
it  ||| S:16402 E:16405 ||| PRP
much  ||| S:16405 E:16410 ||| RB
more  ||| S:16410 E:16415 ||| RBR
difficult  ||| S:16415 E:16425 ||| JJ
to  ||| S:16425 E:16428 ||| TO
assign  ||| S:16428 E:16435 ||| VB
the  ||| S:16435 E:16449 ||| DT
correct  ||| S:16449 E:16457 ||| JJ
functional  ||| S:16457 E:16468 ||| JJ
group  ||| S:16468 E:16474 ||| NN
to  ||| S:16474 E:16477 ||| TO
this  ||| S:16477 E:16482 ||| DT
amino  ||| S:16482 E:16488 ||| JJ
acid  ||| S:16488 E:16493 ||| NN
since  ||| S:16493 E:16499 ||| IN
it  ||| S:16499 E:16512 ||| PRP
suggests  ||| S:16512 E:16521 ||| VBZ
that  ||| S:16521 E:16526 ||| IN
one  ||| S:16526 E:16530 ||| CD
or  ||| S:16530 E:16533 ||| CC
both  ||| S:16533 E:16538 ||| DT
of  ||| S:16538 E:16541 ||| IN
the  ||| S:16541 E:16545 ||| DT
compounds  ||| S:16545 E:16555 ||| NN
is  ||| S:16555 E:16558 ||| VBZ
no  ||| S:16558 E:16561 ||| RB
longer  ||| S:16561 E:16578 ||| RB
binding  ||| S:16578 E:16586 ||| VBG
the  ||| S:16586 E:16590 ||| DT
receptor  ||| S:16590 E:16599 ||| NN
in  ||| S:16599 E:16602 ||| IN
precisely  ||| S:16602 E:16612 ||| RB
the  ||| S:16612 E:16616 ||| DT
same  ||| S:16616 E:16621 ||| JJ
manner  ||| S:16621 E:16628 ||| NN
as  ||| S:16628 E:16641 ||| IN
lerisetron ||| S:16641 E:16651 ||| NN
.  ||| S:16651 E:16653 ||| .
Considering  ||| S:16653 E:16665 ||| VBG
the  ||| S:16665 E:16669 ||| DT
small  ||| S:16669 E:16675 ||| JJ
change  ||| S:16675 E:16682 ||| NN
observed  ||| S:16682 E:16691 ||| VBD
for  ||| S:16691 E:16705 ||| IN
lerisetron  ||| S:16705 E:16716 ||| JJ
binding  ||| S:16716 E:16724 ||| NN
as  ||| S:16724 E:16727 ||| IN
a  ||| S:16727 E:16729 ||| DT
result  ||| S:16729 E:16736 ||| NN
of  ||| S:16736 E:16739 ||| IN
this  ||| S:16739 E:16744 ||| DT
mutation ||| S:16744 E:16752 ||| NN
,  ||| S:16752 E:16754 ||| ,
even  ||| S:16754 E:16759 ||| RB
a  ||| S:16759 E:16771 ||| DT
slight  ||| S:16771 E:16778 ||| JJ
reorientation  ||| S:16778 E:16792 ||| NN
of  ||| S:16792 E:16795 ||| IN
the  ||| S:16795 E:16799 ||| DT
molecule  ||| S:16799 E:16808 ||| NN
in  ||| S:16808 E:16811 ||| IN
the  ||| S:16811 E:16815 ||| DT
binding  ||| S:16815 E:16823 ||| JJ
site  ||| S:16823 E:16838 ||| NN
could  ||| S:16838 E:16844 ||| MD
result  ||| S:16844 E:16851 ||| VB
in  ||| S:16851 E:16854 ||| IN
the  ||| S:16854 E:16858 ||| DT
loss  ||| S:16858 E:16863 ||| NN
of  ||| S:16863 E:16866 ||| IN
this  ||| S:16866 E:16871 ||| DT
interaction ||| S:16871 E:16882 ||| NN
.  ||| S:16882 E:16912 ||| .
Functional  ||| S:16912 E:16923 ||| JJ
group  ||| S:16923 E:16929 ||| NN
interactions  ||| S:16929 E:16942 ||| NNS
of  ||| S:16942 E:16945 ||| IN
Y142  ||| S:16945 E:16960 ||| CD
The  ||| S:16960 E:16964 ||| DT
K  ||| S:16964 E:16977 ||| NNP
i  ||| S:16977 E:16979 ||| FW
values  ||| S:16979 E:16986 ||| NNS
for  ||| S:16986 E:16990 ||| IN
inhibition  ||| S:16990 E:17001 ||| NN
of  ||| S:17001 E:17004 ||| IN
[  ||| S:17004 E:17016 ||| -LRB-
3H ||| S:17016 E:17018 ||| NNP
] ||| S:17018 E:17019 ||| -RRB-
granisetron  ||| S:17019 E:17031 ||| JJ
binding  ||| S:17031 E:17039 ||| NN
by  ||| S:17039 E:17042 ||| IN
analogs  ||| S:17042 E:17050 ||| CD
1  ||| S:17050 E:17052 ||| CD
and  ||| S:17052 E:17056 ||| CC
2  ||| S:17056 E:17058 ||| CD
were  ||| S:17058 E:17063 ||| VBD
altered  ||| S:17063 E:17081 ||| VBN
only  ||| S:17081 E:17086 ||| RB
slightly  ||| S:17086 E:17095 ||| RB
by  ||| S:17095 E:17098 ||| IN
the  ||| S:17098 E:17102 ||| DT
Y142A  ||| S:17102 E:17108 ||| JJ
mutation ||| S:17108 E:17116 ||| NN
.  ||| S:17116 E:17118 ||| .
The  ||| S:17118 E:17122 ||| DT
magnitude  ||| S:17122 E:17132 ||| NN
of  ||| S:17132 E:17135 ||| IN
the  ||| S:17135 E:17149 ||| DT
increase  ||| S:17149 E:17158 ||| NN
in  ||| S:17158 E:17161 ||| IN
K  ||| S:17161 E:17174 ||| NNP
i  ||| S:17174 E:17176 ||| NN
for  ||| S:17176 E:17180 ||| IN
lerisetron ||| S:17180 E:17190 ||| NN
,  ||| S:17190 E:17192 ||| ,
however ||| S:17192 E:17199 ||| RB
,  ||| S:17199 E:17201 ||| ,
was  ||| S:17201 E:17215 ||| VBD
considerably  ||| S:17215 E:17228 ||| RB
larger  ||| S:17228 E:17235 ||| JJR
( ||| S:17235 E:17236 ||| -LRB-
160  ||| S:17236 E:17240 ||| CD
fold ||| S:17240 E:17244 ||| CD
)  ||| S:17244 E:17246 ||| -RRB-
and  ||| S:17246 E:17250 ||| CC
is  ||| S:17250 E:17253 ||| VBZ
indicative  ||| S:17253 E:17264 ||| VBN
of  ||| S:17264 E:17267 ||| IN
an  ||| S:17267 E:17280 ||| DT
important  ||| S:17280 E:17290 ||| JJ
interaction  ||| S:17290 E:17302 ||| NN
of  ||| S:17302 E:17305 ||| IN
the  ||| S:17305 E:17309 ||| DT
compound  ||| S:17309 E:17318 ||| NN
with  ||| S:17318 E:17323 ||| IN
Y142 ||| S:17323 E:17327 ||| CD
.  ||| S:17327 E:17329 ||| .
The  ||| S:17329 E:17333 ||| DT
lack  ||| S:17333 E:17348 ||| NN
of  ||| S:17348 E:17351 ||| IN
a  ||| S:17351 E:17353 ||| DT
large  ||| S:17353 E:17359 ||| JJ
change  ||| S:17359 E:17366 ||| NN
in  ||| S:17366 E:17369 ||| IN
K  ||| S:17369 E:17382 ||| NNP
i  ||| S:17382 E:17384 ||| NN
for  ||| S:17384 E:17388 ||| IN
both  ||| S:17388 E:17393 ||| DT
analogs  ||| S:17393 E:17401 ||| NN
makes  ||| S:17401 E:17407 ||| VBZ
it  ||| S:17407 E:17410 ||| PRP
difficult  ||| S:17410 E:17430 ||| JJ
to  ||| S:17430 E:17433 ||| TO
interpret  ||| S:17433 E:17443 ||| VB
this  ||| S:17443 E:17448 ||| DT
data  ||| S:17448 E:17453 ||| NNS
since  ||| S:17453 E:17459 ||| IN
one  ||| S:17459 E:17463 ||| CD
or  ||| S:17463 E:17466 ||| CC
both  ||| S:17466 E:17471 ||| DT
of  ||| S:17471 E:17474 ||| IN
the  ||| S:17474 E:17478 ||| DT
compounds  ||| S:17478 E:17498 ||| NN
appears  ||| S:17498 E:17506 ||| VBZ
to  ||| S:17506 E:17509 ||| TO
be  ||| S:17509 E:17512 ||| VB
interacting  ||| S:17512 E:17524 ||| VBN
differently  ||| S:17524 E:17536 ||| RB
with  ||| S:17536 E:17541 ||| IN
the  ||| S:17541 E:17545 ||| DT
binding  ||| S:17545 E:17563 ||| JJ
site  ||| S:17563 E:17568 ||| NN
than  ||| S:17568 E:17573 ||| IN
lerisetron ||| S:17573 E:17583 ||| NN
.  ||| S:17583 E:17595 ||| .
Analogs  ||| S:17595 E:17603 ||| NNP
1  ||| S:17603 E:17605 ||| CD
and  ||| S:17605 E:17609 ||| CC
2  ||| S:17609 E:17611 ||| CD
differ  ||| S:17611 E:17618 ||| NN
from  ||| S:17618 E:17623 ||| IN
each  ||| S:17623 E:17628 ||| DT
other  ||| S:17628 E:17634 ||| JJ
both  ||| S:17634 E:17639 ||| CC
in  ||| S:17639 E:17642 ||| IN
the  ||| S:17642 E:17656 ||| DT
functional  ||| S:17656 E:17667 ||| JJ
groups  ||| S:17667 E:17674 ||| NNS
contained  ||| S:17674 E:17684 ||| VBN
in  ||| S:17684 E:17687 ||| IN
the  ||| S:17687 E:17691 ||| DT
molecule  ||| S:17691 E:17700 ||| NN
and  ||| S:17700 E:17704 ||| CC
their  ||| S:17704 E:17720 ||| PRP$
structural  ||| S:17720 E:17731 ||| JJ
similarity  ||| S:17731 E:17742 ||| NN
to  ||| S:17742 E:17745 ||| TO
lerisetron ||| S:17745 E:17755 ||| VB
.  ||| S:17755 E:17757 ||| .
Analog  ||| S:17757 E:17764 ||| NNP
2  ||| S:17764 E:17766 ||| CD
is  ||| S:17766 E:17769 ||| VBZ
most  ||| S:17769 E:17784 ||| RBS
similar  ||| S:17784 E:17792 ||| JJ
in  ||| S:17792 E:17795 ||| IN
overall  ||| S:17795 E:17803 ||| JJ
structure ||| S:17803 E:17812 ||| NN
.  ||| S:17812 E:17814 ||| .
The  ||| S:17814 E:17818 ||| DT
substitution  ||| S:17818 E:17831 ||| NN
of  ||| S:17831 E:17834 ||| IN
oxygen  ||| S:17834 E:17851 ||| NN
for  ||| S:17851 E:17855 ||| IN
the  ||| S:17855 E:17859 ||| DT
distal  ||| S:17859 E:17866 ||| JJ
amino  ||| S:17866 E:17872 ||| NNS
nitrogen  ||| S:17872 E:17881 ||| VBP
alters  ||| S:17881 E:17888 ||| VBG
the  ||| S:17888 E:17892 ||| DT
potential  ||| S:17892 E:17912 ||| JJ
interactions  ||| S:17912 E:17925 ||| NNS
formed  ||| S:17925 E:17932 ||| VBN
at  ||| S:17932 E:17935 ||| IN
this  ||| S:17935 E:17940 ||| DT
position ||| S:17940 E:17948 ||| NN
,  ||| S:17948 E:17950 ||| ,
but  ||| S:17950 E:17954 ||| CC
is  ||| S:17954 E:17957 ||| VBZ
likely  ||| S:17957 E:17964 ||| JJ
to  ||| S:17964 E:17977 ||| TO
have  ||| S:17977 E:17982 ||| VB
a  ||| S:17982 E:17984 ||| DT
small  ||| S:17984 E:17990 ||| JJ
effect  ||| S:17990 E:17997 ||| NN
on  ||| S:17997 E:18000 ||| IN
the  ||| S:18000 E:18004 ||| DT
overall  ||| S:18004 E:18012 ||| JJ
size  ||| S:18012 E:18017 ||| NN
and  ||| S:18017 E:18021 ||| CC
shape  ||| S:18021 E:18027 ||| NN
of  ||| S:18027 E:18030 ||| IN
the  ||| S:18030 E:18044 ||| DT
molecule ||| S:18044 E:18052 ||| NN
.  ||| S:18052 E:18054 ||| .
Analog  ||| S:18054 E:18061 ||| NNP
1  ||| S:18061 E:18063 ||| CD
is  ||| S:18063 E:18066 ||| VBZ
far  ||| S:18066 E:18070 ||| RB
less  ||| S:18070 E:18075 ||| RBR
similar  ||| S:18075 E:18083 ||| JJ
to  ||| S:18083 E:18086 ||| TO
lerisetron  ||| S:18086 E:18097 ||| VB
and  ||| S:18097 E:18111 ||| CC
more  ||| S:18111 E:18116 ||| RBR
similar  ||| S:18116 E:18124 ||| JJ
to  ||| S:18124 E:18127 ||| TO
the  ||| S:18127 E:18131 ||| DT
5-HT  ||| S:18131 E:18147 ||| CD
3  ||| S:18147 E:18149 ||| CD
R  ||| S:18149 E:18151 ||| NN
antagonist  ||| S:18151 E:18162 ||| NN
granisetron ||| S:18162 E:18173 ||| NN
.  ||| S:18173 E:18175 ||| .
Previous  ||| S:18175 E:18194 ||| JJ
studies  ||| S:18194 E:18202 ||| NNS
have  ||| S:18202 E:18207 ||| VBP
shown  ||| S:18207 E:18213 ||| VBN
that  ||| S:18213 E:18218 ||| IN
the  ||| S:18218 E:18222 ||| DT
binding  ||| S:18222 E:18230 ||| NN
of  ||| S:18230 E:18233 ||| IN
granisetron  ||| S:18233 E:18245 ||| NN
is  ||| S:18245 E:18248 ||| VBZ
not  ||| S:18248 E:18262 ||| RB
affected  ||| S:18262 E:18271 ||| VBN
by  ||| S:18271 E:18274 ||| IN
the  ||| S:18274 E:18278 ||| DT
Y142A  ||| S:18278 E:18284 ||| JJ
mutation  ||| S:18284 E:18293 ||| NN
[  ||| S:18293 E:18295 ||| -LRB-
25  ||| S:18295 E:18298 ||| CD
]  ||| S:18298 E:18300 ||| -RRB-
.  ||| S:18300 E:18302 ||| .
Analog  ||| S:18302 E:18309 ||| NNP
1  ||| S:18309 E:18311 ||| CD
may  ||| S:18311 E:18315 ||| MD
bind  ||| S:18315 E:18330 ||| VB
more  ||| S:18330 E:18335 ||| RBR
similar  ||| S:18335 E:18343 ||| JJ
to  ||| S:18343 E:18346 ||| TO
granisetron  ||| S:18346 E:18358 ||| VB
than  ||| S:18358 E:18363 ||| IN
lerisetron  ||| S:18363 E:18374 ||| NN
and  ||| S:18374 E:18378 ||| CC
thus  ||| S:18378 E:18393 ||| RB
would  ||| S:18393 E:18399 ||| MD
be  ||| S:18399 E:18402 ||| VB
unaffected  ||| S:18402 E:18413 ||| VBN
by  ||| S:18413 E:18416 ||| IN
mutations  ||| S:18416 E:18426 ||| NNS
at  ||| S:18426 E:18429 ||| IN
Y142 ||| S:18429 E:18433 ||| CD
.  ||| S:18433 E:18435 ||| .
This  ||| S:18435 E:18440 ||| DT
is  ||| S:18440 E:18443 ||| VBZ
less  ||| S:18443 E:18458 ||| RBR
likely  ||| S:18458 E:18465 ||| JJ
to  ||| S:18465 E:18468 ||| TO
be  ||| S:18468 E:18471 ||| VB
the  ||| S:18471 E:18475 ||| DT
case  ||| S:18475 E:18480 ||| NN
with  ||| S:18480 E:18485 ||| IN
analog  ||| S:18485 E:18492 ||| CD
2 ||| S:18492 E:18493 ||| CD
.  ||| S:18493 E:18505 ||| .
The  ||| S:18505 E:18509 ||| DT
strength  ||| S:18509 E:18518 ||| NN
of  ||| S:18518 E:18521 ||| IN
the  ||| S:18521 E:18525 ||| DT
putative  ||| S:18525 E:18534 ||| JJ
interaction  ||| S:18534 E:18546 ||| NN
at  ||| S:18546 E:18549 ||| IN
Y142  ||| S:18549 E:18554 ||| NNP
can  ||| S:18554 E:18568 ||| MD
be  ||| S:18568 E:18571 ||| VB
identified  ||| S:18571 E:18582 ||| VBN
by  ||| S:18582 E:18585 ||| IN
examining  ||| S:18585 E:18595 ||| VBG
the  ||| S:18595 E:18599 ||| DT
change  ||| S:18599 E:18606 ||| NN
in  ||| S:18606 E:18609 ||| IN
binding  ||| S:18609 E:18617 ||| VBG
of  ||| S:18617 E:18630 ||| IN
lerisetron  ||| S:18630 E:18641 ||| NN
as  ||| S:18641 E:18644 ||| IN
a  ||| S:18644 E:18646 ||| DT
result  ||| S:18646 E:18653 ||| NN
of  ||| S:18653 E:18656 ||| IN
the  ||| S:18656 E:18660 ||| DT
Y142A  ||| S:18660 E:18666 ||| JJ
mutation ||| S:18666 E:18674 ||| NN
.  ||| S:18674 E:18676 ||| .
The  ||| S:18676 E:18680 ||| DT
Y142A  ||| S:18680 E:18696 ||| JJ
mutation  ||| S:18696 E:18705 ||| NN
produced  ||| S:18705 E:18714 ||| VBD
a  ||| S:18714 E:18716 ||| DT
160  ||| S:18716 E:18720 ||| CD
fold  ||| S:18720 E:18725 ||| JJ
change  ||| S:18725 E:18732 ||| NN
in  ||| S:18732 E:18735 ||| IN
K  ||| S:18735 E:18748 ||| NNP
i  ||| S:18748 E:18750 ||| FW
.  ||| S:18750 E:18752 ||| .
This  ||| S:18752 E:18757 ||| DT
change  ||| S:18757 E:18764 ||| NN
reflects  ||| S:18764 E:18773 ||| VBZ
the  ||| S:18773 E:18777 ||| DT
binding  ||| S:18777 E:18795 ||| JJ
energy  ||| S:18795 E:18802 ||| NN
lost  ||| S:18802 E:18807 ||| VBD
as  ||| S:18807 E:18810 ||| IN
a  ||| S:18810 E:18812 ||| DT
result  ||| S:18812 E:18819 ||| NN
of  ||| S:18819 E:18822 ||| IN
the  ||| S:18822 E:18826 ||| DT
alanine  ||| S:18826 E:18834 ||| JJ
substitution ||| S:18834 E:18846 ||| NN
.  ||| S:18846 E:18848 ||| .
The  ||| S:18848 E:18862 ||| DT
observed  ||| S:18862 E:18871 ||| JJ
change  ||| S:18871 E:18878 ||| NN
in  ||| S:18878 E:18881 ||| IN
Ki  ||| S:18881 E:18884 ||| NNP
on  ||| S:18884 E:18887 ||| IN
wt  ||| S:18887 E:18890 ||| JJ
receptors  ||| S:18890 E:18900 ||| NN
is  ||| S:18900 E:18903 ||| VBZ
much  ||| S:18903 E:18908 ||| RB
larger  ||| S:18908 E:18915 ||| JJR
than  ||| S:18915 E:18930 ||| IN
that  ||| S:18930 E:18935 ||| WDT
observed  ||| S:18935 E:18944 ||| VBD
for  ||| S:18944 E:18948 ||| IN
removal  ||| S:18948 E:18956 ||| NN
of  ||| S:18956 E:18959 ||| IN
the  ||| S:18959 E:18963 ||| DT
N-benzyl  ||| S:18963 E:18972 ||| JJ
group  ||| S:18972 E:18978 ||| NN
( ||| S:18978 E:18979 ||| -LRB-
31  ||| S:18979 E:18992 ||| CD
fold ||| S:18992 E:18996 ||| CD
) ||| S:18996 E:18997 ||| -RRB-
,  ||| S:18997 E:18999 ||| ,
but  ||| S:18999 E:19003 ||| CC
is  ||| S:19003 E:19006 ||| VBZ
similar  ||| S:19006 E:19014 ||| JJ
to  ||| S:19014 E:19017 ||| TO
that  ||| S:19017 E:19022 ||| WDT
observed  ||| S:19022 E:19031 ||| VBD
for  ||| S:19031 E:19035 ||| IN
substitution  ||| S:19035 E:19058 ||| NN
of  ||| S:19058 E:19061 ||| IN
the  ||| S:19061 E:19065 ||| DT
distal  ||| S:19065 E:19072 ||| JJ
amino  ||| S:19072 E:19078 ||| JJ
nitrogen  ||| S:19078 E:19087 ||| NN
in  ||| S:19087 E:19090 ||| IN
analog  ||| S:19090 E:19097 ||| CD
2  ||| S:19097 E:19099 ||| CD
( ||| S:19099 E:19100 ||| -LRB-
400  ||| S:19100 E:19104 ||| CD
fold ||| S:19104 E:19108 ||| CD
) ||| S:19108 E:19109 ||| -RRB-
.  ||| S:19109 E:19121 ||| .
Taken  ||| S:19121 E:19127 ||| VBN
together  ||| S:19127 E:19136 ||| RP
with  ||| S:19136 E:19141 ||| IN
the  ||| S:19141 E:19145 ||| DT
close  ||| S:19145 E:19151 ||| JJ
structural  ||| S:19151 E:19162 ||| JJ
similarity  ||| S:19162 E:19173 ||| NN
of  ||| S:19173 E:19186 ||| IN
analog  ||| S:19186 E:19193 ||| CD
2  ||| S:19193 E:19195 ||| CD
to  ||| S:19195 E:19198 ||| TO
lerisetron ||| S:19198 E:19208 ||| VB
,  ||| S:19208 E:19210 ||| ,
it  ||| S:19210 E:19213 ||| PRP
can  ||| S:19213 E:19217 ||| MD
be  ||| S:19217 E:19220 ||| VB
concluded  ||| S:19220 E:19230 ||| VBN
that  ||| S:19230 E:19245 ||| IN
comparison  ||| S:19245 E:19256 ||| NN
of  ||| S:19256 E:19259 ||| IN
analog  ||| S:19259 E:19266 ||| CD
2  ||| S:19266 E:19268 ||| CD
and  ||| S:19268 E:19272 ||| CC
lerisetron  ||| S:19272 E:19283 ||| NNS
should  ||| S:19283 E:19290 ||| MD
provide  ||| S:19290 E:19298 ||| VB
the  ||| S:19298 E:19312 ||| DT
best  ||| S:19312 E:19317 ||| JJS
means  ||| S:19317 E:19323 ||| NNS
of  ||| S:19323 E:19326 ||| IN
identifying  ||| S:19326 E:19338 ||| VBG
the  ||| S:19338 E:19342 ||| DT
interaction  ||| S:19342 E:19354 ||| NN
at  ||| S:19354 E:19357 ||| IN
Y142 ||| S:19357 E:19361 ||| CD
.  ||| S:19361 E:19363 ||| .
No  ||| S:19363 E:19376 ||| DT
change  ||| S:19376 E:19383 ||| NN
in  ||| S:19383 E:19386 ||| IN
K  ||| S:19386 E:19399 ||| NNP
i  ||| S:19399 E:19401 ||| NN
was  ||| S:19401 E:19405 ||| VBD
observed  ||| S:19405 E:19414 ||| VBN
for  ||| S:19414 E:19418 ||| IN
analog  ||| S:19418 E:19425 ||| CD
2  ||| S:19425 E:19427 ||| CD
as  ||| S:19427 E:19430 ||| IN
a  ||| S:19430 E:19442 ||| DT
result  ||| S:19442 E:19449 ||| NN
of  ||| S:19449 E:19452 ||| IN
the  ||| S:19452 E:19456 ||| DT
Y142A  ||| S:19456 E:19462 ||| JJ
mutation  ||| S:19462 E:19471 ||| NN
indicating  ||| S:19471 E:19482 ||| VBG
a  ||| S:19482 E:19484 ||| DT
lack  ||| S:19484 E:19489 ||| NN
of  ||| S:19489 E:19492 ||| IN
any  ||| S:19492 E:19506 ||| DT
significant  ||| S:19506 E:19518 ||| JJ
interaction  ||| S:19518 E:19530 ||| NN
of  ||| S:19530 E:19533 ||| IN
this  ||| S:19533 E:19538 ||| DT
compound  ||| S:19538 E:19547 ||| NN
with  ||| S:19547 E:19552 ||| IN
Y142 ||| S:19552 E:19556 ||| CD
.  ||| S:19556 E:19558 ||| .
These  ||| S:19558 E:19574 ||| DT
data  ||| S:19574 E:19579 ||| NNS
support  ||| S:19579 E:19587 ||| VBP
our  ||| S:19587 E:19591 ||| PRP$
hypothesis  ||| S:19591 E:19602 ||| NN
that  ||| S:19602 E:19607 ||| IN
Y142  ||| S:19607 E:19612 ||| CD
interacts  ||| S:19612 E:19622 ||| NN
with  ||| S:19622 E:19627 ||| IN
the  ||| S:19627 E:19641 ||| DT
distal  ||| S:19641 E:19648 ||| JJ
piperazine  ||| S:19648 E:19659 ||| JJ
nitrogen  ||| S:19659 E:19668 ||| NN
of  ||| S:19668 E:19671 ||| IN
lerisetron ||| S:19671 E:19681 ||| NN
.  ||| S:19681 E:19683 ||| .
A  ||| S:19683 E:19685 ||| DT
second  ||| S:19685 E:19692 ||| JJ
amino  ||| S:19692 E:19708 ||| JJ
acid  ||| S:19708 E:19713 ||| NN
may  ||| S:19713 E:19717 ||| MD
also  ||| S:19717 E:19722 ||| RB
be  ||| S:19722 E:19725 ||| VB
involved  ||| S:19725 E:19734 ||| VBN
since  ||| S:19734 E:19740 ||| IN
the  ||| S:19740 E:19744 ||| DT
change  ||| S:19744 E:19751 ||| NN
in  ||| S:19751 E:19754 ||| IN
K  ||| S:19754 E:19767 ||| NNP
i  ||| S:19767 E:19769 ||| NN
for  ||| S:19769 E:19773 ||| IN
lerisetron  ||| S:19773 E:19784 ||| JJ
binding  ||| S:19784 E:19792 ||| NN
as  ||| S:19792 E:19795 ||| IN
a  ||| S:19795 E:19797 ||| DT
result  ||| S:19797 E:19814 ||| NN
of  ||| S:19814 E:19817 ||| IN
the  ||| S:19817 E:19821 ||| DT
Y142A  ||| S:19821 E:19827 ||| JJ
mutation  ||| S:19827 E:19836 ||| NN
was  ||| S:19836 E:19840 ||| VBD
smaller  ||| S:19840 E:19848 ||| JJR
than  ||| S:19848 E:19853 ||| IN
the  ||| S:19853 E:19857 ||| DT
change  ||| S:19857 E:19874 ||| NN
produced  ||| S:19874 E:19883 ||| VBN
by  ||| S:19883 E:19886 ||| IN
substitution  ||| S:19886 E:19899 ||| NN
of  ||| S:19899 E:19902 ||| IN
the  ||| S:19902 E:19906 ||| DT
piperazine  ||| S:19906 E:19917 ||| JJ
nitrogen ||| S:19917 E:19925 ||| NN
.  ||| S:19925 E:19927 ||| .
As  ||| S:19927 E:19940 ||| RB
described  ||| S:19940 E:19950 ||| VBN
below ||| S:19950 E:19955 ||| RB
,  ||| S:19955 E:19957 ||| ,
one  ||| S:19957 E:19961 ||| CD
candidate  ||| S:19961 E:19971 ||| NN
for  ||| S:19971 E:19975 ||| IN
this  ||| S:19975 E:19980 ||| DT
second  ||| S:19980 E:19987 ||| JJ
amino  ||| S:19987 E:19993 ||| JJ
acid  ||| S:19993 E:20008 ||| NN
is  ||| S:20008 E:20011 ||| VBZ
Y152 ||| S:20011 E:20015 ||| CD
.  ||| S:20015 E:20045 ||| .
Functional  ||| S:20045 E:20056 ||| JJ
group  ||| S:20056 E:20062 ||| NN
interactions  ||| S:20062 E:20075 ||| NNS
of  ||| S:20075 E:20078 ||| IN
Y152  ||| S:20078 E:20093 ||| CD
The  ||| S:20093 E:20097 ||| DT
Y152A  ||| S:20097 E:20103 ||| NNP
mutation  ||| S:20103 E:20112 ||| VBD
produced  ||| S:20112 E:20121 ||| VBN
increases  ||| S:20121 E:20131 ||| NNS
in  ||| S:20131 E:20134 ||| IN
K  ||| S:20134 E:20147 ||| NNP
i  ||| S:20147 E:20149 ||| NN
for  ||| S:20149 E:20153 ||| IN
all  ||| S:20153 E:20157 ||| DT
three  ||| S:20157 E:20163 ||| CD
compounds  ||| S:20163 E:20173 ||| NN
although  ||| S:20173 E:20182 ||| IN
the  ||| S:20182 E:20196 ||| DT
magnitude  ||| S:20196 E:20206 ||| NN
of  ||| S:20206 E:20209 ||| IN
the  ||| S:20209 E:20213 ||| DT
change  ||| S:20213 E:20220 ||| NN
differed ||| S:20220 E:20228 ||| NN
.  ||| S:20228 E:20230 ||| .
The  ||| S:20230 E:20234 ||| DT
increases  ||| S:20234 E:20244 ||| NNS
in  ||| S:20244 E:20247 ||| IN
the  ||| S:20247 E:20251 ||| DT
K  ||| S:20251 E:20264 ||| NNP
i  ||| S:20264 E:20266 ||| FW
values  ||| S:20266 E:20273 ||| NNS
were  ||| S:20273 E:20278 ||| VBD
190  ||| S:20278 E:20282 ||| CD
fold  ||| S:20282 E:20287 ||| NN
for  ||| S:20287 E:20291 ||| IN
lerisetron ||| S:20291 E:20301 ||| NN
,  ||| S:20301 E:20313 ||| ,
98  ||| S:20313 E:20316 ||| CD
fold  ||| S:20316 E:20321 ||| NN
for  ||| S:20321 E:20325 ||| IN
analog  ||| S:20325 E:20332 ||| CD
1  ||| S:20332 E:20334 ||| CD
and  ||| S:20334 E:20338 ||| CC
only  ||| S:20338 E:20343 ||| RB
40  ||| S:20343 E:20346 ||| CD
fold  ||| S:20346 E:20351 ||| NN
for  ||| S:20351 E:20355 ||| IN
analog  ||| S:20355 E:20362 ||| CD
2 ||| S:20362 E:20363 ||| CD
.  ||| S:20363 E:20365 ||| .
Thus ||| S:20365 E:20369 ||| RB
,  ||| S:20369 E:20381 ||| ,
analog  ||| S:20381 E:20388 ||| CD
1  ||| S:20388 E:20390 ||| CD
retains  ||| S:20390 E:20398 ||| VBZ
much  ||| S:20398 E:20403 ||| RB
of  ||| S:20403 E:20406 ||| IN
its  ||| S:20406 E:20410 ||| PRP$
ability  ||| S:20410 E:20418 ||| NN
to  ||| S:20418 E:20421 ||| TO
interact  ||| S:20421 E:20430 ||| VB
with  ||| S:20430 E:20445 ||| IN
Y152  ||| S:20445 E:20450 ||| CD
despite  ||| S:20450 E:20458 ||| IN
the  ||| S:20458 E:20462 ||| DT
absence  ||| S:20462 E:20470 ||| NN
of  ||| S:20470 E:20473 ||| IN
the  ||| S:20473 E:20477 ||| DT
N-benzyl  ||| S:20477 E:20486 ||| JJ
group ||| S:20486 E:20491 ||| NN
,  ||| S:20491 E:20493 ||| ,
while  ||| S:20493 E:20509 ||| IN
analog  ||| S:20509 E:20516 ||| CD
2  ||| S:20516 E:20518 ||| CD
interacts  ||| S:20518 E:20528 ||| NN
more  ||| S:20528 E:20533 ||| RBR
weakly  ||| S:20533 E:20540 ||| JJ
with  ||| S:20540 E:20545 ||| IN
this  ||| S:20545 E:20550 ||| DT
amino  ||| S:20550 E:20556 ||| JJ
acid ||| S:20556 E:20560 ||| NN
.  ||| S:20560 E:20572 ||| .
Since  ||| S:20572 E:20578 ||| IN
the  ||| S:20578 E:20582 ||| DT
K  ||| S:20582 E:20595 ||| NNP
i  ||| S:20595 E:20597 ||| NN
for  ||| S:20597 E:20601 ||| IN
analog  ||| S:20601 E:20608 ||| CD
1  ||| S:20608 E:20610 ||| CD
is  ||| S:20610 E:20613 ||| VBZ
increased  ||| S:20613 E:20623 ||| VBN
by  ||| S:20623 E:20626 ||| IN
the  ||| S:20626 E:20640 ||| DT
Y152A  ||| S:20640 E:20646 ||| JJ
mutation ||| S:20646 E:20654 ||| NN
,  ||| S:20654 E:20656 ||| ,
it  ||| S:20656 E:20659 ||| PRP
is  ||| S:20659 E:20662 ||| VBZ
unlikely  ||| S:20662 E:20671 ||| JJ
that  ||| S:20671 E:20676 ||| IN
the  ||| S:20676 E:20680 ||| DT
N-benzyl  ||| S:20680 E:20689 ||| JJ
group  ||| S:20689 E:20705 ||| NN
interacts  ||| S:20705 E:20715 ||| NN
with  ||| S:20715 E:20720 ||| IN
Y152 ||| S:20720 E:20724 ||| CD
.  ||| S:20724 E:20726 ||| .
The  ||| S:20726 E:20730 ||| DT
small  ||| S:20730 E:20736 ||| JJ
change  ||| S:20736 E:20743 ||| NN
in  ||| S:20743 E:20746 ||| IN
K  ||| S:20746 E:20759 ||| NNP
i  ||| S:20759 E:20761 ||| NN
for  ||| S:20761 E:20765 ||| IN
analog  ||| S:20765 E:20772 ||| CD
2  ||| S:20772 E:20774 ||| CD
supports  ||| S:20774 E:20783 ||| VBZ
a  ||| S:20783 E:20785 ||| DT
partial  ||| S:20785 E:20803 ||| JJ
interaction  ||| S:20803 E:20815 ||| NN
of  ||| S:20815 E:20818 ||| IN
Y152  ||| S:20818 E:20823 ||| CD
with  ||| S:20823 E:20828 ||| IN
the  ||| S:20828 E:20832 ||| DT
distal  ||| S:20832 E:20839 ||| JJ
piperazine  ||| S:20839 E:20850 ||| JJ
nitrogen  ||| S:20850 E:20869 ||| NN
although  ||| S:20869 E:20878 ||| IN
some  ||| S:20878 E:20883 ||| DT
interaction  ||| S:20883 E:20895 ||| NN
with  ||| S:20895 E:20900 ||| IN
another  ||| S:20900 E:20908 ||| DT
group  ||| S:20908 E:20914 ||| NN
is  ||| S:20914 E:20917 ||| VBZ
also  ||| S:20917 E:20932 ||| RB
apparent ||| S:20932 E:20940 ||| JJ
.  ||| S:20940 E:20942 ||| .
This  ||| S:20942 E:20947 ||| DT
other  ||| S:20947 E:20953 ||| JJ
group  ||| S:20953 E:20959 ||| NN
would  ||| S:20959 E:20965 ||| MD
be  ||| S:20965 E:20968 ||| VB
expected  ||| S:20968 E:20977 ||| VBN
to  ||| S:20977 E:20980 ||| TO
be  ||| S:20980 E:20983 ||| VB
in  ||| S:20983 E:20996 ||| IN
close  ||| S:20996 E:21002 ||| JJ
proximity  ||| S:21002 E:21012 ||| NN
to  ||| S:21012 E:21015 ||| TO
the  ||| S:21015 E:21019 ||| DT
distal  ||| S:21019 E:21026 ||| JJ
nitrogen ||| S:21026 E:21034 ||| NN
.  ||| S:21034 E:21036 ||| .
The  ||| S:21036 E:21040 ||| DT
most  ||| S:21040 E:21045 ||| RBS
likely  ||| S:21045 E:21062 ||| JJ
candidate  ||| S:21062 E:21072 ||| NN
is  ||| S:21072 E:21075 ||| VBZ
the  ||| S:21075 E:21079 ||| DT
other  ||| S:21079 E:21085 ||| JJ
nitrogen  ||| S:21085 E:21094 ||| NN
of  ||| S:21094 E:21097 ||| IN
the  ||| S:21097 E:21101 ||| DT
piperazine  ||| S:21101 E:21112 ||| JJ
ring ||| S:21112 E:21116 ||| NN
.  ||| S:21116 E:21128 ||| .
Thus  ||| S:21128 E:21133 ||| RB
Y152A  ||| S:21133 E:21139 ||| CD
may  ||| S:21139 E:21143 ||| MD
form  ||| S:21143 E:21148 ||| VB
a  ||| S:21148 E:21150 ||| DT
partial  ||| S:21150 E:21158 ||| JJ
interaction  ||| S:21158 E:21170 ||| NN
with  ||| S:21170 E:21175 ||| IN
both  ||| S:21175 E:21190 ||| DT
piperazine  ||| S:21190 E:21201 ||| JJ
nitrogens ||| S:21201 E:21210 ||| NN
.  ||| S:21210 E:21243 ||| .
Conclusions  ||| S:21243 E:21263 ||| NNP
Figure  ||| S:21263 E:21270 ||| NNP
6shows  ||| S:21270 E:21277 ||| CD
a  ||| S:21277 E:21279 ||| DT
hypothetical  ||| S:21279 E:21292 ||| JJ
model  ||| S:21292 E:21298 ||| NN
of  ||| S:21298 E:21301 ||| IN
the  ||| S:21301 E:21313 ||| DT
lerisetron-binding  ||| S:21313 E:21332 ||| JJ
site  ||| S:21332 E:21337 ||| NN
supported  ||| S:21337 E:21347 ||| VBN
by  ||| S:21347 E:21350 ||| IN
our  ||| S:21350 E:21354 ||| PRP$
observations ||| S:21354 E:21366 ||| NNS
.  ||| S:21366 E:21368 ||| .
The  ||| S:21368 E:21380 ||| DT
model  ||| S:21380 E:21386 ||| NN
illustrates  ||| S:21386 E:21398 ||| VBZ
the  ||| S:21398 E:21402 ||| DT
secondary  ||| S:21402 E:21412 ||| JJ
structure  ||| S:21412 E:21422 ||| NN
of  ||| S:21422 E:21425 ||| IN
the  ||| S:21425 E:21429 ||| DT
region  ||| S:21429 E:21436 ||| NN
of  ||| S:21436 E:21447 ||| IN
the  ||| S:21447 E:21451 ||| DT
receptor  ||| S:21451 E:21460 ||| NN
from  ||| S:21460 E:21465 ||| IN
Y140  ||| S:21465 E:21470 ||| CD
-  ||| S:21470 E:21472 ||| :
Y152  ||| S:21472 E:21477 ||| CD
in  ||| S:21477 E:21480 ||| IN
a  ||| S:21480 E:21482 ||| DT
loop  ||| S:21482 E:21487 ||| JJ
configuration ||| S:21487 E:21500 ||| NN
.  ||| S:21500 E:21502 ||| .
This  ||| S:21502 E:21515 ||| DT
structure  ||| S:21515 E:21525 ||| NN
is  ||| S:21525 E:21528 ||| VBZ
supported  ||| S:21528 E:21538 ||| VBN
by  ||| S:21538 E:21541 ||| IN
site-directed  ||| S:21541 E:21555 ||| JJ
mutagenesis  ||| S:21555 E:21567 ||| JJ
data  ||| S:21567 E:21572 ||| NNS
[  ||| S:21572 E:21582 ||| -LRB-
25  ||| S:21582 E:21585 ||| CD
]  ||| S:21585 E:21587 ||| -RRB-
as  ||| S:21587 E:21590 ||| IN
well  ||| S:21590 E:21595 ||| RB
as  ||| S:21595 E:21598 ||| IN
structural  ||| S:21598 E:21609 ||| JJ
predictions  ||| S:21609 E:21621 ||| NNS
obtained  ||| S:21621 E:21630 ||| VBN
from  ||| S:21630 E:21635 ||| IN
other  ||| S:21635 E:21649 ||| JJ
LGIC  ||| S:21649 E:21654 ||| NN
receptors  ||| S:21654 E:21664 ||| NNS
[  ||| S:21664 E:21666 ||| -LRB-
31  ||| S:21666 E:21669 ||| CD
]  ||| S:21669 E:21671 ||| -RRB-
.  ||| S:21671 E:21673 ||| .
The  ||| S:21673 E:21677 ||| DT
recent  ||| S:21677 E:21684 ||| JJ
determination  ||| S:21684 E:21698 ||| NN
of  ||| S:21698 E:21701 ||| IN
the  ||| S:21701 E:21713 ||| DT
structure  ||| S:21713 E:21723 ||| NN
of  ||| S:21723 E:21726 ||| IN
a  ||| S:21726 E:21728 ||| DT
nicotinic  ||| S:21728 E:21738 ||| FW
acetylcholine  ||| S:21738 E:21752 ||| FW
binding  ||| S:21752 E:21760 ||| FW
protein  ||| S:21760 E:21768 ||| FW
[  ||| S:21768 E:21770 ||| -LRB-
27  ||| S:21770 E:21781 ||| CD
]  ||| S:21781 E:21783 ||| -RRB-
that  ||| S:21783 E:21788 ||| IN
shares  ||| S:21788 E:21795 ||| NNS
significant  ||| S:21795 E:21807 ||| JJ
homology  ||| S:21807 E:21816 ||| NN
with  ||| S:21816 E:21821 ||| IN
the  ||| S:21821 E:21825 ||| DT
LGIC  ||| S:21825 E:21830 ||| NNP
family  ||| S:21830 E:21845 ||| NN
also  ||| S:21845 E:21850 ||| RB
supports  ||| S:21850 E:21859 ||| VBZ
a  ||| S:21859 E:21861 ||| DT
loop  ||| S:21861 E:21866 ||| JJ
structure  ||| S:21866 E:21876 ||| NN
in  ||| S:21876 E:21879 ||| IN
this  ||| S:21879 E:21884 ||| DT
part  ||| S:21884 E:21889 ||| NN
of  ||| S:21889 E:21892 ||| IN
the  ||| S:21892 E:21896 ||| DT
protein ||| S:21896 E:21903 ||| NN
.  ||| S:21903 E:21913 ||| .
The  ||| S:21913 E:21917 ||| DT
region  ||| S:21917 E:21924 ||| NN
from  ||| S:21924 E:21929 ||| IN
W89  ||| S:21929 E:21933 ||| CD
through  ||| S:21933 E:21941 ||| IN
Y93  ||| S:21941 E:21945 ||| NNP
is  ||| S:21945 E:21948 ||| VBZ
shown  ||| S:21948 E:21954 ||| VBN
as  ||| S:21954 E:21957 ||| IN
a  ||| S:21957 E:21959 ||| DT
β-sheet  ||| S:21959 E:21967 ||| JJ
as  ||| S:21967 E:21978 ||| RB
has  ||| S:21978 E:21982 ||| VBZ
been  ||| S:21982 E:21987 ||| VBN
hypothesized  ||| S:21987 E:22000 ||| VBN
based  ||| S:22000 E:22006 ||| VBN
on  ||| S:22006 E:22009 ||| IN
site-directed  ||| S:22009 E:22023 ||| JJ
mutagenesis  ||| S:22023 E:22043 ||| JJ
studies  ||| S:22043 E:22051 ||| NNS
of  ||| S:22051 E:22054 ||| IN
this  ||| S:22054 E:22059 ||| DT
strand  ||| S:22059 E:22066 ||| NN
of  ||| S:22066 E:22069 ||| IN
the  ||| S:22069 E:22073 ||| DT
5-HT  ||| S:22073 E:22087 ||| CD
3  ||| S:22087 E:22089 ||| CD
R  ||| S:22089 E:22091 ||| NN
[  ||| S:22091 E:22093 ||| -LRB-
24  ||| S:22093 E:22096 ||| CD
]  ||| S:22096 E:22098 ||| -RRB-
.  ||| S:22098 E:22100 ||| .
Our  ||| S:22100 E:22104 ||| PRP$
data  ||| S:22104 E:22109 ||| NNS
indicate  ||| S:22109 E:22118 ||| VBP
the  ||| S:22118 E:22130 ||| DT
functional  ||| S:22130 E:22141 ||| JJ
groups  ||| S:22141 E:22148 ||| NNS
of  ||| S:22148 E:22151 ||| IN
lerisetron  ||| S:22151 E:22162 ||| NNS
that  ||| S:22162 E:22167 ||| WDT
may  ||| S:22167 E:22171 ||| MD
interact  ||| S:22171 E:22180 ||| VB
with  ||| S:22180 E:22185 ||| IN
W89 ||| S:22185 E:22188 ||| NNP
,  ||| S:22188 E:22198 ||| ,
R91 ||| S:22198 E:22201 ||| NNP
,  ||| S:22201 E:22203 ||| ,
Y142  ||| S:22203 E:22208 ||| NNP
and  ||| S:22208 E:22212 ||| CC
Y152 ||| S:22212 E:22216 ||| NNP
.  ||| S:22216 E:22226 ||| .
W89  ||| S:22226 E:22230 ||| NNP
is  ||| S:22230 E:22233 ||| VBZ
shown  ||| S:22233 E:22239 ||| VBN
interacting  ||| S:22239 E:22251 ||| VBN
with  ||| S:22251 E:22256 ||| IN
the  ||| S:22256 E:22260 ||| DT
aromatic  ||| S:22260 E:22269 ||| JJ
benzimidazole  ||| S:22269 E:22291 ||| JJ
group  ||| S:22291 E:22297 ||| NN
of  ||| S:22297 E:22300 ||| IN
lerisetron  ||| S:22300 E:22311 ||| NN
although  ||| S:22311 E:22320 ||| IN
the  ||| S:22320 E:22324 ||| DT
precise  ||| S:22324 E:22332 ||| JJ
position  ||| S:22332 E:22341 ||| NN
of  ||| S:22341 E:22344 ||| IN
W89  ||| S:22344 E:22356 ||| CD
relative  ||| S:22356 E:22365 ||| JJ
to  ||| S:22365 E:22368 ||| TO
this  ||| S:22368 E:22373 ||| DT
group  ||| S:22373 E:22379 ||| NN
is  ||| S:22379 E:22382 ||| VBZ
not  ||| S:22382 E:22386 ||| RB
known ||| S:22386 E:22391 ||| VBN
.  ||| S:22391 E:22393 ||| .
The  ||| S:22393 E:22397 ||| DT
W89  ||| S:22397 E:22401 ||| JJ
interaction  ||| S:22401 E:22421 ||| NN
with  ||| S:22421 E:22426 ||| IN
this  ||| S:22426 E:22431 ||| DT
group  ||| S:22431 E:22437 ||| NN
is  ||| S:22437 E:22440 ||| VBZ
supported  ||| S:22440 E:22450 ||| VBN
by  ||| S:22450 E:22453 ||| IN
the  ||| S:22453 E:22457 ||| DT
observed  ||| S:22457 E:22466 ||| JJ
increase  ||| S:22466 E:22475 ||| NN
in  ||| S:22475 E:22478 ||| IN
K  ||| S:22478 E:22489 ||| NNP
i  ||| S:22489 E:22491 ||| NN
for  ||| S:22491 E:22495 ||| IN
lerisetron ||| S:22495 E:22505 ||| NN
,  ||| S:22505 E:22507 ||| ,
analog  ||| S:22507 E:22514 ||| CD
1  ||| S:22514 E:22516 ||| CD
and  ||| S:22516 E:22520 ||| CC
analog  ||| S:22520 E:22527 ||| CD
2 ||| S:22527 E:22528 ||| CD
.  ||| S:22528 E:22538 ||| .
Since  ||| S:22538 E:22544 ||| IN
the  ||| S:22544 E:22548 ||| DT
benzimidazole  ||| S:22548 E:22562 ||| JJ
group  ||| S:22562 E:22568 ||| NN
is  ||| S:22568 E:22571 ||| VBZ
common  ||| S:22571 E:22578 ||| JJ
to  ||| S:22578 E:22581 ||| TO
all  ||| S:22581 E:22585 ||| DT
three  ||| S:22585 E:22599 ||| CD
compounds  ||| S:22599 E:22609 ||| NN
it  ||| S:22609 E:22612 ||| PRP
is  ||| S:22612 E:22615 ||| VBZ
the  ||| S:22615 E:22619 ||| DT
most  ||| S:22619 E:22624 ||| RBS
likely  ||| S:22624 E:22631 ||| JJ
point  ||| S:22631 E:22637 ||| NN
of  ||| S:22637 E:22640 ||| IN
interaction ||| S:22640 E:22651 ||| NN
.  ||| S:22651 E:22653 ||| .
W89  ||| S:22653 E:22665 ||| NNP
also  ||| S:22665 E:22670 ||| RB
represents  ||| S:22670 E:22681 ||| VBZ
a  ||| S:22681 E:22683 ||| DT
common  ||| S:22683 E:22690 ||| JJ
interaction  ||| S:22690 E:22702 ||| NN
in  ||| S:22702 E:22705 ||| IN
the  ||| S:22705 E:22709 ||| DT
binding  ||| S:22709 E:22717 ||| JJ
site  ||| S:22717 E:22730 ||| NN
for  ||| S:22730 E:22734 ||| IN
both  ||| S:22734 E:22739 ||| DT
lerisetron  ||| S:22739 E:22750 ||| NN
and  ||| S:22750 E:22754 ||| CC
[ ||| S:22754 E:22755 ||| -LRB-
3H ||| S:22755 E:22757 ||| NNP
] ||| S:22757 E:22758 ||| -RRB-
granisetron ||| S:22758 E:22769 ||| NN
.  ||| S:22769 E:22779 ||| .
Y142  ||| S:22779 E:22784 ||| NNP
is  ||| S:22784 E:22787 ||| VBZ
shown  ||| S:22787 E:22793 ||| VBN
interacting  ||| S:22793 E:22805 ||| VBN
with  ||| S:22805 E:22810 ||| IN
the  ||| S:22810 E:22814 ||| DT
distal  ||| S:22814 E:22821 ||| JJ
piperazine  ||| S:22821 E:22840 ||| NNS
nitrogen  ||| S:22840 E:22849 ||| VBP
possibly  ||| S:22849 E:22858 ||| RB
through  ||| S:22858 E:22866 ||| IN
a  ||| S:22866 E:22868 ||| DT
cation-π  ||| S:22868 E:22877 ||| JJ
interaction ||| S:22877 E:22888 ||| NN
.  ||| S:22888 E:22890 ||| .
This  ||| S:22890 E:22903 ||| DT
orientation  ||| S:22903 E:22915 ||| NN
of  ||| S:22915 E:22918 ||| IN
an  ||| S:22918 E:22921 ||| DT
amino  ||| S:22921 E:22927 ||| JJ
group  ||| S:22927 E:22933 ||| NN
interacting  ||| S:22933 E:22945 ||| NN
with  ||| S:22945 E:22950 ||| IN
an  ||| S:22950 E:22953 ||| DT
aromatic  ||| S:22953 E:22970 ||| JJ
amino  ||| S:22970 E:22976 ||| JJ
acid  ||| S:22976 E:22981 ||| NN
in  ||| S:22981 E:22984 ||| IN
a  ||| S:22984 E:22986 ||| DT
cation-π  ||| S:22986 E:22995 ||| JJ
interaction  ||| S:22995 E:23007 ||| NN
has  ||| S:23007 E:23011 ||| VBZ
been  ||| S:23011 E:23016 ||| VBN
shown  ||| S:23016 E:23022 ||| VBN
for  ||| S:23022 E:23026 ||| IN
the  ||| S:23026 E:23038 ||| DT
nicotinic  ||| S:23038 E:23048 ||| JJ
acetylcholine  ||| S:23048 E:23062 ||| JJ
receptor  ||| S:23062 E:23071 ||| NN
and  ||| S:23071 E:23075 ||| CC
has  ||| S:23075 E:23079 ||| VBZ
been  ||| S:23079 E:23084 ||| VBN
hypothesized  ||| S:23084 E:23105 ||| VBN
for  ||| S:23105 E:23109 ||| IN
many  ||| S:23109 E:23114 ||| JJ
LGIC  ||| S:23114 E:23119 ||| NN
receptors  ||| S:23119 E:23129 ||| NNS
[  ||| S:23129 E:23131 ||| -LRB-
28  ||| S:23131 E:23134 ||| CD
29  ||| S:23134 E:23137 ||| CD
30  ||| S:23137 E:23140 ||| CD
26  ||| S:23140 E:23143 ||| CD
]  ||| S:23143 E:23145 ||| -RRB-
.  ||| S:23145 E:23147 ||| .
This  ||| S:23147 E:23152 ||| DT
conclusion  ||| S:23152 E:23171 ||| NN
is  ||| S:23171 E:23174 ||| VBZ
based  ||| S:23174 E:23180 ||| VBN
on  ||| S:23180 E:23183 ||| IN
both  ||| S:23183 E:23188 ||| PDT
the  ||| S:23188 E:23192 ||| DT
magnitude  ||| S:23192 E:23202 ||| NN
of  ||| S:23202 E:23205 ||| IN
the  ||| S:23205 E:23209 ||| DT
change  ||| S:23209 E:23216 ||| NN
observed  ||| S:23216 E:23225 ||| VBD
on  ||| S:23225 E:23236 ||| IN
the  ||| S:23236 E:23240 ||| DT
wild  ||| S:23240 E:23245 ||| JJ
type  ||| S:23245 E:23250 ||| NN
receptor  ||| S:23250 E:23259 ||| NN
for  ||| S:23259 E:23263 ||| IN
removal  ||| S:23263 E:23271 ||| NN
of  ||| S:23271 E:23274 ||| IN
the  ||| S:23274 E:23278 ||| DT
amino  ||| S:23278 E:23284 ||| JJ
group  ||| S:23284 E:23290 ||| NN
( ||| S:23290 E:23291 ||| -LRB-
400  ||| S:23291 E:23303 ||| CD
fold ||| S:23303 E:23307 ||| CD
)  ||| S:23307 E:23309 ||| -RRB-
compared  ||| S:23309 E:23318 ||| VBN
to  ||| S:23318 E:23321 ||| TO
the  ||| S:23321 E:23325 ||| DT
effect  ||| S:23325 E:23332 ||| NN
of  ||| S:23332 E:23335 ||| IN
the  ||| S:23335 E:23339 ||| DT
Y142A  ||| S:23339 E:23345 ||| JJ
mutation  ||| S:23345 E:23354 ||| NN
on  ||| S:23354 E:23365 ||| IN
lerisetron  ||| S:23365 E:23376 ||| JJ
binding  ||| S:23376 E:23384 ||| NNS
( ||| S:23384 E:23385 ||| -LRB-
160  ||| S:23385 E:23389 ||| CD
fold ||| S:23389 E:23393 ||| CD
)  ||| S:23393 E:23395 ||| -RRB-
and  ||| S:23395 E:23399 ||| CC
the  ||| S:23399 E:23403 ||| DT
lack  ||| S:23403 E:23408 ||| NN
of  ||| S:23408 E:23411 ||| IN
any  ||| S:23411 E:23415 ||| DT
major  ||| S:23415 E:23429 ||| JJ
change  ||| S:23429 E:23436 ||| NN
in  ||| S:23436 E:23439 ||| IN
K  ||| S:23439 E:23450 ||| NNP
i  ||| S:23450 E:23452 ||| NN
for  ||| S:23452 E:23456 ||| IN
analog  ||| S:23456 E:23463 ||| CD
2  ||| S:23463 E:23465 ||| CD
as  ||| S:23465 E:23468 ||| IN
a  ||| S:23468 E:23470 ||| DT
result  ||| S:23470 E:23477 ||| NN
of  ||| S:23477 E:23480 ||| IN
this  ||| S:23480 E:23493 ||| DT
mutation ||| S:23493 E:23501 ||| NN
.  ||| S:23501 E:23503 ||| .
Our  ||| S:23503 E:23507 ||| PRP$
data  ||| S:23507 E:23512 ||| NN
does  ||| S:23512 E:23517 ||| VBZ
not  ||| S:23517 E:23521 ||| RB
support  ||| S:23521 E:23529 ||| VB
an  ||| S:23529 E:23532 ||| DT
interaction  ||| S:23532 E:23544 ||| NN
of  ||| S:23544 E:23547 ||| IN
this  ||| S:23547 E:23560 ||| DT
amino  ||| S:23560 E:23566 ||| JJ
acid  ||| S:23566 E:23571 ||| NN
with  ||| S:23571 E:23576 ||| IN
either  ||| S:23576 E:23583 ||| RB
the  ||| S:23583 E:23587 ||| DT
N-benzyl  ||| S:23587 E:23596 ||| JJ
or  ||| S:23596 E:23599 ||| CC
benzimidazole  ||| S:23599 E:23621 ||| JJ
portions  ||| S:23621 E:23630 ||| NNS
of  ||| S:23630 E:23633 ||| IN
lerisetron ||| S:23633 E:23643 ||| NN
.  ||| S:23643 E:23653 ||| .
Y152  ||| S:23653 E:23658 ||| NNP
is  ||| S:23658 E:23661 ||| VBZ
shown  ||| S:23661 E:23667 ||| VBN
positioned  ||| S:23667 E:23678 ||| VBN
between  ||| S:23678 E:23686 ||| IN
the  ||| S:23686 E:23690 ||| DT
two  ||| S:23690 E:23694 ||| CD
piperazine  ||| S:23694 E:23713 ||| CD
nitrogens ||| S:23713 E:23722 ||| NNS
.  ||| S:23722 E:23724 ||| .
This  ||| S:23724 E:23729 ||| DT
conclusion  ||| S:23729 E:23740 ||| NN
is  ||| S:23740 E:23743 ||| VBZ
supported  ||| S:23743 E:23753 ||| VBN
by  ||| S:23753 E:23756 ||| IN
the  ||| S:23756 E:23760 ||| DT
smaller  ||| S:23760 E:23776 ||| JJR
increase  ||| S:23776 E:23785 ||| NN
in  ||| S:23785 E:23788 ||| IN
K  ||| S:23788 E:23799 ||| NNP
i  ||| S:23799 E:23801 ||| NN
for  ||| S:23801 E:23805 ||| IN
analog  ||| S:23805 E:23812 ||| CD
2  ||| S:23812 E:23814 ||| CD
( ||| S:23814 E:23815 ||| -LRB-
40  ||| S:23815 E:23818 ||| CD
fold ||| S:23818 E:23822 ||| CD
)  ||| S:23822 E:23824 ||| -RRB-
compared  ||| S:23824 E:23833 ||| VBN
to  ||| S:23833 E:23844 ||| TO
that  ||| S:23844 E:23849 ||| WDT
observed  ||| S:23849 E:23858 ||| VBD
for  ||| S:23858 E:23862 ||| IN
lerisetron  ||| S:23862 E:23873 ||| NNS
( ||| S:23873 E:23874 ||| -LRB-
190  ||| S:23874 E:23878 ||| CD
fold ||| S:23878 E:23882 ||| CD
) ||| S:23882 E:23883 ||| -RRB-
.  ||| S:23883 E:23885 ||| .
These  ||| S:23885 E:23891 ||| DT
results  ||| S:23891 E:23907 ||| NNS
suggest  ||| S:23907 E:23915 ||| VBP
a  ||| S:23915 E:23917 ||| DT
partial  ||| S:23917 E:23925 ||| JJ
interaction  ||| S:23925 E:23937 ||| NN
of  ||| S:23937 E:23940 ||| IN
Y152  ||| S:23940 E:23945 ||| CD
with  ||| S:23945 E:23950 ||| IN
the  ||| S:23950 E:23954 ||| DT
distal  ||| S:23954 E:23969 ||| JJ
piperazine  ||| S:23969 E:23980 ||| JJ
nitrogen ||| S:23980 E:23988 ||| NN
.  ||| S:23988 E:23990 ||| .
Since  ||| S:23990 E:23996 ||| IN
some  ||| S:23996 E:24001 ||| DT
change  ||| S:24001 E:24008 ||| NN
was  ||| S:24008 E:24012 ||| VBD
observed ||| S:24012 E:24020 ||| VBN
,  ||| S:24020 E:24022 ||| ,
a  ||| S:24022 E:24032 ||| DT
second  ||| S:24032 E:24039 ||| JJ
interaction  ||| S:24039 E:24051 ||| NN
is  ||| S:24051 E:24054 ||| VBZ
also  ||| S:24054 E:24059 ||| RB
likely ||| S:24059 E:24065 ||| JJ
.  ||| S:24065 E:24067 ||| .
The  ||| S:24067 E:24071 ||| DT
functional  ||| S:24071 E:24082 ||| JJ
group  ||| S:24082 E:24088 ||| NN
in  ||| S:24088 E:24099 ||| IN
closest  ||| S:24099 E:24107 ||| JJS
proximity  ||| S:24107 E:24117 ||| NN
to  ||| S:24117 E:24120 ||| TO
the  ||| S:24120 E:24124 ||| DT
distal  ||| S:24124 E:24131 ||| JJ
piperazine  ||| S:24131 E:24142 ||| JJ
nitrogen  ||| S:24142 E:24151 ||| NN
is  ||| S:24151 E:24154 ||| VBZ
the  ||| S:24154 E:24166 ||| DT
other  ||| S:24166 E:24172 ||| JJ
nitrogen  ||| S:24172 E:24181 ||| NN
on  ||| S:24181 E:24184 ||| IN
the  ||| S:24184 E:24188 ||| DT
piperazine  ||| S:24188 E:24199 ||| JJ
ring ||| S:24199 E:24203 ||| NN
.  ||| S:24203 E:24205 ||| .
Another  ||| S:24205 E:24213 ||| DT
possibility  ||| S:24213 E:24233 ||| NN
would  ||| S:24233 E:24239 ||| MD
be  ||| S:24239 E:24242 ||| VB
the  ||| S:24242 E:24246 ||| DT
N-benzyl  ||| S:24246 E:24255 ||| JJ
interaction ||| S:24255 E:24266 ||| NN
,  ||| S:24266 E:24268 ||| ,
however ||| S:24268 E:24275 ||| RB
,  ||| S:24275 E:24277 ||| ,
since  ||| S:24277 E:24283 ||| IN
the  ||| S:24283 E:24287 ||| DT
Y152A  ||| S:24287 E:24301 ||| JJ
mutation  ||| S:24301 E:24310 ||| NN
also  ||| S:24310 E:24315 ||| RB
produced  ||| S:24315 E:24324 ||| VBN
a  ||| S:24324 E:24326 ||| DT
large  ||| S:24326 E:24332 ||| JJ
increase  ||| S:24332 E:24341 ||| NN
in  ||| S:24341 E:24344 ||| IN
K  ||| S:24344 E:24355 ||| NNP
i  ||| S:24355 E:24357 ||| NN
for  ||| S:24357 E:24361 ||| IN
analog  ||| S:24361 E:24368 ||| CD
2 ||| S:24368 E:24369 ||| CD
,  ||| S:24369 E:24371 ||| ,
this  ||| S:24371 E:24376 ||| DT
conclusion  ||| S:24376 E:24387 ||| NN
is  ||| S:24387 E:24390 ||| VBZ
not  ||| S:24390 E:24402 ||| RB
supported  ||| S:24402 E:24412 ||| VBN
by  ||| S:24412 E:24415 ||| IN
our  ||| S:24415 E:24419 ||| PRP$
data ||| S:24419 E:24423 ||| NNS
.  ||| S:24423 E:24433 ||| .
R91  ||| S:24433 E:24437 ||| NNP
is  ||| S:24437 E:24440 ||| VBZ
shown  ||| S:24440 E:24446 ||| VBN
as  ||| S:24446 E:24449 ||| IN
interacting  ||| S:24449 E:24461 ||| NN
with  ||| S:24461 E:24466 ||| IN
the  ||| S:24466 E:24470 ||| DT
N-benzyl  ||| S:24470 E:24479 ||| JJ
group ||| S:24479 E:24484 ||| NN
.  ||| S:24484 E:24494 ||| .
This  ||| S:24494 E:24499 ||| DT
is  ||| S:24499 E:24502 ||| VBZ
a  ||| S:24502 E:24504 ||| DT
difficult  ||| S:24504 E:24514 ||| JJ
conclusion  ||| S:24514 E:24525 ||| NN
to  ||| S:24525 E:24528 ||| TO
make  ||| S:24528 E:24533 ||| VB
considering  ||| S:24533 E:24545 ||| VBG
the  ||| S:24545 E:24557 ||| DT
small  ||| S:24557 E:24563 ||| JJ
effect  ||| S:24563 E:24570 ||| NN
of  ||| S:24570 E:24573 ||| IN
the  ||| S:24573 E:24577 ||| DT
R91A  ||| S:24577 E:24582 ||| JJ
mutation  ||| S:24582 E:24591 ||| NN
on  ||| S:24591 E:24594 ||| IN
lerisetron  ||| S:24594 E:24605 ||| JJ
binding ||| S:24605 E:24612 ||| NN
.  ||| S:24612 E:24622 ||| .
The  ||| S:24622 E:24626 ||| DT
interaction  ||| S:24626 E:24638 ||| NN
is  ||| S:24638 E:24641 ||| VBZ
included  ||| S:24641 E:24650 ||| VBN
in  ||| S:24650 E:24653 ||| IN
the  ||| S:24653 E:24657 ||| DT
model  ||| S:24657 E:24663 ||| NN
based  ||| S:24663 E:24669 ||| VBN
on  ||| S:24669 E:24680 ||| IN
structural  ||| S:24680 E:24691 ||| JJ
information  ||| S:24691 E:24703 ||| NN
obtained  ||| S:24703 E:24712 ||| VBN
from  ||| S:24712 E:24717 ||| IN
the  ||| S:24717 E:24721 ||| DT
crystal  ||| S:24721 E:24729 ||| NN
structure  ||| S:24729 E:24747 ||| NN
of  ||| S:24747 E:24750 ||| IN
AChBP  ||| S:24750 E:24756 ||| NNP
[  ||| S:24756 E:24758 ||| -LRB-
27  ||| S:24758 E:24761 ||| CD
]  ||| S:24761 E:24763 ||| -RRB-
.  ||| S:24763 E:24765 ||| .
The  ||| S:24765 E:24769 ||| DT
region  ||| S:24769 E:24776 ||| NN
of  ||| S:24776 E:24779 ||| IN
this  ||| S:24779 E:24784 ||| DT
protein  ||| S:24784 E:24792 ||| NN
homologous  ||| S:24792 E:24803 ||| NN
to  ||| S:24803 E:24814 ||| TO
loop  ||| S:24814 E:24819 ||| VB
E  ||| S:24819 E:24821 ||| NN
and  ||| S:24821 E:24825 ||| CC
loop  ||| S:24825 E:24830 ||| JJ
D  ||| S:24830 E:24832 ||| NNP
of  ||| S:24832 E:24835 ||| IN
the  ||| S:24835 E:24839 ||| DT
5-HT  ||| S:24839 E:24853 ||| CD
3A  ||| S:24853 E:24856 ||| CD
receptor  ||| S:24856 E:24865 ||| NN
suggests  ||| S:24865 E:24874 ||| VBZ
a  ||| S:24874 E:24876 ||| DT
loop  ||| S:24876 E:24881 ||| JJ
structure  ||| S:24881 E:24899 ||| NN
from  ||| S:24899 E:24904 ||| IN
Y140  ||| S:24904 E:24909 ||| CD
to  ||| S:24909 E:24912 ||| TO
Y152  ||| S:24912 E:24917 ||| CD
and  ||| S:24917 E:24921 ||| CC
a  ||| S:24921 E:24923 ||| DT
3-residue  ||| S:24923 E:24933 ||| NNP
turn  ||| S:24933 E:24938 ||| VBP
containing  ||| S:24938 E:24949 ||| VBG
a  ||| S:24949 E:24951 ||| DT
glycine  ||| S:24951 E:24967 ||| NN
at  ||| S:24967 E:24970 ||| IN
position  ||| S:24970 E:24979 ||| NN
147  ||| S:24979 E:24983 ||| CD
and  ||| S:24983 E:24987 ||| CC
the  ||| S:24987 E:24991 ||| DT
β-strand  ||| S:24991 E:25000 ||| JJ
from  ||| S:25000 E:25005 ||| IN
W89  ||| S:25005 E:25009 ||| CD
through  ||| S:25009 E:25017 ||| IN
Y93  ||| S:25017 E:25029 ||| CD
oriented  ||| S:25029 E:25038 ||| VBN
as  ||| S:25038 E:25041 ||| RB
shown  ||| S:25041 E:25047 ||| VBN
in  ||| S:25047 E:25050 ||| IN
Figure  ||| S:25050 E:25057 ||| NNP
6 ||| S:25057 E:25058 ||| CD
.  ||| S:25058 E:25060 ||| .
The  ||| S:25060 E:25064 ||| DT
orientation  ||| S:25064 E:25076 ||| NN
of  ||| S:25076 E:25087 ||| IN
lerisetron  ||| S:25087 E:25098 ||| NN
between  ||| S:25098 E:25106 ||| IN
W89  ||| S:25106 E:25110 ||| NNP
and  ||| S:25110 E:25114 ||| CC
Y142A  ||| S:25114 E:25120 ||| NNP
as  ||| S:25120 E:25123 ||| RB
shown  ||| S:25123 E:25129 ||| VBN
would  ||| S:25129 E:25135 ||| MD
enable  ||| S:25135 E:25142 ||| VB
the  ||| S:25142 E:25154 ||| DT
N-benzyl  ||| S:25154 E:25163 ||| JJ
group  ||| S:25163 E:25169 ||| NN
to  ||| S:25169 E:25172 ||| TO
be  ||| S:25172 E:25175 ||| VB
positioned  ||| S:25175 E:25186 ||| VBN
in  ||| S:25186 E:25189 ||| IN
close  ||| S:25189 E:25195 ||| JJ
proximity  ||| S:25195 E:25205 ||| NN
to  ||| S:25205 E:25208 ||| TO
R91 ||| S:25208 E:25211 ||| CD
.  ||| S:25211 E:25221 ||| .
If  ||| S:25221 E:25224 ||| IN
this  ||| S:25224 E:25229 ||| DT
is  ||| S:25229 E:25232 ||| VBZ
the  ||| S:25232 E:25236 ||| DT
case ||| S:25236 E:25240 ||| NN
,  ||| S:25240 E:25242 ||| ,
then  ||| S:25242 E:25247 ||| RB
a  ||| S:25247 E:25249 ||| DT
small  ||| S:25249 E:25255 ||| JJ
alteration  ||| S:25255 E:25266 ||| NN
in  ||| S:25266 E:25269 ||| IN
position  ||| S:25269 E:25278 ||| NN
of  ||| S:25278 E:25289 ||| IN
analog  ||| S:25289 E:25296 ||| CD
1  ||| S:25296 E:25298 ||| CD
or  ||| S:25298 E:25301 ||| CC
2  ||| S:25301 E:25303 ||| CD
in  ||| S:25303 E:25306 ||| IN
the  ||| S:25306 E:25310 ||| DT
binding  ||| S:25310 E:25318 ||| JJ
site  ||| S:25318 E:25323 ||| NN
could  ||| S:25323 E:25329 ||| MD
result  ||| S:25329 E:25336 ||| VB
in  ||| S:25336 E:25339 ||| IN
the  ||| S:25339 E:25343 ||| DT
loss  ||| S:25343 E:25356 ||| NN
of  ||| S:25356 E:25359 ||| IN
this  ||| S:25359 E:25364 ||| DT
presumably  ||| S:25364 E:25375 ||| RB
weak  ||| S:25375 E:25380 ||| JJ
interaction ||| S:25380 E:25391 ||| NN
.  ||| S:25391 E:25393 ||| .
The  ||| S:25393 E:25397 ||| DT
apparent  ||| S:25397 E:25414 ||| JJ
alterations  ||| S:25414 E:25426 ||| NN
in  ||| S:25426 E:25429 ||| IN
the  ||| S:25429 E:25433 ||| DT
binding  ||| S:25433 E:25441 ||| JJ
site  ||| S:25441 E:25446 ||| NN
location  ||| S:25446 E:25455 ||| NN
of  ||| S:25455 E:25458 ||| IN
analog  ||| S:25458 E:25465 ||| CD
1  ||| S:25465 E:25467 ||| CD
would  ||| S:25467 E:25481 ||| MD
be  ||| S:25481 E:25484 ||| VB
consistent  ||| S:25484 E:25495 ||| JJ
with  ||| S:25495 E:25500 ||| IN
this  ||| S:25500 E:25505 ||| DT
hypothesis ||| S:25505 E:25515 ||| NN
.  ||| S:25515 E:25517 ||| .
An  ||| S:25517 E:25520 ||| DT
alternate  ||| S:25520 E:25530 ||| JJ
hypothesis  ||| S:25530 E:25549 ||| NN
would  ||| S:25549 E:25555 ||| MD
place  ||| S:25555 E:25561 ||| VB
the  ||| S:25561 E:25565 ||| DT
N-benzyl  ||| S:25565 E:25574 ||| JJ
group  ||| S:25574 E:25580 ||| NN
in  ||| S:25580 E:25583 ||| IN
a  ||| S:25583 E:25585 ||| DT
different  ||| S:25585 E:25595 ||| JJ
position ||| S:25595 E:25603 ||| NN
,  ||| S:25603 E:25613 ||| ,
interacting  ||| S:25613 E:25625 ||| VBG
with  ||| S:25625 E:25630 ||| IN
another  ||| S:25630 E:25638 ||| DT
amino  ||| S:25638 E:25644 ||| JJ
acid ||| S:25644 E:25648 ||| NN
;  ||| S:25648 E:25650 ||| :
either  ||| S:25650 E:25657 ||| CC
solely  ||| S:25657 E:25664 ||| RB
or  ||| S:25664 E:25667 ||| CC
in  ||| S:25667 E:25678 ||| IN
concert  ||| S:25678 E:25686 ||| NN
with  ||| S:25686 E:25691 ||| IN
R91 ||| S:25691 E:25694 ||| CD
.  ||| S:25694 E:25704 ||| .
Our  ||| S:25704 E:25708 ||| PRP$
data  ||| S:25708 E:25713 ||| NNS
support  ||| S:25713 E:25721 ||| VBP
a  ||| S:25721 E:25723 ||| DT
binding  ||| S:25723 E:25731 ||| JJ
site  ||| S:25731 E:25736 ||| NN
for  ||| S:25736 E:25740 ||| IN
lerisetron  ||| S:25740 E:25751 ||| NN
on  ||| S:25751 E:25754 ||| IN
the  ||| S:25754 E:25766 ||| DT
5-HT  ||| S:25766 E:25780 ||| CD
3  ||| S:25780 E:25782 ||| CD
R  ||| S:25782 E:25784 ||| NN
that  ||| S:25784 E:25789 ||| IN
spans  ||| S:25789 E:25795 ||| VBG
the  ||| S:25795 E:25799 ||| DT
D  ||| S:25799 E:25801 ||| NNP
and  ||| S:25801 E:25805 ||| CC
E  ||| S:25805 E:25807 ||| NN
loop  ||| S:25807 E:25812 ||| NN
regions ||| S:25812 E:25819 ||| NNS
.  ||| S:25819 E:25829 ||| .
Table  ||| S:25829 E:25835 ||| NN
2shows  ||| S:25835 E:25842 ||| VBZ
the  ||| S:25842 E:25846 ||| DT
sequence  ||| S:25846 E:25855 ||| JJ
alignment  ||| S:25855 E:25865 ||| NN
for  ||| S:25865 E:25869 ||| IN
the  ||| S:25869 E:25873 ||| DT
5-HT  ||| S:25873 E:25887 ||| CD
3  ||| S:25887 E:25889 ||| CD
R ||| S:25889 E:25890 ||| NN
,  ||| S:25890 E:25892 ||| ,
the  ||| S:25892 E:25896 ||| DT
α7  ||| S:25896 E:25899 ||| JJ
receptor  ||| S:25899 E:25908 ||| NN
and  ||| S:25908 E:25912 ||| CC
the  ||| S:25912 E:25916 ||| DT
AChBP  ||| S:25916 E:25922 ||| JJ
for  ||| S:25922 E:25934 ||| IN
these  ||| S:25934 E:25940 ||| DT
loops ||| S:25940 E:25945 ||| NNS
.  ||| S:25945 E:25947 ||| .
Sequence  ||| S:25947 E:25956 ||| JJ
alignment  ||| S:25956 E:25966 ||| NN
of  ||| S:25966 E:25969 ||| IN
mouse  ||| S:25969 E:25975 ||| CD
5-HT  ||| S:25975 E:25989 ||| CD
3  ||| S:25989 E:25991 ||| CD
AR ||| S:25991 E:25993 ||| NNP
,  ||| S:25993 E:25995 ||| ,
α7  ||| S:25995 E:25998 ||| NNP
nAchR  ||| S:25998 E:26004 ||| NNP
and  ||| S:26004 E:26008 ||| CC
AChBP  ||| S:26008 E:26014 ||| JJ
result  ||| S:26014 E:26021 ||| NN
in  ||| S:26021 E:26032 ||| IN
alignment  ||| S:26032 E:26042 ||| NN
of  ||| S:26042 E:26045 ||| IN
the  ||| S:26045 E:26049 ||| DT
proposed  ||| S:26049 E:26058 ||| JJ
D  ||| S:26058 E:26060 ||| NNP
and  ||| S:26060 E:26064 ||| CC
E  ||| S:26064 E:26066 ||| NN
loop  ||| S:26066 E:26071 ||| NN
of  ||| S:26071 E:26074 ||| IN
the  ||| S:26074 E:26078 ||| DT
5-HT  ||| S:26078 E:26092 ||| CD
3  ||| S:26092 E:26094 ||| CD
AR  ||| S:26094 E:26097 ||| NN
with  ||| S:26097 E:26102 ||| IN
corresponding  ||| S:26102 E:26116 ||| JJ
regions  ||| S:26116 E:26124 ||| NNS
of  ||| S:26124 E:26127 ||| IN
the  ||| S:26127 E:26139 ||| DT
α7  ||| S:26139 E:26142 ||| NNP
nAchR  ||| S:26142 E:26148 ||| NNP
and  ||| S:26148 E:26152 ||| CC
AChBP ||| S:26152 E:26157 ||| JJ
.  ||| S:26157 E:26159 ||| .
The  ||| S:26159 E:26163 ||| DT
amino  ||| S:26163 E:26169 ||| JJ
acids  ||| S:26169 E:26175 ||| JJ
W89 ||| S:26175 E:26178 ||| NN
,  ||| S:26178 E:26180 ||| ,
R91  ||| S:26180 E:26184 ||| NNP
Y140 ||| S:26184 E:26188 ||| NNP
,  ||| S:26188 E:26190 ||| ,
Y142  ||| S:26190 E:26195 ||| NNP
and  ||| S:26195 E:26207 ||| CC
Y152  ||| S:26207 E:26212 ||| CD
of  ||| S:26212 E:26215 ||| IN
the  ||| S:26215 E:26219 ||| DT
5HT  ||| S:26219 E:26232 ||| CD
3  ||| S:26232 E:26234 ||| CD
A  ||| S:26234 E:26236 ||| DT
R  ||| S:26236 E:26238 ||| NN
can  ||| S:26238 E:26242 ||| MD
be  ||| S:26242 E:26245 ||| VB
aligned  ||| S:26245 E:26253 ||| VBN
with  ||| S:26253 E:26258 ||| IN
W53 ||| S:26258 E:26261 ||| NNP
,  ||| S:26261 E:26263 ||| ,
Q55 ||| S:26263 E:26266 ||| NNP
,  ||| S:26266 E:26276 ||| ,
L102 ||| S:26276 E:26280 ||| NNP
,  ||| S:26280 E:26282 ||| ,
R104 ||| S:26282 E:26286 ||| NNP
,  ||| S:26286 E:26288 ||| ,
and  ||| S:26288 E:26292 ||| CC
M114  ||| S:26292 E:26297 ||| CD
of  ||| S:26297 E:26300 ||| IN
the  ||| S:26300 E:26304 ||| DT
AChBP  ||| S:26304 E:26310 ||| JJ
( ||| S:26310 E:26311 ||| -LRB-
Figure  ||| S:26311 E:26318 ||| NNP
6 ||| S:26318 E:26319 ||| CD
) ||| S:26319 E:26320 ||| -RRB-
.  ||| S:26320 E:26322 ||| .
These  ||| S:26322 E:26328 ||| DT
amino  ||| S:26328 E:26342 ||| JJ
acids  ||| S:26342 E:26348 ||| NNS
form  ||| S:26348 E:26353 ||| VBP
a  ||| S:26353 E:26355 ||| DT
cluster  ||| S:26355 E:26363 ||| NN
in  ||| S:26363 E:26366 ||| IN
the  ||| S:26366 E:26370 ||| DT
proposed  ||| S:26370 E:26379 ||| JJ
acetylcholine  ||| S:26379 E:26393 ||| JJ
binding  ||| S:26393 E:26409 ||| JJ
domain  ||| S:26409 E:26416 ||| NN
of  ||| S:26416 E:26419 ||| IN
AChBP  ||| S:26419 E:26425 ||| JJ
similar  ||| S:26425 E:26433 ||| JJ
to  ||| S:26433 E:26436 ||| TO
that  ||| S:26436 E:26441 ||| DT
proposed  ||| S:26441 E:26450 ||| VBN
in  ||| S:26450 E:26453 ||| IN
our  ||| S:26453 E:26457 ||| PRP$
model ||| S:26457 E:26462 ||| NN
.  ||| S:26462 E:26464 ||| .
Both  ||| S:26464 E:26477 ||| DT
loops  ||| S:26477 E:26483 ||| NNS
have  ||| S:26483 E:26488 ||| VBP
been  ||| S:26488 E:26493 ||| VBN
identified  ||| S:26493 E:26504 ||| VBN
on  ||| S:26504 E:26507 ||| IN
the  ||| S:26507 E:26511 ||| DT
complementary  ||| S:26511 E:26525 ||| JJ
face  ||| S:26525 E:26530 ||| NN
of  ||| S:26530 E:26533 ||| IN
the  ||| S:26533 E:26545 ||| DT
binding  ||| S:26545 E:26553 ||| JJ
site  ||| S:26553 E:26558 ||| NN
of  ||| S:26558 E:26561 ||| IN
the  ||| S:26561 E:26565 ||| DT
nAChR ||| S:26565 E:26570 ||| JJ
.  ||| S:26570 E:26572 ||| .
It  ||| S:26572 E:26575 ||| PRP
is  ||| S:26575 E:26578 ||| VBZ
unknown  ||| S:26578 E:26586 ||| VBN
if  ||| S:26586 E:26589 ||| IN
lerisetron  ||| S:26589 E:26608 ||| JJ
utilizes  ||| S:26608 E:26617 ||| JJ
amino  ||| S:26617 E:26623 ||| JJ
acids  ||| S:26623 E:26629 ||| NNS
on  ||| S:26629 E:26632 ||| IN
the  ||| S:26632 E:26636 ||| DT
principal  ||| S:26636 E:26646 ||| JJ
face  ||| S:26646 E:26651 ||| NN
although  ||| S:26651 E:26660 ||| IN
none  ||| S:26660 E:26673 ||| NN
have  ||| S:26673 E:26678 ||| VBP
been  ||| S:26678 E:26683 ||| VBN
identified ||| S:26683 E:26693 ||| VBN
.  ||| S:26693 E:26695 ||| .
The  ||| S:26695 E:26699 ||| DT
model  ||| S:26699 E:26705 ||| NN
for  ||| S:26705 E:26709 ||| IN
lerisetron  ||| S:26709 E:26720 ||| JJ
binding  ||| S:26720 E:26728 ||| NN
will  ||| S:26728 E:26741 ||| MD
be  ||| S:26741 E:26744 ||| VB
further  ||| S:26744 E:26752 ||| RB
refined  ||| S:26752 E:26760 ||| VBN
as  ||| S:26760 E:26763 ||| IN
its  ||| S:26763 E:26767 ||| PRP$
interactions  ||| S:26767 E:26780 ||| NNS
with  ||| S:26780 E:26785 ||| IN
other  ||| S:26785 E:26791 ||| JJ
binding  ||| S:26791 E:26807 ||| JJ
site  ||| S:26807 E:26812 ||| NN
amino  ||| S:26812 E:26818 ||| NN
acids  ||| S:26818 E:26824 ||| NNS
are  ||| S:26824 E:26828 ||| VBP
investigated  ||| S:26828 E:26841 ||| VBN
[  ||| S:26841 E:26843 ||| -LRB-
26  ||| S:26843 E:26846 ||| CD
32  ||| S:26846 E:26849 ||| CD
33  ||| S:26849 E:26852 ||| CD
]  ||| S:26852 E:26854 ||| -RRB-
.  ||| S:26854 E:26856 ||| .
Of  ||| S:26856 E:26867 ||| IN
particular  ||| S:26867 E:26878 ||| JJ
interest  ||| S:26878 E:26887 ||| NN
would  ||| S:26887 E:26893 ||| MD
be  ||| S:26893 E:26896 ||| VB
potential  ||| S:26896 E:26906 ||| JJ
interactions  ||| S:26906 E:26919 ||| NNS
of  ||| S:26919 E:26922 ||| IN
the  ||| S:26922 E:26934 ||| DT
N-benzyl  ||| S:26934 E:26943 ||| JJ
group  ||| S:26943 E:26949 ||| NN
that  ||| S:26949 E:26954 ||| WDT
would  ||| S:26954 E:26960 ||| MD
account  ||| S:26960 E:26968 ||| VB
for  ||| S:26968 E:26972 ||| IN
the  ||| S:26972 E:26976 ||| DT
decrease  ||| S:26976 E:26985 ||| NN
in  ||| S:26985 E:26996 ||| IN
binding  ||| S:26996 E:27004 ||| JJ
affinity  ||| S:27004 E:27013 ||| NN
of  ||| S:27013 E:27016 ||| IN
analog  ||| S:27016 E:27023 ||| CD
2 ||| S:27023 E:27024 ||| CD
.  ||| S:27024 E:27026 ||| .
Additional  ||| S:27026 E:27037 ||| JJ
information  ||| S:27037 E:27049 ||| NN
gained  ||| S:27049 E:27064 ||| VBD
from  ||| S:27064 E:27069 ||| IN
comparison  ||| S:27069 E:27080 ||| NN
of  ||| S:27080 E:27083 ||| IN
our  ||| S:27083 E:27087 ||| PRP$
model  ||| S:27087 E:27093 ||| NN
with  ||| S:27093 E:27098 ||| IN
the  ||| S:27098 E:27102 ||| DT
recent  ||| S:27102 E:27109 ||| JJ
crystal  ||| S:27109 E:27125 ||| NN
structure  ||| S:27125 E:27135 ||| NN
of  ||| S:27135 E:27138 ||| IN
the  ||| S:27138 E:27142 ||| DT
AChBP  ||| S:27142 E:27148 ||| JJ
demonstrates  ||| S:27148 E:27161 ||| NN
that  ||| S:27161 E:27166 ||| IN
lerisetron  ||| S:27166 E:27177 ||| NNS
can  ||| S:27177 E:27181 ||| MD
be  ||| S:27181 E:27192 ||| VB
roughly  ||| S:27192 E:27200 ||| RB
' ||| S:27200 E:27201 ||| POS
fit ||| S:27201 E:27204 ||| NN
'  ||| S:27204 E:27206 ||| ''
into  ||| S:27206 E:27211 ||| IN
the  ||| S:27211 E:27215 ||| DT
binding  ||| S:27215 E:27223 ||| JJ
site  ||| S:27223 E:27228 ||| NN
such  ||| S:27228 E:27233 ||| JJ
that  ||| S:27233 E:27238 ||| IN
all  ||| S:27238 E:27242 ||| PDT
the  ||| S:27242 E:27254 ||| DT
residues  ||| S:27254 E:27263 ||| JJ
line  ||| S:27263 E:27268 ||| NN
up  ||| S:27268 E:27271 ||| RB
as  ||| S:27271 E:27274 ||| RB
shown  ||| S:27274 E:27280 ||| VBN
in  ||| S:27280 E:27283 ||| IN
our  ||| S:27283 E:27287 ||| PRP$
model ||| S:27287 E:27292 ||| NN
.  ||| S:27292 E:27294 ||| .
While  ||| S:27294 E:27300 ||| IN
this  ||| S:27300 E:27305 ||| DT
is  ||| S:27305 E:27308 ||| VBZ
not  ||| S:27308 E:27320 ||| RB
direct  ||| S:27320 E:27327 ||| JJ
evidence  ||| S:27327 E:27336 ||| NN
that  ||| S:27336 E:27341 ||| IN
the  ||| S:27341 E:27345 ||| DT
model  ||| S:27345 E:27351 ||| NN
is  ||| S:27351 E:27354 ||| VBZ
correct ||| S:27354 E:27361 ||| JJ
,  ||| S:27361 E:27363 ||| ,
subsequent  ||| S:27363 E:27382 ||| JJ
molecular  ||| S:27382 E:27392 ||| JJ
modeling  ||| S:27392 E:27401 ||| NN
of  ||| S:27401 E:27404 ||| IN
the  ||| S:27404 E:27408 ||| DT
data  ||| S:27408 E:27413 ||| NNS
presented  ||| S:27413 E:27423 ||| VBN
in  ||| S:27423 E:27426 ||| IN
this  ||| S:27426 E:27431 ||| DT
paper  ||| S:27431 E:27437 ||| NN
may  ||| S:27437 E:27449 ||| MD
provide  ||| S:27449 E:27457 ||| VB
further  ||| S:27457 E:27465 ||| JJ
support  ||| S:27465 E:27473 ||| NN
for  ||| S:27473 E:27477 ||| IN
our  ||| S:27477 E:27481 ||| PRP$
hypothesis ||| S:27481 E:27491 ||| NN
.  ||| S:27491 E:27493 ||| .
Our  ||| S:27493 E:27497 ||| PRP$
current  ||| S:27497 E:27513 ||| JJ
model  ||| S:27513 E:27519 ||| NN
provides  ||| S:27519 E:27528 ||| VBZ
an  ||| S:27528 E:27531 ||| DT
initial  ||| S:27531 E:27539 ||| JJ
working  ||| S:27539 E:27547 ||| NN
hypothesis  ||| S:27547 E:27558 ||| NNS
that  ||| S:27558 E:27563 ||| WDT
can  ||| S:27563 E:27567 ||| MD
form  ||| S:27567 E:27580 ||| VB
the  ||| S:27580 E:27584 ||| DT
basis  ||| S:27584 E:27590 ||| NN
of  ||| S:27590 E:27593 ||| IN
further  ||| S:27593 E:27601 ||| JJ
investigation ||| S:27601 E:27614 ||| NN
.  ||| S:27614 E:27616 ||| .
Also ||| S:27616 E:27620 ||| RB
,  ||| S:27620 E:27622 ||| ,
while  ||| S:27622 E:27628 ||| IN
it  ||| S:27628 E:27631 ||| PRP
is  ||| S:27631 E:27642 ||| VBZ
unclear  ||| S:27642 E:27650 ||| JJ
whether  ||| S:27650 E:27658 ||| IN
the  ||| S:27658 E:27662 ||| DT
information  ||| S:27662 E:27674 ||| NN
obtained  ||| S:27674 E:27683 ||| VBN
in  ||| S:27683 E:27686 ||| IN
this  ||| S:27686 E:27691 ||| DT
study  ||| S:27691 E:27697 ||| NN
can  ||| S:27697 E:27709 ||| MD
be  ||| S:27709 E:27712 ||| VB
extended  ||| S:27712 E:27721 ||| VBN
to  ||| S:27721 E:27724 ||| TO
other  ||| S:27724 E:27730 ||| JJ
5-HT  ||| S:27730 E:27744 ||| CD
3  ||| S:27744 E:27746 ||| CD
R  ||| S:27746 E:27748 ||| NN
ligands ||| S:27748 E:27755 ||| NN
,  ||| S:27755 E:27757 ||| ,
a  ||| S:27757 E:27759 ||| DT
similar  ||| S:27759 E:27767 ||| JJ
approach  ||| S:27767 E:27776 ||| NN
would  ||| S:27776 E:27782 ||| MD
be  ||| S:27782 E:27793 ||| VB
useful  ||| S:27793 E:27800 ||| JJ
in  ||| S:27800 E:27803 ||| IN
identifying  ||| S:27803 E:27815 ||| VBG
functional  ||| S:27815 E:27826 ||| JJ
group  ||| S:27826 E:27832 ||| NN
interactions  ||| S:27832 E:27845 ||| NNS
for  ||| S:27845 E:27857 ||| IN
mCPBG ||| S:27857 E:27862 ||| NNP
,  ||| S:27862 E:27864 ||| ,
5-HT ||| S:27864 E:27868 ||| NNP
,  ||| S:27868 E:27870 ||| ,
dtC  ||| S:27870 E:27874 ||| JJ
and  ||| S:27874 E:27878 ||| CC
granisetron ||| S:27878 E:27889 ||| NN
.  ||| S:27889 E:27913 ||| .
Materials  ||| S:27913 E:27923 ||| NNS
and  ||| S:27923 E:27927 ||| CC
Methods  ||| S:27927 E:27954 ||| NNP
Mutagenesis  ||| S:27954 E:27976 ||| NNP
Wild  ||| S:27976 E:27981 ||| NNP
type  ||| S:27981 E:27986 ||| FW
5-HT  ||| S:27986 E:28002 ||| FW
3AS  ||| S:28002 E:28006 ||| FW
mouse  ||| S:28006 E:28012 ||| FW
receptor  ||| S:28012 E:28021 ||| FW
cDNA  ||| S:28021 E:28026 ||| NNP
was  ||| S:28026 E:28030 ||| VBD
derived  ||| S:28030 E:28048 ||| VBN
from  ||| S:28048 E:28053 ||| IN
N1E-115  ||| S:28053 E:28061 ||| CD
neuroblastoma  ||| S:28061 E:28075 ||| CD
cells  ||| S:28075 E:28081 ||| NNS
as  ||| S:28081 E:28084 ||| IN
previously  ||| S:28084 E:28095 ||| RB
described  ||| S:28095 E:28115 ||| VBN
[  ||| S:28115 E:28117 ||| -LRB-
24  ||| S:28117 E:28120 ||| CD
]  ||| S:28120 E:28122 ||| -RRB-
.  ||| S:28122 E:28124 ||| .
Mutant  ||| S:28124 E:28131 ||| JJ
receptors  ||| S:28131 E:28141 ||| NNS
were  ||| S:28141 E:28146 ||| VBD
constructed  ||| S:28146 E:28158 ||| VBN
using  ||| S:28158 E:28174 ||| VBG
polymerase  ||| S:28174 E:28185 ||| JJ
chain  ||| S:28185 E:28191 ||| NN
reaction  ||| S:28191 E:28200 ||| NN
( ||| S:28200 E:28201 ||| -LRB-
Quick  ||| S:28201 E:28207 ||| RB
change  ||| S:28207 E:28214 ||| VB
mutagenesis  ||| S:28214 E:28226 ||| JJ
kit ||| S:28226 E:28229 ||| NN
,  ||| S:28229 E:28241 ||| ,
Promega ||| S:28241 E:28248 ||| NNP
) ||| S:28248 E:28249 ||| -RRB-
.  ||| S:28249 E:28251 ||| .
All  ||| S:28251 E:28255 ||| DT
mutations  ||| S:28255 E:28265 ||| NN
were  ||| S:28265 E:28270 ||| VBD
confirmed  ||| S:28270 E:28280 ||| VBN
by  ||| S:28280 E:28283 ||| IN
DNA  ||| S:28283 E:28297 ||| NNP
sequencing ||| S:28297 E:28307 ||| NN
.  ||| S:28307 E:28337 ||| .
Cell  ||| S:28337 E:28342 ||| NN
culture  ||| S:28342 E:28350 ||| NN
methods  ||| S:28350 E:28358 ||| NNS
and  ||| S:28358 E:28362 ||| CC
transfections  ||| S:28362 E:28386 ||| CD
tsA201  ||| S:28386 E:28393 ||| CD
cells  ||| S:28393 E:28399 ||| NNS
( ||| S:28399 E:28400 ||| -LRB-
a  ||| S:28400 E:28402 ||| DT
derivative  ||| S:28402 E:28413 ||| JJ
of  ||| S:28413 E:28416 ||| IN
the  ||| S:28416 E:28420 ||| DT
HEK293  ||| S:28420 E:28427 ||| JJ
cell  ||| S:28427 E:28432 ||| NN
line ||| S:28432 E:28436 ||| NN
)  ||| S:28436 E:28448 ||| -RRB-
were  ||| S:28448 E:28453 ||| VBD
grown  ||| S:28453 E:28459 ||| VBN
in  ||| S:28459 E:28462 ||| IN
Dulbecco ||| S:28462 E:28470 ||| NNP
's  ||| S:28470 E:28473 ||| POS
modified  ||| S:28473 E:28482 ||| JJ
Eagles  ||| S:28482 E:28489 ||| JJ
medium  ||| S:28489 E:28496 ||| NN
( ||| S:28496 E:28497 ||| -LRB-
D-MEM ||| S:28497 E:28502 ||| NNP
)  ||| S:28502 E:28514 ||| -RRB-
containing  ||| S:28514 E:28525 ||| VBG
10 ||| S:28525 E:28527 ||| CD
%  ||| S:28527 E:28529 ||| NN
FBS  ||| S:28529 E:28533 ||| NNP
and  ||| S:28533 E:28537 ||| CC
100-units ||| S:28537 E:28546 ||| FW
/ ||| S:28546 E:28547 ||| FW
ml  ||| S:28547 E:28560 ||| FW
penicillin ||| S:28560 E:28570 ||| FW
/ ||| S:28570 E:28571 ||| FW
streptomycin ||| S:28571 E:28583 ||| FW
.  ||| S:28583 E:28585 ||| .
Cultures  ||| S:28585 E:28594 ||| NNS
were  ||| S:28594 E:28599 ||| VBD
maintained  ||| S:28599 E:28610 ||| VBN
in  ||| S:28610 E:28623 ||| IN
humidified  ||| S:28623 E:28634 ||| JJ
atmosphere  ||| S:28634 E:28645 ||| NN
of  ||| S:28645 E:28648 ||| IN
5 ||| S:28648 E:28649 ||| CD
%  ||| S:28649 E:28651 ||| NN
CO  ||| S:28651 E:28665 ||| NNP
2  ||| S:28665 E:28667 ||| CD
at  ||| S:28667 E:28670 ||| IN
37°C ||| S:28670 E:28674 ||| CD
.  ||| S:28674 E:28676 ||| .
For  ||| S:28676 E:28680 ||| IN
binding  ||| S:28680 E:28688 ||| JJ
studies ||| S:28688 E:28695 ||| NNS
,  ||| S:28695 E:28697 ||| ,
tsA201  ||| S:28697 E:28714 ||| CD
cells  ||| S:28714 E:28720 ||| NNS
were  ||| S:28720 E:28725 ||| VBD
plated  ||| S:28725 E:28732 ||| VBN
at  ||| S:28732 E:28735 ||| IN
a  ||| S:28735 E:28737 ||| DT
density  ||| S:28737 E:28745 ||| NN
of  ||| S:28745 E:28748 ||| IN
5  ||| S:28748 E:28750 ||| CD
×  ||| S:28750 E:28752 ||| CD
10  ||| S:28752 E:28755 ||| CD
6cells ||| S:28755 E:28761 ||| CD
/ ||| S:28761 E:28762 ||| CD
75  ||| S:28762 E:28765 ||| CD
cm  ||| S:28765 E:28778 ||| NNS
2and  ||| S:28778 E:28783 ||| VBP
grown  ||| S:28783 E:28789 ||| VBN
for  ||| S:28789 E:28793 ||| IN
9  ||| S:28793 E:28795 ||| CD
hours  ||| S:28795 E:28801 ||| NNS
prior  ||| S:28801 E:28807 ||| RB
to  ||| S:28807 E:28810 ||| TO
transfection ||| S:28810 E:28822 ||| VB
.  ||| S:28822 E:28824 ||| .
Cells  ||| S:28824 E:28830 ||| NNS
were  ||| S:28830 E:28845 ||| VBD
transfected  ||| S:28845 E:28857 ||| VBN
with  ||| S:28857 E:28862 ||| IN
10  ||| S:28862 E:28865 ||| CD
μg  ||| S:28865 E:28868 ||| FW
murine  ||| S:28868 E:28875 ||| FW
5-HT  ||| S:28875 E:28891 ||| FW
3AS  ||| S:28891 E:28895 ||| FW
R  ||| S:28895 E:28897 ||| FW
cDNA  ||| S:28897 E:28902 ||| FW
using  ||| S:28902 E:28908 ||| FW
calcium  ||| S:28908 E:28916 ||| FW
phosphate  ||| S:28916 E:28936 ||| FW
co-precipitation  ||| S:28936 E:28953 ||| FW
( ||| S:28953 E:28954 ||| -LRB-
New  ||| S:28954 E:28958 ||| NNP
Life  ||| S:28958 E:28963 ||| NNP
Technologies ||| S:28963 E:28975 ||| NNPS
,  ||| S:28975 E:28977 ||| ,
NY ||| S:28977 E:28979 ||| NNP
) ||| S:28979 E:28980 ||| -RRB-
,  ||| S:28980 E:28982 ||| ,
then  ||| S:28982 E:28997 ||| RB
incubated  ||| S:28997 E:29007 ||| CD
36  ||| S:29007 E:29010 ||| CD
hours  ||| S:29010 E:29016 ||| NNS
prior  ||| S:29016 E:29022 ||| RB
to  ||| S:29022 E:29025 ||| TO
harvesting ||| S:29025 E:29035 ||| VB
.  ||| S:29035 E:29037 ||| .
For  ||| S:29037 E:29041 ||| IN
whole  ||| S:29041 E:29047 ||| JJ
cell  ||| S:29047 E:29062 ||| NN
patch  ||| S:29062 E:29068 ||| NN
clamp  ||| S:29068 E:29074 ||| NN
experiments ||| S:29074 E:29085 ||| NNS
,  ||| S:29085 E:29087 ||| ,
tsA201  ||| S:29087 E:29094 ||| CD
cells  ||| S:29094 E:29100 ||| NNS
were  ||| S:29100 E:29105 ||| VBD
plated  ||| S:29105 E:29112 ||| VBN
at  ||| S:29112 E:29115 ||| IN
a  ||| S:29115 E:29127 ||| DT
density  ||| S:29127 E:29135 ||| NN
of  ||| S:29135 E:29138 ||| IN
0.25  ||| S:29138 E:29143 ||| CD
×  ||| S:29143 E:29145 ||| CD
10  ||| S:29145 E:29148 ||| CD
6cells ||| S:29148 E:29154 ||| CD
/ ||| S:29154 E:29155 ||| CD
27  ||| S:29155 E:29158 ||| CD
cm  ||| S:29158 E:29161 ||| CD
2dish  ||| S:29161 E:29167 ||| CD
and  ||| S:29167 E:29171 ||| CC
grown  ||| S:29171 E:29177 ||| VBN
12  ||| S:29177 E:29190 ||| CD
hours  ||| S:29190 E:29196 ||| NNS
prior  ||| S:29196 E:29202 ||| RB
to  ||| S:29202 E:29205 ||| TO
transfection ||| S:29205 E:29217 ||| VB
.  ||| S:29217 E:29219 ||| .
Cells  ||| S:29219 E:29225 ||| NNS
were  ||| S:29225 E:29230 ||| VBD
washed  ||| S:29230 E:29237 ||| VBN
with  ||| S:29237 E:29242 ||| IN
fresh  ||| S:29242 E:29258 ||| JJ
culture  ||| S:29258 E:29266 ||| NN
medium  ||| S:29266 E:29273 ||| NN
then  ||| S:29273 E:29278 ||| RB
transfected  ||| S:29278 E:29290 ||| VBN
with  ||| S:29290 E:29295 ||| IN
10  ||| S:29295 E:29298 ||| CD
μg  ||| S:29298 E:29301 ||| CD
5-HT  ||| S:29301 E:29317 ||| CD
3AS  ||| S:29317 E:29321 ||| CD
R  ||| S:29321 E:29323 ||| NN
cDNA  ||| S:29323 E:29328 ||| NN
using  ||| S:29328 E:29334 ||| VBG
Qiagen  ||| S:29334 E:29341 ||| NNP
Superfect  ||| S:29341 E:29361 ||| NNP
transfection  ||| S:29361 E:29374 ||| FW
reagent  ||| S:29374 E:29382 ||| FW
( ||| S:29382 E:29383 ||| -LRB-
Qiagen ||| S:29383 E:29389 ||| NNP
,  ||| S:29389 E:29391 ||| ,
CA ||| S:29391 E:29393 ||| NNP
) ||| S:29393 E:29394 ||| -RRB-
.  ||| S:29394 E:29396 ||| .
Transfected  ||| S:29396 E:29408 ||| JJ
cells  ||| S:29408 E:29414 ||| NNS
were  ||| S:29414 E:29429 ||| VBD
incubated  ||| S:29429 E:29439 ||| VBN
with  ||| S:29439 E:29444 ||| IN
this  ||| S:29444 E:29449 ||| DT
mixture  ||| S:29449 E:29457 ||| NN
for  ||| S:29457 E:29461 ||| IN
2.5  ||| S:29461 E:29465 ||| CD
hours ||| S:29465 E:29470 ||| NNS
,  ||| S:29470 E:29472 ||| ,
then  ||| S:29472 E:29477 ||| RB
divided  ||| S:29477 E:29495 ||| VBN
into  ||| S:29495 E:29500 ||| IN
35  ||| S:29500 E:29503 ||| CD
mm  ||| S:29503 E:29506 ||| JJ
culture  ||| S:29506 E:29514 ||| NN
dishes  ||| S:29514 E:29521 ||| NNS
at  ||| S:29521 E:29524 ||| IN
a  ||| S:29524 E:29526 ||| DT
density  ||| S:29526 E:29534 ||| NN
of  ||| S:29534 E:29537 ||| IN
approximately  ||| S:29537 E:29551 ||| RB
5  ||| S:29551 E:29563 ||| CD
×  ||| S:29563 E:29565 ||| CD
10  ||| S:29565 E:29568 ||| CD
4cells ||| S:29568 E:29574 ||| CD
/ ||| S:29574 E:29575 ||| CD
dish  ||| S:29575 E:29580 ||| NN
and  ||| S:29580 E:29584 ||| CC
incubated  ||| S:29584 E:29594 ||| NN
for  ||| S:29594 E:29598 ||| IN
24  ||| S:29598 E:29601 ||| CD
hours  ||| S:29601 E:29607 ||| NNS
at  ||| S:29607 E:29610 ||| IN
37°C  ||| S:29610 E:29625 ||| CD
before  ||| S:29625 E:29632 ||| IN
recording ||| S:29632 E:29641 ||| NN
.  ||| S:29641 E:29671 ||| .
Radioligand  ||| S:29671 E:29683 ||| NNP
Binding  ||| S:29683 E:29691 ||| NNP
Assay  ||| S:29691 E:29707 ||| NNP
Transfected  ||| S:29707 E:29719 ||| NNP
cells  ||| S:29719 E:29725 ||| NNS
were  ||| S:29725 E:29730 ||| VBD
scraped  ||| S:29730 E:29738 ||| VBN
from  ||| S:29738 E:29743 ||| IN
the  ||| S:29743 E:29747 ||| DT
dishes ||| S:29747 E:29753 ||| NNS
,  ||| S:29753 E:29755 ||| ,
washed  ||| S:29755 E:29772 ||| VBD
twice  ||| S:29772 E:29778 ||| RB
with  ||| S:29778 E:29783 ||| IN
Dulbecco ||| S:29783 E:29791 ||| NNP
's  ||| S:29791 E:29794 ||| POS
PBS  ||| S:29794 E:29798 ||| NNP
( ||| S:29798 E:29799 ||| -LRB-
New  ||| S:29799 E:29803 ||| NNP
Life  ||| S:29803 E:29808 ||| NNP
Technologies ||| S:29808 E:29820 ||| NNPS
,  ||| S:29820 E:29822 ||| ,
NY ||| S:29822 E:29824 ||| NNP
) ||| S:29824 E:29825 ||| -RRB-
,  ||| S:29825 E:29837 ||| ,
then  ||| S:29837 E:29842 ||| RB
resuspended  ||| S:29842 E:29854 ||| VBN
in  ||| S:29854 E:29857 ||| IN
1.0  ||| S:29857 E:29861 ||| CD
ml  ||| S:29861 E:29864 ||| JJ
PBS ||| S:29864 E:29867 ||| NNP
/ ||| S:29867 E:29868 ||| CD
100  ||| S:29868 E:29872 ||| CD
mm  ||| S:29872 E:29875 ||| JJ
dish ||| S:29875 E:29879 ||| NN
.  ||| S:29879 E:29881 ||| .
Cells  ||| S:29881 E:29887 ||| NNS
were  ||| S:29887 E:29902 ||| VBD
either  ||| S:29902 E:29909 ||| RB
used  ||| S:29909 E:29914 ||| VBN
fresh  ||| S:29914 E:29920 ||| JJ
or  ||| S:29920 E:29923 ||| CC
frozen  ||| S:29923 E:29930 ||| VBN
at  ||| S:29930 E:29933 ||| IN
this  ||| S:29933 E:29938 ||| DT
step  ||| S:29938 E:29943 ||| NN
until  ||| S:29943 E:29949 ||| IN
needed ||| S:29949 E:29955 ||| VBN
.  ||| S:29955 E:29967 ||| .
Immediately  ||| S:29967 E:29979 ||| RB
prior  ||| S:29979 E:29985 ||| RB
to  ||| S:29985 E:29988 ||| TO
use ||| S:29988 E:29991 ||| VB
,  ||| S:29991 E:29993 ||| ,
cells  ||| S:29993 E:29999 ||| NNS
were  ||| S:29999 E:30004 ||| VBD
homogenized  ||| S:30004 E:30016 ||| VBN
in  ||| S:30016 E:30019 ||| IN
PBS  ||| S:30019 E:30033 ||| NNP
using  ||| S:30033 E:30039 ||| VBG
a  ||| S:30039 E:30041 ||| DT
glass  ||| S:30041 E:30047 ||| NN
tissue  ||| S:30047 E:30054 ||| NN
homogenizer  ||| S:30054 E:30066 ||| VBZ
then  ||| S:30066 E:30071 ||| RB
centrifuged  ||| S:30071 E:30083 ||| VBN
at  ||| S:30083 E:30086 ||| IN
35  ||| S:30086 E:30099 ||| CD
000  ||| S:30099 E:30103 ||| CD
×  ||| S:30103 E:30105 ||| CD
g  ||| S:30105 E:30107 ||| NN
for  ||| S:30107 E:30111 ||| IN
30  ||| S:30111 E:30114 ||| CD
minutes  ||| S:30114 E:30122 ||| NNS
in  ||| S:30122 E:30125 ||| IN
a  ||| S:30125 E:30127 ||| DT
Beckman  ||| S:30127 E:30135 ||| NNP
JA20  ||| S:30135 E:30140 ||| NNP
rotor ||| S:30140 E:30145 ||| NN
.  ||| S:30145 E:30147 ||| .
Membranes  ||| S:30147 E:30167 ||| NNP
were  ||| S:30167 E:30172 ||| VBD
washed  ||| S:30172 E:30179 ||| VBN
once  ||| S:30179 E:30184 ||| RB
more  ||| S:30184 E:30189 ||| JJR
with  ||| S:30189 E:30194 ||| IN
PBS  ||| S:30194 E:30198 ||| NNP
then  ||| S:30198 E:30203 ||| RB
resuspended  ||| S:30203 E:30215 ||| VBN
in  ||| S:30215 E:30218 ||| IN
1  ||| S:30218 E:30220 ||| CD
ml  ||| S:30220 E:30233 ||| JJ
PBS ||| S:30233 E:30236 ||| NNP
/ ||| S:30236 E:30237 ||| CD
100  ||| S:30237 E:30241 ||| CD
mm  ||| S:30241 E:30244 ||| JJ
dish ||| S:30244 E:30248 ||| NN
.  ||| S:30248 E:30250 ||| .
Protein  ||| S:30250 E:30258 ||| NN
content  ||| S:30258 E:30266 ||| NN
was  ||| S:30266 E:30270 ||| VBD
determined  ||| S:30270 E:30281 ||| VBN
using  ||| S:30281 E:30287 ||| VBG
a  ||| S:30287 E:30299 ||| DT
Lowry  ||| S:30299 E:30305 ||| JJ
assay  ||| S:30305 E:30311 ||| NNS
( ||| S:30311 E:30312 ||| -LRB-
Sigma ||| S:30312 E:30317 ||| NNP
.  ||| S:30317 E:30319 ||| .
Diagnostics ||| S:30319 E:30330 ||| NNP
,  ||| S:30330 E:30332 ||| ,
St.  ||| S:30332 E:30336 ||| NNP
Louis ||| S:30336 E:30341 ||| NNP
,  ||| S:30341 E:30343 ||| ,
MO ||| S:30343 E:30345 ||| NNP
) ||| S:30345 E:30346 ||| -RRB-
.  ||| S:30346 E:30348 ||| .
Binding  ||| S:30348 E:30366 ||| JJ
assays  ||| S:30366 E:30373 ||| NN
were  ||| S:30373 E:30378 ||| VBD
performed  ||| S:30378 E:30388 ||| VBN
in  ||| S:30388 E:30391 ||| IN
PBS ||| S:30391 E:30394 ||| NNP
.  ||| S:30394 E:30396 ||| .
For  ||| S:30396 E:30400 ||| IN
K  ||| S:30400 E:30413 ||| NNP
d  ||| S:30413 E:30415 ||| SYM
determinations ||| S:30415 E:30429 ||| FW
,  ||| S:30429 E:30431 ||| ,
100  ||| S:30431 E:30435 ||| CD
μl  ||| S:30435 E:30438 ||| NN
of  ||| S:30438 E:30441 ||| IN
homogenate  ||| S:30441 E:30462 ||| NN
was  ||| S:30462 E:30466 ||| VBD
incubated  ||| S:30466 E:30476 ||| VBN
at  ||| S:30476 E:30479 ||| IN
37°C  ||| S:30479 E:30484 ||| CD
for  ||| S:30484 E:30488 ||| IN
1  ||| S:30488 E:30490 ||| CD
hour  ||| S:30490 E:30495 ||| NN
with  ||| S:30495 E:30500 ||| IN
varying  ||| S:30500 E:30518 ||| VBG
concentrations  ||| S:30518 E:30533 ||| NNS
of  ||| S:30533 E:30536 ||| IN
[  ||| S:30536 E:30538 ||| -LRB-
3H ||| S:30538 E:30540 ||| NNP
]  ||| S:30540 E:30542 ||| -RRB-
granisetron  ||| S:30542 E:30554 ||| NNS
( ||| S:30554 E:30555 ||| -LRB-
NEN ||| S:30555 E:30558 ||| NNP
,  ||| S:30558 E:30560 ||| ,
MA ||| S:30560 E:30562 ||| NNP
) ||| S:30562 E:30563 ||| -RRB-
.  ||| S:30563 E:30565 ||| .
Specific  ||| S:30565 E:30584 ||| JJ
binding  ||| S:30584 E:30592 ||| NN
of  ||| S:30592 E:30595 ||| IN
[  ||| S:30595 E:30597 ||| -LRB-
3H ||| S:30597 E:30599 ||| NNP
]  ||| S:30599 E:30601 ||| -RRB-
granisetron  ||| S:30601 E:30613 ||| NN
was  ||| S:30613 E:30617 ||| VBD
determined  ||| S:30617 E:30628 ||| VBN
as  ||| S:30628 E:30631 ||| IN
the  ||| S:30631 E:30635 ||| DT
bound  ||| S:30635 E:30651 ||| NN
[  ||| S:30651 E:30653 ||| -LRB-
3H ||| S:30653 E:30655 ||| NNP
]  ||| S:30655 E:30657 ||| -RRB-
granisetron  ||| S:30657 E:30669 ||| VBZ
not  ||| S:30669 E:30673 ||| RB
displaced  ||| S:30673 E:30683 ||| VBN
by  ||| S:30683 E:30686 ||| IN
a  ||| S:30686 E:30688 ||| DT
saturating  ||| S:30688 E:30709 ||| JJ
concentration  ||| S:30709 E:30723 ||| NN
of  ||| S:30723 E:30726 ||| IN
a  ||| S:30726 E:30728 ||| DT
competing  ||| S:30728 E:30738 ||| JJ
ligand  ||| S:30738 E:30745 ||| NNS
( ||| S:30745 E:30746 ||| -LRB-
100  ||| S:30746 E:30750 ||| CD
μM  ||| S:30750 E:30753 ||| JJ
mCPBG  ||| S:30753 E:30759 ||| JJ
or  ||| S:30759 E:30762 ||| CC
10  ||| S:30762 E:30775 ||| CD
μM  ||| S:30775 E:30778 ||| JJ
MDL-72222 ||| S:30778 E:30787 ||| CD
) ||| S:30787 E:30788 ||| -RRB-
.  ||| S:30788 E:30790 ||| .
K  ||| S:30790 E:30803 ||| NNP
d  ||| S:30803 E:30805 ||| NN
values  ||| S:30805 E:30812 ||| NNS
were  ||| S:30812 E:30817 ||| VBD
determined  ||| S:30817 E:30828 ||| VBN
by  ||| S:30828 E:30831 ||| IN
fitting  ||| S:30831 E:30849 ||| VBG
the  ||| S:30849 E:30853 ||| DT
binding  ||| S:30853 E:30861 ||| JJ
data  ||| S:30861 E:30866 ||| NNS
to  ||| S:30866 E:30869 ||| TO
the  ||| S:30869 E:30873 ||| DT
following  ||| S:30873 E:30883 ||| JJ
equation  ||| S:30883 E:30892 ||| NN
using  ||| S:30892 E:30898 ||| VBG
GraphPad  ||| S:30898 E:30917 ||| JJ
PRISM  ||| S:30917 E:30923 ||| NNP
( ||| S:30923 E:30924 ||| -LRB-
San  ||| S:30924 E:30928 ||| NNP
Diego  ||| S:30928 E:30934 ||| NNP
CA ||| S:30934 E:30936 ||| NNP
) ||| S:30936 E:30937 ||| -RRB-
:  ||| S:30937 E:30939 ||| :
B  ||| S:30939 E:30941 ||| NNP
=  ||| S:30941 E:30943 ||| NNP
Bmax  ||| S:30943 E:30948 ||| NNP
[ ||| S:30948 E:30949 ||| -LRB-
L ||| S:30949 E:30950 ||| NNP
]  ||| S:30950 E:30952 ||| -RRB-
n  ||| S:30952 E:30954 ||| FW
/  ||| S:30954 E:30956 ||| FW
( ||| S:30956 E:30957 ||| -LRB-
[ ||| S:30957 E:30958 ||| -LRB-
L ||| S:30958 E:30959 ||| NNP
]  ||| S:30959 E:30961 ||| -RRB-
n  ||| S:30961 E:30963 ||| FW
+  ||| S:30963 E:30965 ||| FW
Kn ||| S:30965 E:30967 ||| FW
) ||| S:30967 E:30968 ||| -RRB-
,  ||| S:30968 E:30980 ||| ,
where  ||| S:30980 E:30986 ||| WRB
θ  ||| S:30986 E:30988 ||| NN
is  ||| S:30988 E:30991 ||| VBZ
bound  ||| S:30991 E:30997 ||| VBN
ligand ||| S:30997 E:31003 ||| NN
,  ||| S:31003 E:31005 ||| ,
Bmax  ||| S:31005 E:31010 ||| NNP
is  ||| S:31010 E:31013 ||| VBZ
the  ||| S:31013 E:31017 ||| DT
maximum  ||| S:31017 E:31025 ||| JJ
binding  ||| S:31025 E:31033 ||| NN
at  ||| S:31033 E:31046 ||| IN
equilibrium  ||| S:31046 E:31058 ||| JJ
L  ||| S:31058 E:31060 ||| NNP
is  ||| S:31060 E:31063 ||| VBZ
the  ||| S:31063 E:31067 ||| DT
free  ||| S:31067 E:31072 ||| JJ
ligand  ||| S:31072 E:31079 ||| JJ
concentration  ||| S:31079 E:31093 ||| NN
and  ||| S:31093 E:31097 ||| CC
n  ||| S:31097 E:31099 ||| NN
is  ||| S:31099 E:31112 ||| VBZ
the  ||| S:31112 E:31116 ||| DT
Hill  ||| S:31116 E:31121 ||| NNP
coefficient ||| S:31121 E:31132 ||| NN
.  ||| S:31132 E:31134 ||| .
For  ||| S:31134 E:31138 ||| IN
K  ||| S:31138 E:31151 ||| NNP
i  ||| S:31151 E:31153 ||| FW
determinations ||| S:31153 E:31167 ||| FW
,  ||| S:31167 E:31169 ||| ,
100  ||| S:31169 E:31173 ||| CD
μl  ||| S:31173 E:31176 ||| NN
of  ||| S:31176 E:31179 ||| IN
homogenate  ||| S:31179 E:31200 ||| NN
was  ||| S:31200 E:31204 ||| VBD
incubated  ||| S:31204 E:31214 ||| VBN
at  ||| S:31214 E:31217 ||| IN
37°C  ||| S:31217 E:31222 ||| CD
for  ||| S:31222 E:31226 ||| IN
2  ||| S:31226 E:31228 ||| CD
hours  ||| S:31228 E:31234 ||| NNS
with  ||| S:31234 E:31239 ||| IN
varying  ||| S:31239 E:31257 ||| VBG
concentrations  ||| S:31257 E:31272 ||| NNS
of  ||| S:31272 E:31275 ||| IN
inhibitor  ||| S:31275 E:31285 ||| NN
and  ||| S:31285 E:31289 ||| CC
[  ||| S:31289 E:31291 ||| -LRB-
3H ||| S:31291 E:31293 ||| NNP
]  ||| S:31293 E:31295 ||| -RRB-
granisetron  ||| S:31295 E:31307 ||| NNS
( ||| S:31307 E:31308 ||| -LRB-
NEN ||| S:31308 E:31311 ||| NNP
,  ||| S:31311 E:31323 ||| ,
MA ||| S:31323 E:31325 ||| NNP
) ||| S:31325 E:31326 ||| -RRB-
.  ||| S:31326 E:31328 ||| .
Binding  ||| S:31328 E:31336 ||| NNP
was  ||| S:31336 E:31340 ||| VBD
terminated  ||| S:31340 E:31351 ||| VBN
by  ||| S:31351 E:31354 ||| IN
rapid  ||| S:31354 E:31360 ||| JJ
filtration  ||| S:31360 E:31371 ||| NN
onto  ||| S:31371 E:31376 ||| IN
a  ||| S:31376 E:31388 ||| DT
GF ||| S:31388 E:31390 ||| NNP
/ ||| S:31390 E:31391 ||| NNP
B  ||| S:31391 E:31393 ||| NNP
filters ||| S:31393 E:31400 ||| NNS
.  ||| S:31400 E:31402 ||| .
The  ||| S:31402 E:31406 ||| DT
IC  ||| S:31406 E:31420 ||| NNP
50  ||| S:31420 E:31423 ||| CD
values  ||| S:31423 E:31430 ||| NNS
were  ||| S:31430 E:31435 ||| VBD
calculated  ||| S:31435 E:31446 ||| VBN
by  ||| S:31446 E:31449 ||| IN
fitting  ||| S:31449 E:31467 ||| VBG
the  ||| S:31467 E:31471 ||| DT
data  ||| S:31471 E:31476 ||| NNS
to  ||| S:31476 E:31479 ||| TO
the  ||| S:31479 E:31483 ||| DT
following  ||| S:31483 E:31493 ||| JJ
equation  ||| S:31493 E:31502 ||| NN
using  ||| S:31502 E:31508 ||| VBG
GraphPad  ||| S:31508 E:31517 ||| JJ
PRISM  ||| S:31517 E:31533 ||| NNP
( ||| S:31533 E:31534 ||| -LRB-
San  ||| S:31534 E:31538 ||| NNP
Diego  ||| S:31538 E:31544 ||| NNP
CA ||| S:31544 E:31546 ||| NNP
) ||| S:31546 E:31547 ||| -RRB-
:  ||| S:31547 E:31549 ||| :
θ  ||| S:31549 E:31551 ||| CD
=  ||| S:31551 E:31553 ||| SYM
1 ||| S:31553 E:31554 ||| CD
/  ||| S:31554 E:31556 ||| CD
( ||| S:31556 E:31557 ||| -LRB-
1+ ||| S:31557 E:31559 ||| NNP
( ||| S:31559 E:31560 ||| -LRB-
L ||| S:31560 E:31561 ||| NNP
/ ||| S:31561 E:31562 ||| NNP
IC  ||| S:31562 E:31576 ||| NNP
50  ||| S:31576 E:31579 ||| CD
) ||| S:31579 E:31580 ||| -RRB-
) ||| S:31580 E:31581 ||| -RRB-
,  ||| S:31581 E:31583 ||| ,
where  ||| S:31583 E:31589 ||| WRB
θ  ||| S:31589 E:31591 ||| NN
is  ||| S:31591 E:31594 ||| VBZ
the  ||| S:31594 E:31598 ||| DT
fractional  ||| S:31598 E:31619 ||| JJ
amount  ||| S:31619 E:31626 ||| NN
of  ||| S:31626 E:31629 ||| IN
[  ||| S:31629 E:31631 ||| -LRB-
3H ||| S:31631 E:31633 ||| NNP
]  ||| S:31633 E:31635 ||| -RRB-
granisetron  ||| S:31635 E:31647 ||| VBZ
bound  ||| S:31647 E:31653 ||| VBN
in  ||| S:31653 E:31656 ||| IN
the  ||| S:31656 E:31660 ||| DT
presence  ||| S:31660 E:31669 ||| NN
of  ||| S:31669 E:31682 ||| IN
inhibitor  ||| S:31682 E:31692 ||| NN
at  ||| S:31692 E:31695 ||| IN
concentration  ||| S:31695 E:31709 ||| NN
L  ||| S:31709 E:31711 ||| NNP
as  ||| S:31711 E:31714 ||| RB
compared  ||| S:31714 E:31723 ||| VBN
to  ||| S:31723 E:31726 ||| TO
the  ||| S:31726 E:31730 ||| DT
amount  ||| S:31730 E:31737 ||| NN
of  ||| S:31737 E:31750 ||| IN
[  ||| S:31750 E:31752 ||| -LRB-
3H ||| S:31752 E:31754 ||| NNP
]  ||| S:31754 E:31756 ||| -RRB-
granisetron  ||| S:31756 E:31768 ||| VBZ
bound  ||| S:31768 E:31774 ||| VBN
in  ||| S:31774 E:31777 ||| IN
the  ||| S:31777 E:31781 ||| DT
absence  ||| S:31781 E:31789 ||| NN
of  ||| S:31789 E:31792 ||| IN
inhibitor ||| S:31792 E:31801 ||| NN
.  ||| S:31801 E:31803 ||| .
IC  ||| S:31803 E:31817 ||| NNP
50  ||| S:31817 E:31820 ||| CD
is  ||| S:31820 E:31823 ||| VBZ
the  ||| S:31823 E:31827 ||| DT
concentration  ||| S:31827 E:31841 ||| NN
at  ||| S:31841 E:31844 ||| IN
which  ||| S:31844 E:31850 ||| WDT
θ  ||| S:31850 E:31852 ||| VBD
=  ||| S:31852 E:31864 ||| CD
0.5 ||| S:31864 E:31867 ||| CD
.  ||| S:31867 E:31869 ||| .
The  ||| S:31869 E:31873 ||| DT
K  ||| S:31873 E:31886 ||| NNP
i  ||| S:31886 E:31888 ||| FW
is  ||| S:31888 E:31891 ||| VBZ
calculated  ||| S:31891 E:31902 ||| VBN
from  ||| S:31902 E:31907 ||| IN
the  ||| S:31907 E:31911 ||| DT
IC  ||| S:31911 E:31925 ||| NNP
50  ||| S:31925 E:31928 ||| CD
value  ||| S:31928 E:31934 ||| NN
using  ||| S:31934 E:31940 ||| VBG
the  ||| S:31940 E:31944 ||| DT
Cheng-Prusoff  ||| S:31944 E:31968 ||| JJ
equation ||| S:31968 E:31976 ||| NN
.  ||| S:31976 E:32006 ||| .
Electrophysiological  ||| S:32006 E:32027 ||| NNP
Methods  ||| S:32027 E:32045 ||| NNP
Transfected  ||| S:32045 E:32057 ||| NNP
tsA201  ||| S:32057 E:32064 ||| NNP
cells  ||| S:32064 E:32070 ||| NNS
were  ||| S:32070 E:32075 ||| VBD
transferred  ||| S:32075 E:32087 ||| VBN
to  ||| S:32087 E:32090 ||| TO
a  ||| S:32090 E:32102 ||| DT
recording  ||| S:32102 E:32112 ||| NN
chamber  ||| S:32112 E:32120 ||| NN
and  ||| S:32120 E:32124 ||| CC
submerged  ||| S:32124 E:32134 ||| NN
in  ||| S:32134 E:32137 ||| IN
extracellular  ||| S:32137 E:32161 ||| JJ
recording  ||| S:32161 E:32171 ||| NN
buffer  ||| S:32171 E:32178 ||| NN
containing  ||| S:32178 E:32189 ||| VBG
25  ||| S:32189 E:32192 ||| CD
mM  ||| S:32192 E:32195 ||| JJ
HEPES  ||| S:32195 E:32201 ||| NNP
pH  ||| S:32201 E:32204 ||| NNP
7.4 ||| S:32204 E:32207 ||| CD
,  ||| S:32207 E:32209 ||| ,
140  ||| S:32209 E:32213 ||| CD
mM  ||| S:32213 E:32226 ||| JJ
NaCl ||| S:32226 E:32230 ||| NN
,  ||| S:32230 E:32232 ||| ,
1.7  ||| S:32232 E:32236 ||| CD
mM  ||| S:32236 E:32239 ||| JJ
MgCl  ||| S:32239 E:32255 ||| JJ
2  ||| S:32255 E:32257 ||| CD
,  ||| S:32257 E:32259 ||| ,
5  ||| S:32259 E:32261 ||| CD
mM  ||| S:32261 E:32264 ||| JJ
KCl ||| S:32264 E:32267 ||| NN
,  ||| S:32267 E:32269 ||| ,
1.8  ||| S:32269 E:32273 ||| CD
mM  ||| S:32273 E:32276 ||| JJ
CaCl  ||| S:32276 E:32292 ||| JJ
2  ||| S:32292 E:32294 ||| CD
.  ||| S:32294 E:32296 ||| .
Patch  ||| S:32296 E:32302 ||| JJ
electrodes  ||| S:32302 E:32313 ||| NNS
( ||| S:32313 E:32314 ||| -LRB-
2-2.5  ||| S:32314 E:32320 ||| NNP
MΩ ||| S:32320 E:32322 ||| NNP
)  ||| S:32322 E:32324 ||| -RRB-
were  ||| S:32324 E:32339 ||| VBD
filled  ||| S:32339 E:32346 ||| VBN
with  ||| S:32346 E:32351 ||| IN
intracellular  ||| S:32351 E:32365 ||| JJ
recording  ||| S:32365 E:32375 ||| NN
buffer  ||| S:32375 E:32382 ||| NN
containing  ||| S:32382 E:32393 ||| VBG
25  ||| S:32393 E:32406 ||| CD
mM  ||| S:32406 E:32409 ||| JJ
HEPES  ||| S:32409 E:32415 ||| NNP
pH  ||| S:32415 E:32418 ||| NNP
7.4 ||| S:32418 E:32421 ||| CD
,  ||| S:32421 E:32423 ||| ,
145  ||| S:32423 E:32427 ||| CD
mM  ||| S:32427 E:32430 ||| JJ
KCL ||| S:32430 E:32433 ||| NNP
,  ||| S:32433 E:32435 ||| ,
2  ||| S:32435 E:32437 ||| CD
mM  ||| S:32437 E:32440 ||| JJ
MgCl  ||| S:32440 E:32456 ||| JJ
2  ||| S:32456 E:32458 ||| CD
and  ||| S:32458 E:32462 ||| CC
1  ||| S:32462 E:32464 ||| CD
mM  ||| S:32464 E:32467 ||| JJ
EGTA ||| S:32467 E:32471 ||| NNP
.  ||| S:32471 E:32473 ||| .
Cells  ||| S:32473 E:32479 ||| NNS
were  ||| S:32479 E:32484 ||| VBD
clamped  ||| S:32484 E:32492 ||| VBN
in  ||| S:32492 E:32505 ||| IN
whole  ||| S:32505 E:32511 ||| JJ
cell  ||| S:32511 E:32516 ||| NN
configuration  ||| S:32516 E:32530 ||| NN
at  ||| S:32530 E:32533 ||| IN
a  ||| S:32533 E:32535 ||| DT
holding  ||| S:32535 E:32543 ||| NN
potential  ||| S:32543 E:32553 ||| NN
of  ||| S:32553 E:32556 ||| IN
-60  ||| S:32556 E:32570 ||| NNP
mV ||| S:32570 E:32572 ||| NNP
.  ||| S:32572 E:32574 ||| .
Currents  ||| S:32574 E:32583 ||| JJ
elicited  ||| S:32583 E:32592 ||| NN
by  ||| S:32592 E:32595 ||| IN
agonist  ||| S:32595 E:32603 ||| JJ
application  ||| S:32603 E:32615 ||| NN
were  ||| S:32615 E:32630 ||| VBD
measured  ||| S:32630 E:32639 ||| VBN
using  ||| S:32639 E:32645 ||| VBG
an  ||| S:32645 E:32648 ||| DT
Axopatch  ||| S:32648 E:32657 ||| NNP
200B  ||| S:32657 E:32662 ||| FW
amplifier  ||| S:32662 E:32672 ||| FW
( ||| S:32672 E:32673 ||| -LRB-
Foster  ||| S:32673 E:32680 ||| NNP
City ||| S:32680 E:32684 ||| NNP
,  ||| S:32684 E:32696 ||| ,
CA ||| S:32696 E:32698 ||| NNP
)  ||| S:32698 E:32700 ||| -RRB-
under  ||| S:32700 E:32706 ||| IN
computer  ||| S:32706 E:32715 ||| NN
control  ||| S:32715 E:32723 ||| NN
( ||| S:32723 E:32724 ||| -LRB-
DataPac  ||| S:32724 E:32732 ||| NNP
2000 ||| S:32732 E:32736 ||| CD
,  ||| S:32736 E:32738 ||| ,
RUN  ||| S:32738 E:32752 ||| NNP
Technologies ||| S:32752 E:32764 ||| NNPS
) ||| S:32764 E:32765 ||| -RRB-
.  ||| S:32765 E:32767 ||| .
Agonists  ||| S:32767 E:32776 ||| NNP
and  ||| S:32776 E:32780 ||| CC
antagonists  ||| S:32780 E:32792 ||| NNS
were  ||| S:32792 E:32797 ||| VBD
dissolved  ||| S:32797 E:32807 ||| VBN
in  ||| S:32807 E:32820 ||| IN
extracellular  ||| S:32820 E:32834 ||| JJ
solution  ||| S:32834 E:32843 ||| NN
and  ||| S:32843 E:32847 ||| CC
delivered  ||| S:32847 E:32857 ||| VBN
to  ||| S:32857 E:32860 ||| TO
cells  ||| S:32860 E:32866 ||| NNS
using  ||| S:32866 E:32872 ||| VBG
a  ||| S:32872 E:32884 ||| DT
rapid  ||| S:32884 E:32890 ||| JJ
perfusion  ||| S:32890 E:32900 ||| JJ
system  ||| S:32900 E:32907 ||| NN
( ||| S:32907 E:32908 ||| -LRB-
Warner  ||| S:32908 E:32915 ||| NNP
Instruments ||| S:32915 E:32926 ||| NNP
,  ||| S:32926 E:32928 ||| ,
Hamden ||| S:32928 E:32934 ||| NNP
,  ||| S:32934 E:32936 ||| ,
CT ||| S:32936 E:32938 ||| NNP
) ||| S:32938 E:32939 ||| -RRB-
.  ||| S:32939 E:32951 ||| .
For  ||| S:32951 E:32955 ||| IN
EC  ||| S:32955 E:32969 ||| NNP
50  ||| S:32969 E:32972 ||| CD
determinations ||| S:32972 E:32986 ||| NN
,  ||| S:32986 E:32988 ||| ,
responses  ||| S:32988 E:32998 ||| NNS
were  ||| S:32998 E:33013 ||| VBD
normalized  ||| S:33013 E:33024 ||| VBN
to  ||| S:33024 E:33027 ||| TO
the  ||| S:33027 E:33031 ||| DT
maximum  ||| S:33031 E:33039 ||| JJ
response  ||| S:33039 E:33048 ||| NN
obtained  ||| S:33048 E:33057 ||| VBN
from  ||| S:33057 E:33062 ||| IN
the  ||| S:33062 E:33066 ||| DT
full  ||| S:33066 E:33081 ||| JJ
agonist  ||| S:33081 E:33089 ||| JJ
5-HT  ||| S:33089 E:33094 ||| NN
and  ||| S:33094 E:33098 ||| CC
fitted  ||| S:33098 E:33105 ||| JJ
to  ||| S:33105 E:33108 ||| TO
the  ||| S:33108 E:33112 ||| DT
equation  ||| S:33112 E:33121 ||| NN
Ψ=  ||| S:33121 E:33124 ||| CD
1 ||| S:33124 E:33125 ||| CD
/ ||| S:33125 E:33126 ||| CD
1+ ||| S:33126 E:33128 ||| CD
( ||| S:33128 E:33129 ||| -LRB-
EC50 ||| S:33129 E:33133 ||| NNP
/  ||| S:33133 E:33135 ||| NNP
[ ||| S:33135 E:33136 ||| -LRB-
C ||| S:33136 E:33137 ||| NNP
]  ||| S:33137 E:33149 ||| -RRB-
n ||| S:33149 E:33150 ||| NN
) ||| S:33150 E:33151 ||| -RRB-
,  ||| S:33151 E:33153 ||| ,
where  ||| S:33153 E:33159 ||| WRB
Ψ  ||| S:33159 E:33161 ||| NNP
is  ||| S:33161 E:33164 ||| VBZ
the  ||| S:33164 E:33168 ||| DT
normalized  ||| S:33168 E:33179 ||| JJ
current  ||| S:33179 E:33187 ||| JJ
at  ||| S:33187 E:33190 ||| IN
5-HT  ||| S:33190 E:33205 ||| CD
concentration  ||| S:33205 E:33219 ||| NN
[ ||| S:33219 E:33220 ||| -LRB-
C ||| S:33220 E:33221 ||| NNP
] ||| S:33221 E:33222 ||| -RRB-
,  ||| S:33222 E:33224 ||| ,
EC50  ||| S:33224 E:33229 ||| NNP
is  ||| S:33229 E:33232 ||| VBZ
the  ||| S:33232 E:33236 ||| DT
concentration  ||| S:33236 E:33250 ||| NN
of  ||| S:33250 E:33253 ||| IN
5-HT  ||| S:33253 E:33268 ||| NNP
needed  ||| S:33268 E:33275 ||| VBD
to  ||| S:33275 E:33278 ||| TO
obtain  ||| S:33278 E:33285 ||| VB
half  ||| S:33285 E:33290 ||| DT
maximal  ||| S:33290 E:33298 ||| JJ
activation  ||| S:33298 E:33309 ||| NN
and  ||| S:33309 E:33313 ||| CC
n  ||| S:33313 E:33315 ||| NN
is  ||| S:33315 E:33318 ||| VBZ
the  ||| S:33318 E:33332 ||| DT
apparent  ||| S:33332 E:33341 ||| JJ
Hill  ||| S:33341 E:33346 ||| NNP
coefficient ||| S:33346 E:33357 ||| NN
.  ||| S:33357 E:33359 ||| .
For  ||| S:33359 E:33363 ||| IN
inhibition  ||| S:33363 E:33374 ||| JJ
experiments ||| S:33374 E:33385 ||| NNS
,  ||| S:33385 E:33397 ||| ,
cells  ||| S:33397 E:33403 ||| NNS
were  ||| S:33403 E:33408 ||| VBD
exposed  ||| S:33408 E:33416 ||| VBN
to  ||| S:33416 E:33419 ||| TO
inhibitor  ||| S:33419 E:33429 ||| VB
alone  ||| S:33429 E:33435 ||| RB
for  ||| S:33435 E:33439 ||| IN
30  ||| S:33439 E:33442 ||| CD
s  ||| S:33442 E:33444 ||| VBZ
prior  ||| S:33444 E:33450 ||| RB
to  ||| S:33450 E:33463 ||| TO
co-exposure  ||| S:33463 E:33475 ||| JJ
with  ||| S:33475 E:33480 ||| IN
5-HT ||| S:33480 E:33484 ||| CD
.  ||| S:33484 E:33486 ||| .
Inhibited  ||| S:33486 E:33496 ||| JJ
responses  ||| S:33496 E:33506 ||| NNS
were  ||| S:33506 E:33521 ||| VBD
calculated  ||| S:33521 E:33532 ||| VBN
as  ||| S:33532 E:33535 ||| IN
a  ||| S:33535 E:33537 ||| DT
fraction  ||| S:33537 E:33546 ||| NN
of  ||| S:33546 E:33549 ||| IN
the  ||| S:33549 E:33553 ||| DT
response  ||| S:33553 E:33562 ||| NN
to  ||| S:33562 E:33565 ||| TO
5-HT  ||| S:33565 E:33570 ||| CD
alone ||| S:33570 E:33575 ||| RB
.  ||| S:33575 E:33587 ||| .
Data  ||| S:33587 E:33592 ||| NNP
were  ||| S:33592 E:33597 ||| VBD
plotted  ||| S:33597 E:33605 ||| VBN
as  ||| S:33605 E:33608 ||| IN
the  ||| S:33608 E:33612 ||| DT
fractional  ||| S:33612 E:33623 ||| JJ
response  ||| S:33623 E:33632 ||| NN
versus  ||| S:33632 E:33639 ||| IN
the  ||| S:33639 E:33653 ||| DT
concentration  ||| S:33653 E:33667 ||| NN
of  ||| S:33667 E:33670 ||| IN
inhibitor  ||| S:33670 E:33680 ||| NN
and  ||| S:33680 E:33684 ||| CC
analysed  ||| S:33684 E:33693 ||| VBP
using  ||| S:33693 E:33699 ||| VBG
GraphPad  ||| S:33699 E:33718 ||| JJ
software ||| S:33718 E:33726 ||| NN
.  ||| S:33726 E:33728 ||| .
The  ||| S:33728 E:33732 ||| DT
IC  ||| S:33732 E:33746 ||| NNP
50  ||| S:33746 E:33749 ||| CD
value  ||| S:33749 E:33755 ||| NN
was  ||| S:33755 E:33759 ||| VBD
calculated  ||| S:33759 E:33770 ||| VBN
as  ||| S:33770 E:33773 ||| IN
the  ||| S:33773 E:33787 ||| DT
concentration  ||| S:33787 E:33801 ||| NN
of  ||| S:33801 E:33804 ||| IN
antagonist  ||| S:33804 E:33815 ||| NNS
inhibiting  ||| S:33815 E:33826 ||| VBP
the  ||| S:33826 E:33830 ||| DT
5-HT  ||| S:33830 E:33835 ||| JJ
evoked  ||| S:33835 E:33852 ||| JJ
response  ||| S:33852 E:33861 ||| NN
by  ||| S:33861 E:33864 ||| IN
50 ||| S:33864 E:33866 ||| CD
% ||| S:33866 E:33867 ||| NN
.  ||| S:33867 E:33869 ||| .
A  ||| S:33869 E:33871 ||| DT
K  ||| S:33871 E:33884 ||| NNP
i  ||| S:33884 E:33886 ||| FW
value  ||| S:33886 E:33892 ||| NN
was  ||| S:33892 E:33896 ||| VBD
calculated  ||| S:33896 E:33907 ||| VBN
from  ||| S:33907 E:33912 ||| IN
the  ||| S:33912 E:33916 ||| DT
IC  ||| S:33916 E:33930 ||| NNP
50  ||| S:33930 E:33933 ||| CD
using  ||| S:33933 E:33939 ||| VBG
the  ||| S:33939 E:33943 ||| DT
Cheng-Prusoff  ||| S:33943 E:33967 ||| JJ
equation ||| S:33967 E:33975 ||| NN
.  ||| S:33975 E:34005 ||| .
Synthesis  ||| S:34005 E:34015 ||| NNP
of  ||| S:34015 E:34018 ||| IN
Lerisetron  ||| S:34018 E:34029 ||| NNP
and  ||| S:34029 E:34033 ||| CC
its  ||| S:34033 E:34037 ||| PRP$
analogs  ||| S:34037 E:34055 ||| NNS
All  ||| S:34055 E:34059 ||| DT
target  ||| S:34059 E:34066 ||| NN
molecules  ||| S:34066 E:34076 ||| NNS
were  ||| S:34076 E:34081 ||| VBD
prepared  ||| S:34081 E:34090 ||| VBN
according  ||| S:34090 E:34100 ||| VBG
to  ||| S:34100 E:34103 ||| TO
a  ||| S:34103 E:34115 ||| DT
general  ||| S:34115 E:34123 ||| JJ
2-step  ||| S:34123 E:34130 ||| CD
synthesis  ||| S:34130 E:34140 ||| NNS
reported  ||| S:34140 E:34149 ||| VBD
previously  ||| S:34149 E:34160 ||| RB
by  ||| S:34160 E:34163 ||| IN
Orjales  ||| S:34163 E:34182 ||| NNP
et  ||| S:34182 E:34185 ||| FW
al  ||| S:34185 E:34188 ||| FW
.  ||| S:34188 E:34190 ||| FW
with  ||| S:34190 E:34195 ||| IN
only  ||| S:34195 E:34200 ||| RB
slight  ||| S:34200 E:34217 ||| JJ
modification  ||| S:34217 E:34230 ||| NN
[  ||| S:34230 E:34232 ||| -LRB-
22  ||| S:34232 E:34235 ||| CD
23  ||| S:34235 E:34238 ||| CD
]  ||| S:34238 E:34240 ||| -RRB-
.  ||| S:34240 E:34242 ||| .
Commercially  ||| S:34242 E:34255 ||| RB
available  ||| S:34255 E:34275 ||| JJ
2-chlorobenzimidazole ||| S:34275 E:34296 ||| NN
,  ||| S:34296 E:34298 ||| ,
in  ||| S:34298 E:34301 ||| IN
dry  ||| S:34301 E:34305 ||| JJ
DMF  ||| S:34305 E:34309 ||| NNP
was  ||| S:34309 E:34313 ||| VBD
treated  ||| S:34313 E:34321 ||| VBN
with  ||| S:34321 E:34326 ||| IN
a  ||| S:34326 E:34338 ||| DT
slight  ||| S:34338 E:34345 ||| JJ
excess  ||| S:34345 E:34352 ||| NN
of  ||| S:34352 E:34355 ||| IN
NaH ||| S:34355 E:34358 ||| NNP
,  ||| S:34358 E:34360 ||| ,
( ||| S:34360 E:34361 ||| -LRB-
1.1eq ||| S:34361 E:34366 ||| NNP
) ||| S:34366 E:34367 ||| -RRB-
.  ||| S:34367 E:34369 ||| .
After  ||| S:34369 E:34375 ||| IN
stirring  ||| S:34375 E:34384 ||| VBG
for  ||| S:34384 E:34388 ||| IN
1  ||| S:34388 E:34390 ||| CD
hour  ||| S:34390 E:34405 ||| NN
at  ||| S:34405 E:34408 ||| IN
room  ||| S:34408 E:34413 ||| NN
temperature ||| S:34413 E:34424 ||| NN
,  ||| S:34424 E:34426 ||| ,
one  ||| S:34426 E:34430 ||| CD
equivalent  ||| S:34430 E:34441 ||| NN
of  ||| S:34441 E:34444 ||| IN
the  ||| S:34444 E:34448 ||| DT
appropriate  ||| S:34448 E:34470 ||| JJ
alkyl  ||| S:34470 E:34476 ||| JJ
bromide  ||| S:34476 E:34484 ||| NN
was  ||| S:34484 E:34488 ||| VBD
added  ||| S:34488 E:34494 ||| VBN
slowly  ||| S:34494 E:34501 ||| RB
and  ||| S:34501 E:34505 ||| CC
the  ||| S:34505 E:34509 ||| DT
reaction  ||| S:34509 E:34518 ||| NN
mixture  ||| S:34518 E:34536 ||| VBZ
heated  ||| S:34536 E:34543 ||| VBN
under  ||| S:34543 E:34549 ||| IN
reflux  ||| S:34549 E:34556 ||| NN
for  ||| S:34556 E:34560 ||| IN
>  ||| S:34560 E:34562 ||| CD
5  ||| S:34562 E:34564 ||| CD
hours  ||| S:34564 E:34570 ||| NNS
( ||| S:34570 E:34571 ||| -LRB-
the  ||| S:34571 E:34575 ||| DT
reaction  ||| S:34575 E:34584 ||| NN
was  ||| S:34584 E:34598 ||| VBD
monitored  ||| S:34598 E:34608 ||| VBN
by  ||| S:34608 E:34611 ||| IN
TLC ||| S:34611 E:34614 ||| NNP
) ||| S:34614 E:34615 ||| -RRB-
.  ||| S:34615 E:34617 ||| .
Reaction  ||| S:34617 E:34626 ||| NN
product  ||| S:34626 E:34634 ||| NN
was  ||| S:34634 E:34638 ||| VBD
partitioned  ||| S:34638 E:34660 ||| VBN
between  ||| S:34660 E:34668 ||| IN
water  ||| S:34668 E:34674 ||| NN
and  ||| S:34674 E:34678 ||| CC
methylene  ||| S:34678 E:34688 ||| JJ
chloride ||| S:34688 E:34696 ||| NN
;  ||| S:34696 E:34698 ||| :
organic  ||| S:34698 E:34706 ||| JJ
layer  ||| S:34706 E:34712 ||| NN
was  ||| S:34712 E:34726 ||| VBD
dried  ||| S:34726 E:34732 ||| VBN
( ||| S:34732 E:34733 ||| -LRB-
Na  ||| S:34733 E:34747 ||| NNP
2  ||| S:34747 E:34749 ||| CD
SO  ||| S:34749 E:34763 ||| CD
4  ||| S:34763 E:34765 ||| CD
)  ||| S:34765 E:34767 ||| -RRB-
and  ||| S:34767 E:34771 ||| CC
concentrated  ||| S:34771 E:34784 ||| VBN
in  ||| S:34784 E:34787 ||| IN
vacuum ||| S:34787 E:34793 ||| NN
.  ||| S:34793 E:34795 ||| .
The  ||| S:34795 E:34809 ||| DT
solid  ||| S:34809 E:34815 ||| JJ
residue  ||| S:34815 E:34823 ||| NN
was  ||| S:34823 E:34827 ||| VBD
purified  ||| S:34827 E:34836 ||| VBN
by  ||| S:34836 E:34839 ||| IN
Flash  ||| S:34839 E:34845 ||| NNP
chromatography ||| S:34845 E:34859 ||| NN
,  ||| S:34859 E:34861 ||| ,
which  ||| S:34861 E:34877 ||| WDT
afforded  ||| S:34877 E:34886 ||| VBZ
the  ||| S:34886 E:34890 ||| DT
corresponding  ||| S:34890 E:34904 ||| JJ
N-substituted  ||| S:34904 E:34928 ||| JJ
2-Chlorobenzimidazole  ||| S:34928 E:34950 ||| CD
intermediates  ||| S:34950 E:34964 ||| NN
in  ||| S:34964 E:34967 ||| IN
good  ||| S:34967 E:34972 ||| JJ
yield ||| S:34972 E:34977 ||| NN
.  ||| S:34977 E:34979 ||| .
The  ||| S:34979 E:34993 ||| DT
final  ||| S:34993 E:34999 ||| JJ
step  ||| S:34999 E:35004 ||| NN
involved  ||| S:35004 E:35013 ||| VBD
a  ||| S:35013 E:35015 ||| DT
nucleophilic  ||| S:35015 E:35028 ||| JJ
substitution  ||| S:35028 E:35041 ||| NN
of  ||| S:35041 E:35044 ||| IN
the  ||| S:35044 E:35058 ||| DT
2-chloro  ||| S:35058 E:35067 ||| JJ
group  ||| S:35067 E:35073 ||| NN
by  ||| S:35073 E:35076 ||| IN
piperazine  ||| S:35076 E:35087 ||| NN
at  ||| S:35087 E:35090 ||| IN
high  ||| S:35090 E:35095 ||| JJ
temperatures ||| S:35095 E:35107 ||| NNS
.  ||| S:35107 E:35109 ||| .
The  ||| S:35109 E:35123 ||| DT
reaction  ||| S:35123 E:35132 ||| NN
was  ||| S:35132 E:35136 ||| VBD
performed  ||| S:35136 E:35146 ||| VBN
neat  ||| S:35146 E:35151 ||| JJ
using  ||| S:35151 E:35157 ||| VBG
4-10  ||| S:35157 E:35162 ||| RB
fold  ||| S:35162 E:35167 ||| VB
excess  ||| S:35167 E:35184 ||| JJ
piperazine  ||| S:35184 E:35195 ||| NN
and  ||| S:35195 E:35199 ||| CC
typically  ||| S:35199 E:35209 ||| RB
heated  ||| S:35209 E:35216 ||| VBN
for  ||| S:35216 E:35220 ||| IN
a  ||| S:35220 E:35222 ||| DT
short  ||| S:35222 E:35228 ||| JJ
period  ||| S:35228 E:35235 ||| NN
only ||| S:35235 E:35239 ||| RB
,  ||| S:35239 E:35251 ||| ,
( ||| S:35251 E:35252 ||| -LRB-
30-45  ||| S:35252 E:35258 ||| FW
min ||| S:35258 E:35261 ||| FW
) ||| S:35261 E:35262 ||| -RRB-
.  ||| S:35262 E:35264 ||| .
Similar  ||| S:35264 E:35272 ||| JJ
work-up  ||| S:35272 E:35280 ||| NN
afforded  ||| S:35280 E:35289 ||| VBN
a  ||| S:35289 E:35291 ||| DT
residue  ||| S:35291 E:35299 ||| NN
that  ||| S:35299 E:35304 ||| WDT
was  ||| S:35304 E:35318 ||| VBD
purified  ||| S:35318 E:35327 ||| VBN
by  ||| S:35327 E:35330 ||| IN
either  ||| S:35330 E:35337 ||| DT
crystallization  ||| S:35337 E:35353 ||| NN
or  ||| S:35353 E:35356 ||| CC
chromatography ||| S:35356 E:35370 ||| NN
.  ||| S:35370 E:35372 ||| .
The  ||| S:35372 E:35386 ||| DT
yields  ||| S:35386 E:35393 ||| NNS
ranged  ||| S:35393 E:35400 ||| VBD
from  ||| S:35400 E:35405 ||| IN
40-95 ||| S:35405 E:35410 ||| CD
% ||| S:35410 E:35411 ||| NN
.  ||| S:35411 E:35413 ||| .
All  ||| S:35413 E:35417 ||| DT
compounds  ||| S:35417 E:35427 ||| NN
were  ||| S:35427 E:35442 ||| VBD
characterized  ||| S:35442 E:35456 ||| VBN
by  ||| S:35456 E:35459 ||| IN
NMR ||| S:35459 E:35462 ||| NNP
,  ||| S:35462 E:35464 ||| ,
MS ||| S:35464 E:35466 ||| NNP
,  ||| S:35466 E:35468 ||| ,
HRMS ||| S:35468 E:35472 ||| NNP
,  ||| S:35472 E:35474 ||| ,
and  ||| S:35474 E:35478 ||| CC
/ ||| S:35478 E:35479 ||| NNP
or  ||| S:35479 E:35482 ||| CC
elemental  ||| S:35482 E:35502 ||| JJ
analysis  ||| S:35502 E:35511 ||| NN
or  ||| S:35511 E:35514 ||| CC
were  ||| S:35514 E:35519 ||| VBD
identical  ||| S:35519 E:35529 ||| JJ
to  ||| S:35529 E:35532 ||| TO
literature  ||| S:35532 E:35543 ||| VB
reports ||| S:35543 E:35550 ||| NNS
.  ||| S:35550 E:35580 ||| .
Materials  ||| S:35580 E:35600 ||| NNPS
D-MEM ||| S:35600 E:35605 ||| NNP
,  ||| S:35605 E:35607 ||| ,
Penicillin-Streptomycin ||| S:35607 E:35630 ||| NNP
,  ||| S:35630 E:35632 ||| ,
fetal  ||| S:35632 E:35638 ||| JJ
bovine  ||| S:35638 E:35645 ||| JJ
serum ||| S:35645 E:35650 ||| NN
,  ||| S:35650 E:35662 ||| ,
and  ||| S:35662 E:35666 ||| CC
Trypsin  ||| S:35666 E:35674 ||| NNP
were  ||| S:35674 E:35679 ||| VBD
obtained  ||| S:35679 E:35688 ||| VBN
from  ||| S:35688 E:35693 ||| IN
New  ||| S:35693 E:35697 ||| NNP
Life  ||| S:35697 E:35702 ||| NNP
Technologies.  ||| S:35702 E:35726 ||| NNP
5-HT  ||| S:35726 E:35731 ||| NNP
and  ||| S:35731 E:35735 ||| CC
MDL-72222  ||| S:35735 E:35745 ||| NNP
were  ||| S:35745 E:35750 ||| VBD
obtained  ||| S:35750 E:35759 ||| VBN
from  ||| S:35759 E:35764 ||| IN
RBI.  ||| S:35764 E:35769 ||| NNP
[  ||| S:35769 E:35781 ||| -LRB-
3H ||| S:35781 E:35783 ||| NNP
] ||| S:35783 E:35784 ||| -RRB-
-granisetron  ||| S:35784 E:35797 ||| NNP
( ||| S:35797 E:35798 ||| -LRB-
84  ||| S:35798 E:35801 ||| CD
Ci ||| S:35801 E:35803 ||| CD
/ ||| S:35803 E:35804 ||| CD
mmol ||| S:35804 E:35808 ||| CD
)  ||| S:35808 E:35810 ||| -RRB-
was  ||| S:35810 E:35814 ||| VBD
purchased  ||| S:35814 E:35824 ||| VBN
from  ||| S:35824 E:35829 ||| IN
New  ||| S:35829 E:35843 ||| NNP
England  ||| S:35843 E:35851 ||| NNP
Nuclear ||| S:35851 E:35858 ||| NNP
.  ||| S:35858 E:35884 ||| .
